



Daix (France), 04 June 2026

Dear Shareholder,

We are pleased to invite you to Inventiva's 2026 Shareholders Meeting, which will be held on Tuesday, June 30, 2026, at 2 p.m. at Hotel Villa M, 24-30 boulevard Pasteur, 75015 Paris. This meeting will provide an opportunity to discuss the company's recent progress and upcoming milestones.

As we approach our Annual General Meeting, I want to take a moment to reflect on what has been a transformative period for Inventiva, one marked by significant clinical progress, a strengthened leadership team, and a series of financial transactions that have fundamentally repositioned the company for the road ahead.

Inventiva recently completed a comprehensive refinancing that meaningfully improves our financial position and operational flexibility and simplifies our capital structure.

On June 1, 2026, the company entered into an agreement with the European Investment Bank (EIB) to fully repay our outstanding loan and restructure the terms of the warrants subscribed by the EIB in connection with the provision of this loan. As part of this transaction, the company will repurchase for €50 million a part of the warrants, representing approximately 22.7 million underlying shares, a discount of approximately 40% to their intrinsic value, and issue approximately 15.7 million new warrants in substitution, subject to your approval at the meeting. These new warrants will have terms that are more standard and in line with market practice. The warrants repurchase and loan repayment are expected to be completed before June 30, 2026.

In parallel, up to €130 million in new debt financing was secured from BlackRock and Claret, and the company successfully completed a €95 million equity raise with existing and new investors, further strengthening our balance sheet.

All of these transactions, to which the T3 of our Structured Financing of October 2024 may be added (assuming its full completion and the satisfaction of the conditions precedent), extend the cash runway to early first quarter 2028¹ and position Inventiva very favorably ahead of our anticipated NATiV3 topline data readout in the fourth quarter of 2026. We are grateful for the confidence our investors have placed in Inventiva.

¹ These estimates are based on the Company's current business plan and assume the successful closing of the Equity Offering, the completion of the EIB Transactions and the issuance of Tranches A, B and C of the Financing Transaction, and the exercise in full of the Tranche 3 warrants previously issued by the Company in the Structured Financing for potential proceeds of up to €116.0 million, and exclude any potential milestones payable to or by the Company and any additional expenditures related to the product candidate or resulting from the potential in licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue. The Company may have based these estimates on assumptions that are incorrect, and the Company may end up using its resources sooner than anticipated. These estimates may be shortened in the event of an increase, in expenditure relating to the development programs beyond the Company's expectations, or if the development program progresses more quickly than expected. There can be no assurance whether, and to what extent, the Tranche 3 warrants will be exercised, if at all.

The Board has also continued to evolve. We are pleased to present for your approval the renewal of two experienced directors, Renée Aguiar-Lucander and Heinz Mäusli, as well as the appointment of three new directors: Camilla Soenderby, Anne Prener, and Barbara Krebs-Pohl.

These appointments further strengthen the diversity of experience and perspectives on your Board as we navigate this critical phase.

Your participation in our General Meeting is invaluable as we continue to advance our strategic priorities and work to build long-term shareholder value. If you are unable to attend in person, we encourage you to vote online or by mail following the instructions in the proxy statement, your vote ensures your shares are represented.

On behalf of the entire Board, thank you for your continued confidence and support of Inventiva. We enter this next phase with a stronger balance sheet, a focused team, and a clear path forward. We look forward to sharing our progress with you.

Sincerely,

Mark Pruzanski, MD

Signed by:

82FD367588084B9...
Chairman of the Board of Directors of Inventiva

INVENTIVA

Société Anonyme with a Board of Directors
With a share capital of EUR 2,090,074.75
Registered Office: 50, Rue de Dijon, 21121 Daix
537 530 255 Trade and Companies Register of Dijon

ORDINARY AND EXTRAORDINARY GENERAL MEETING DATED JUNE 30, 2026

The shareholders of INVENTIVA (the “**Company**”) are hereby informed that the ordinary and extraordinary general meeting (the “**General Meeting**”) it is to be held on **June 30, 2026, at 2 p.m.**, at: Hôtel Villa M, 24-30, boulevard Pasteur – 75015 Paris, France, as mentioned in the prior notice of meeting published in the *Bulletin des Annonces Légales et Obligatoires* (BALO) n°61 dated May 22nd, 2026.

The Ordinary and Extraordinary General Meeting will have to deliberate on the following agenda:

Agenda

Reading of the reports of the Board of Directors and KPMG S.A. (the “Statutory Auditors”);

Ordinary items

1. Approval of the statutory financial statements for the financial year ended December 31, 2025;
2. Approval of the consolidated financial statements for the financial year ended December 31, 2025;
3. Appropriation of profit/loss for the financial year ended December 31, 2025;
4. Approval of the expenses and charges referred to in Article 39(4) of the French General Tax Code;
5. Approval of the subscription agreement signed on May 2, 2025 between the Company and Samsara BioCapital L.P., for new shares with warrants issued by the Company, in accordance with Articles L.225-38 et seq. of the French Commercial Code;
6. Final approval of the fixed and variable compensation paid or awarded to Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors for the financial year ended December 31, 2025;
7. Final approval of the fixed and variable compensation paid or awarded to Mr. Frédéric Cren in his capacity as Chief Executive Officer until September 30, 2025, for the financial year ended December 31, 2025;
8. Final approval of the fixed and variable compensation paid or awarded to Mr. Andrew Obenshain in his capacity as Chief Executive Officer from October 1, 2025, for the financial year ended December 31, 2025;
9. Final approval of the fixed and variable compensation paid or awarded to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer until June 30, 2025, for the financial year ended December 31, 2025;
10. Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code;
11. Approval of the compensation policy for Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors;

12. Approval of the compensation policy for Mr. Andrew Obenshain in his capacity as Chief Executive Officer;
13. Total compensation paid to members of the Board of Directors;
14. Approval of the compensation policy of the Company's directors;
15. Renewal of the Director's mandate of Ms. Renée Aguiar-Lucander;
16. Renewal of the Director's mandate of Mr. Heinz Maeusli;
17. Appointment of Ms. Camilla Soenderby, as Director of the Company;
18. Appointment of Ms. Anne Prener, as Director of the Company;
19. Appointment of Ms. Barbara Krebs-Pohl, as Director of the Company;
20. Authorization granted to the Board of Directors to buyback the Company's shares;

Extraordinary items

21. Authorization to the Board of Directors to reduce the share capital by cancellation of shares;
22. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, with shareholders' preemptive subscription rights maintained;
23. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders' preemptive subscription rights, by way of public offerings, excluding offers referred to in Article L.411-2- 1° of the French *Code monétaire et financier*;
24. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders' preemptive subscription rights, by way of public offerings referred to in Article L.411-2 1° of the French *Code monétaire et financier*;
25. Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders' preemptive subscription rights;
26. Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in favor of one or more persons specifically designated by the Board of Directors, without shareholders' preemptive subscription rights;
27. Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares, immediately or in the future, reserved for certain specific categories of beneficiaries meeting specific characteristics within the framework of an equity financing agreement on the U.S. market called "At-the-market" or "ATM", without shareholders' preemptive subscription rights;
28. Authorization to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders' preemptive subscription rights;

Translation for information purpose only

29. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares and securities giving access to the share capital of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company;
30. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in consideration for contributions in kind within the limits set by legal and regulatory provisions, excluding the case of a public exchange offer initiated by the Company;
31. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code du travail, without shareholders' preferential subscription rights;
32. Delegation of authority to the Board of Directors to increase the share capital of the Company by incorporating reserves, profits or premiums;
33. Authorization to the Board of Directors to grant free shares to employees and/or certain corporate officers;
34. Authorization to the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies of the group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options;
35. Delegation of authority to the Board of Directors to decide on the issuance of share subscription warrants, without shareholders' preemptive subscription rights, to the benefit of categories of persons;
36. Decision to be taken in application of article L. 225-248 of the French Commercial Code (shareholders' equity less than half the share capital);
37. Harmonization of the articles of association of the Company with applicable laws and regulations, resulting from the French Decree no. 2026-94 of February 13, 2026, relating to the modernization of communication means with their shareholders of some commercial companies;
38. Amendment of article 23 (censor) of the articles of association of the Company;
39. Decision to issue share subscription warrants of the Company without shareholders' preferential subscription rights to the benefit of the European Investment Bank and delegation of authority to the Board of Directors;

On an ordinary basis

40. Power for formalities.

DRAFT TEXT OF RESOLUTIONS
TO BE SUBMITTED TO THE VOTE
OF THE ORDINARY AND EXTRAORDINARY GENERAL MEETING
OF JUNE 30, 2026

ORDINARY RESOLUTIONS

FIRST RESOLUTION (*Approval of the statutory financial statements for the financial year ended December 31, 2025*)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the management report of the Board of Directors and the general report of the Statutory Auditors on the annual statutory financial statements,

Approves the financial statements for the financial year ended December 31, 2025 as presented, including the balance sheet, income statement and appendix to the financial statements, as well as the transactions reflected in these financial statements and summarized in these reports, showing a net accounting loss of EUR 207,965,630.56.

SECOND RESOLUTION (*Approval of the consolidated financial statements for the financial year ended December 31, 2025*)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the management report of the Board of Directors and the general report of the Statutory Auditors on the consolidated financial statements,

Approves the consolidated financial statements for the financial year ended December 31, 2025 as presented, as well as the transactions reflected in these accounts or summarized in these reports.

THIRD RESOLUTION (*Appropriation of profit/loss for the financial year ended December 31, 2025*)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the management report of the Board of Directors, as well as the general report of the Statutory Auditors,

Having recorded that the annual financial statements showed a net accounting loss of EUR 207,965,630.56,

Resolves to wholly allocate this net accounting loss of EUR 207,965,630.56 to the "Report à Nouveau" account, bringing its debit amount to EUR 583,594,899.42.

Notes that no dividend has been distributed since the Company's incorporation.

FOURTH RESOLUTION (*Approval of the expenses and charges referred to in Article 39(4) of the French General Tax Code*)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the management report of the Board of Directors, as well as the general report of the Statutory Auditors, acting in accordance with the provisions of Article 223 quater of the French General Tax Code,

Approves the non-deductible expenses and charges for tax purposes, referred to in Article 39, paragraph 4 of the said Code, which amount to EUR 6,276 for the financial year 2025, and acknowledges the absence of corporate income tax borne in respect of these expenses and charges in view of the loss for said financial year.

FIFTH RESOLUTION (*Approval of the subscription agreement signed on May 2, 2025 between the Company and Samsara BioCapital L.P., for new shares with warrants issued by the Company, in accordance with Articles L.225-38 et seq. of the French Commercial Code*)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the special report of the Statutory Auditors on related-party agreements referred to in Article L.225-38 seq. of the French Commercial Code, acknowledges the conclusions of this report and in particular the information relating to agreements entered into and authorized in prior years, the performance of which continued in the year ended December 31, 2024, and approves the subscription agreement signed on May 2, 2025 between the Company and Samsara BioCapital L.P., for new shares with warrants issued by the Company.

SIXTH RESOLUTION (*Final approval of the fixed and variable compensation paid or awarded to Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors for the financial year ended December 31, 2025*)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the report on corporate governance referred to in Article L.225-37 of the French Commercial Code,

Approves, pursuant to Article L.22-10-34 II. of the French Commercial Code, the fixed, variable and exceptional elements composing the total compensation and benefits of any kind paid during the previous fiscal year or awarded in respect of the same financial year to Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors, contained therein, as presented in the Universal Registration Document including the 2025 Annual Financial Report, Part 3, Section 3.5.1.5.

SEVENTH RESOLUTION (*Final approval of the fixed and variable compensation paid or awarded to Mr. Frédéric Cren in his capacity as Chief Executive Officer until September 30, 2025 for the financial year ended December 31, 2025*)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the report on corporate governance referred to in Article L.225-37 of the French Commercial Code,

Approves, pursuant to Article L.22-10-34 II. of the French Commercial Code, the fixed, variable and exceptional elements composing the total compensation and benefits of any kind paid during the previous fiscal year or awarded in respect of the same financial year to Mr. Frédéric Cren in his capacity as Chief Executive Officer until September 30, 2025, contained therein, as presented in the Universal Registration Document including the 2025 Annual Financial Report, Part 3, Section 3.5.1.5.

EIGHTH RESOLUTION (*Final approval of the fixed and variable compensation paid or awarded to Mr. Andrew Obenshain in his capacity as Chief Executive Officer from October 1, 2025 for the financial year ended December 31, 2025*)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the report on corporate governance referred to in Article L.225-37 of the French Commercial Code,

Approves, pursuant to Article L.22-10-34 II. of the French Commercial Code, the fixed, variable and exceptional elements composing the total compensation and benefits of any kind paid during the previous fiscal year or awarded in respect of the same financial year to Mr. Andrew Obenshain in his capacity as Chief Executive Officer from October 1, 2025, contained therein, as presented in the Universal Registration Document including the Annual Financial Report, Part 3, Section 3.5.1.5.

Translation for information purpose only

NINTH RESOLUTION (Final approval of the fixed and variable compensation paid or awarded to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer until June 30, 2025 for the financial year ended December 31, 2025)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the report on corporate governance referred to in Article L.225-37 of the French Commercial Code,

Approves, pursuant to Article L.22-10-34 II. of the French Commercial Code, the fixed, variable and exceptional elements composing the total compensation and benefits of any kind paid during the previous fiscal year or awarded in respect of the same financial year to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer until June 30, 2025, contained therein, as presented in the Universal Registration Document including the 2025 Annual Financial Report, Part 3, Section 3.5.1.5.

TENTH RESOLUTION (Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the report on corporate governance referred to in Article L.225-37 of the French Commercial Code,

Approves, pursuant to Article L.22-10-34 I. of the French Commercial Code, the information mentioned in Article L.22-10-9 I. of the French Commercial Code, contained therein, as presented in the Universal Registration Document including the 2025 Annual Financial Report, Part 3, Section 3.5.1.6.

ELEVENTH RESOLUTION (Approval of the compensation policy for Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the report on corporate governance referred to in Article L.225-37 of the French Commercial Code describing the components of the compensation policy of corporate officers,

Approves, pursuant to Article L.22-10-8 II. of the French Commercial Code, the compensation policy of the Chairman of the Board of Directors, Mr. Mark Pruzanski, including the policy applicable to all corporate officers and the provisions specific to him, contained therein, as presented in the notice of meeting brochure relating to this General Meeting published on the Company's website.

TWELFTH RESOLUTION (Approval of the compensation policy for Mr. Andrew Obenshain in his capacity as Chief Executive Officer)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the report on corporate governance referred to in Article L.225-37 of the French Commercial Code describing the components of the compensation policy of corporate officers,

Approves, pursuant to Article L.22-10-8 II. of the French Commercial Code, the compensation policy of the Chief Executive Officer, Mr. Andrew Obenshain, including the policy applicable to all corporate officers and the provisions specific to him, contained therein, as presented in the Universal Registration Document including the 2025 Annual Financial Report, Part 3, Sections 3.5.1.1 and 3.5.1.2.

THIRTEENTH RESOLUTION (Total compensation paid to members of the Board of Directors)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the management report of the Board of Directors,

Approves, until otherwise decided, the allocation to members of the Board of Directors of a maximum aggregate amount of 1,500,000 euros, in respect of the compensation provided for in Article L. 225-45 of the French Commercial Code,

Gives, power to the Board of Directors to allocate all or part of this amount among its members in accordance with the terms and conditions it shall determine.

FOURTEENTH RESOLUTION (Approval of the compensation policy of the Company's Directors)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the report on corporate governance referred to in Article L.225-37 of the French Commercial Code describing the components of the compensation policy of corporate officers,

Approves, pursuant to Article L.22-10-8 II. of the French Commercial Code, the compensation policy of the Directors, including the policy applicable to all corporate officers and the provisions specific to them, contained therein, as presented in the Universal Registration Document including the 2025 Annual Financial Report, Part 3, Sections 3.5.1.1 et 3.5.1.3.

FIFTEENTH RESOLUTION (Renewal of the Director term of Ms. Renée Aguiar-Lucander)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the management report of the Board of Directors, noting that the Director's term of Ms. Renée Aguiar-Lucander comes to an end after this General Meeting,

Resolves to renew its term for a period of three (3) years, expiring after the 2029 General Meeting convened to approve the financial statements for the fiscal year ended December 31, 2028.

SIXTEENTH RESOLUTION (Renewal of the Director term of Mr. Heinz Maeusli)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the management report of the Board of Directors, noting that the Director's term of Mr. Heinz Maeusli comes to an end after this General Meeting,

Resolves to renew its term for a period of three (3) years, expiring after the 2029 General Meeting convened to approve the financial statements for the fiscal year ended December 31, 2028.

SEVENTEENTH RESOLUTION (Appointment of Ms. Camilla Soenderby, as Director of the Company)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the management report of the Board of Directors,

Resolves to appoint Ms. Camilla Soenderby as Director for a period of three (3) years, expiring after the 2029 General Meeting convened to approve the financial statements for the fiscal year ended December 31, 2028.

EIGHTEENTH RESOLUTION (Appointment of Ms. Anne Prener, as Director of the Company)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the management report of the Board of Directors,

Resolves to appoint Ms. Anne Prener as Director for a period of three (3) years, expiring after the 2029 General Meeting convened to approve the financial statements for the fiscal year ended December 31, 2028.

NINETEENTH RESOLUTION (*Appointment of Ms. Barbara Krebs-Pohl, as Director of the Company*)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the management report of the Board of Directors,

Resolves to appoint Ms. Barbara Krebs-Pohl as Director for a period of three (3) years, expiring after the 2029 General Meeting convened to approve the financial statements for the fiscal year ended December 31, 2028.

TWENTIETH RESOLUTION (*Authorization granted to the Board of Directors to buyback the Company's shares*)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings, having acquainted itself with the management report of the Board of Directors,

1. Authorizes the Board of Directors, with the power to sub-delegate under the conditions provided for by law and for a period of eighteen (18) months from this day, in accordance with the provisions of Articles L.22-10-62 seq. of the French Commercial Code, Articles 241-1 to 241-5 of the General Regulations of the *Autorité des marchés financiers* (“AMF”), and the European regulations applicable to market abuse and market practices permitted by the AMF, to purchase, on one or more occasions and at the times it shall determine, a number of ordinary shares of the Company not to exceed 10% of the total number of shares comprising the share capital at any time.

This percentage applies to a number of shares adjusted, if necessary, to reflect transactions that may affect the share capital subsequent to this General Meeting, and when shares are purchased to promote liquidity under the conditions defined by the General Regulations of the AMF, the number of shares taken into account for the calculation of the aforementioned 10% limit corresponds to the number of shares purchased, less the number of shares resold during the authorization period.

Under no circumstances may the Company hold more than 10% of the shares comprising its share capital at any time as a result of acquisitions made by the Company.

2. Resolves that the buyback of these ordinary shares can be carried out in order:

- to implement and perform obligations related to stock option programs or other share allocations to employees and corporate officers of the Company and, in particular, to allocate shares to employees and corporate officers of the Company in connection with (i) profit-sharing, or (ii) any share purchase, stock option or free share allocation plan under the conditions provided for by law, in particular by Articles L.3331-1 seq. of the French Labor Code (including any sale of shares referred to in Article L.3332-24 of the French Labor Code), and to carry out any hedging transactions relating to such transactions;
- to purchase or sell shares under a liquidity agreement entered into with an investment services provider, in accordance with the conditions set by the market authorities;
- to deliver ordinary shares upon the exercise of rights attached to securities carrying rights to shares of the Company by redemption, conversion, exchange, presentation of a warrant or any other means;
- to reduce the Company's capital by cancelling all or some of the shares acquired; and
- more generally, to carry out any transaction that may be authorized by law or any market practice that may be admitted by the market authorities, it being specified that, in such a case, the Company would inform its shareholders by means of a press release.

3. Resolves that the maximum unit purchase price may not exceed, excluding charges, forty euros (EUR 40) (or the equivalent value of this amount on the same date in any other currency). The Board of Directors may, however, in the event of transactions affecting the Company's share capital, in particular a change in the par value of the ordinary share, a capital increase by incorporation of reserves followed by the creation and allocation of free shares, a stock split or reverse stock split, distribution of reserves or any other assets, amortization of capital or any other transaction affecting shareholders' equity, adjust the aforementioned maximum purchase price to take into account the impact of such transactions on the value of the share.

4. Resolves that the purchase, sale or transfer of these shares may be carried out and paid for by any means authorized by current or future regulations, on a regulated market, on a multilateral trading facility, with a systematic internalizer or on an electronic communications network, in particular through the purchase or sale of

blocks of shares, through the use of options or other forward financial instruments or forward contracts, or through the use of warrants or, more generally, of securities carrying rights to shares of the Company, at the times the Board of Directors shall determine.

5. **Resolves** that the Board of Directors shall have full powers, with the option to sub-delegate such powers, to carry out, in compliance with the relevant legal and regulatory provisions, the permitted reallocation of shares purchased for one of the objectives of the program to one or more of its other objectives, or to sell them, whether on or off-market.

6. **Resolves** that the Board of Directors shall have full powers, with the option to sub-delegate such powers, to decide and implement this authorization and to determine the terms and conditions thereof in accordance with the law and this resolution, and in particular to place any and all stock market orders, enter into any and all agreements, in particular for the keeping of registers of purchases and sales of shares, make any and all declarations to the AMF or any other authority, draw up any and all documents, in particular information documents, complete any and all formalities, and generally do whatever is necessary.

7. **Acknowledges** that the Board of Directors shall inform the General Meeting of the transactions carried out under this authorization, as required by law.

8. **Resolves** that this authorization, as from its use by the Board of Directors, cancels and replaces, for the remaining period and unused amounts, the authorization granted to the Board of Directors by the general meeting of shareholders of May 22, 2025 (the “**Combined General Meeting**”), in its 22nd resolution.

EXTRAORDINARY RESOLUTIONS

***TWENTY-FIRST RESOLUTION** (Authorization to the Board of Directors to reduce the share capital by cancellation of shares)*

The General Meeting, voting under the rules of quorum and majority required for extraordinary general meetings, having reviewed managements report of the Board of Directors report and the special report of the Statutory Auditors and acting pursuant to the provisions of Article L.22-10-62 of the French Commercial Code,

1. **Authorize** the Board of Directors to cancel, in the proportions and at the times it deems fit, in one or more times, all or part of the ordinary shares acquired by the Company and/or which it may acquire in the future under any authorization given by the ordinary general shareholders' meeting pursuant to Article L. 22-10-62 of the French Commercial Code, up to a limit of 10% of the Company's share capital per 24-month period, it being recalled that this 10% limit applies to a number of shares adjusted, if necessary, according to the transactions that may affect the share capital after this General Meeting.

2. **Decides** that the excess of the purchase price of the ordinary shares over their nominal value will be charged to the "share premium" account or to any available reserve account, including the legal reserve, up to a limit of 10% of the capital reduction carried out.

3. **Authorize** the Board of Directors to reduce the share capital accordingly.

4. **Decides** that the Board of Directors will have full authority, with the right to subdelegate under the conditions provided by French law, to implement this resolution and in particular:

- determine the final amount of such capital reduction, set the terms and conditions thereof and record the completion thereof;
- charge the difference between the carrying amount of the cancelled ordinary shares and their nominal amount to all available reserves and premiums, including the legal reserve, up to a maximum of 10% of the cancelled capital;
- amend the bylaws accordingly; and
- carry out all formalities (in particular with the AMF), take all steps and make all declarations to all institutions and, in general, do all that is necessary.

5. Decides that the aforementioned delegation is granted for a period of eighteen (18) months as from the date of this General Meeting and terminates, with immediate effect, any previous delegation granted for the same purpose. It therefore supersedes the delegation granted by the Combined General Meeting in its 23rd resolution.

TWENTY- SECOND RESOLUTION (*Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, with shareholders' preemptive subscription rights maintained*)

The General Meeting, voting under the rules of quorum and majority required for extraordinary general meetings, having reviewed the management report of the Board of Directors and the special report of the Statutory Auditors and duly noting that the share capital has been fully paid up, and acting pursuant to the provisions of Articles L. 225-129 *et seq.* of the French Commercial Code, and in particular Articles L. 225-129-2, L. 225-132 to L. 225-134 and L. 228-91 *et seq.* of the French Commercial Code,

1. Delegates to the Board of Directors, with the right to subdelegate under the conditions provided by French law, the authority to proceed with, one or more issuances, in France and/or abroad, in euros or in any other currency or currency units established by reference to several currencies, with maintenance of the shareholders' preemptive subscription rights, of ordinary shares of the Company and/or any securities giving access, immediately or in the future, to ordinary shares to be issued by the Company, including through the free allocation of share subscription warrants, which may be subscribed for either in cash or by offsetting against claims, in the amount and at the times it deems appropriate.

2. Decides that the shareholders shall have, proportionally to the amount of their shares on an irreducible basis, preferential subscription rights over the ordinary shares and securities giving access to the share capital of the Company to be issued and that the Board of Directors may grant shareholders excess subscription rights for ordinary shares or securities issued, to be exercised in proportion to their subscription rights and within the limit of their requests. If the subscriptions on an irreducible basis and, as the case may be, on a reducible basis, do not absorb the entire issuance of ordinary shares or securities giving access to the share capital of the Company pursuant to this resolution, the Board of Directors may use the options provided by Article L. 225-134 of the French Commercial Code, in the order of its choice, or only some of them, and in particular the limitations of the issuance to the amount of subscriptions received, provided that such amount reaches at least three-quarters of the issuance decided upon, or decides to offer to the public all or part of the securities not subscribed in France and/or abroad.

3. Decides that the maximum nominal amount of the share capital increases that may be performed, immediately or in the future, pursuant to this resolution shall not exceed two million euros (EUR 2,000,000), it being specified that the maximum nominal amount of the share capital increases that may be performed, immediately or in the future, pursuant to this resolution as well as resolutions 23 to 31 of this General Meeting, will count towards this overall cap. Added to this cap will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company.

4. Decides that securities giving access, immediately or in the future, to ordinary shares to be issued by the Company may notably consist of debt securities or be associated with the issuance of such securities, or allow their issuance as intermediate securities, and that the debt securities issued pursuant to this resolution may take the form of subordinated or non-subordinated securities, for a fixed or indefinite term, and be issued in France and/or abroad, in euros, or in any other currency or currency units established by reference to several currencies.

The maximum nominal amount of such debt securities that may be issued pursuant to this resolution shall not exceed five hundred million euros (EUR 500,000,000) or the counter-value of this amount in another currency or in any currency units established by reference to several currencies. This amount is a global cap which applies to all of the debt securities whose issuance is provided for pursuant to this resolution and resolutions 23 to 30 of this General Meeting. This cap is independent from the debt securities whose issuance would be decided or authorized by the Board of Directors pursuant to Article L. 228-40 of the French Commercial Code.

5. Acknowledges that, in accordance with the provisions of Article L. 225-132 paragraph 6 of the French Commercial Code, this resolution includes the waiver of the shareholders' preemptive subscription rights over the ordinary shares of the Company to which any securities issued pursuant to this resolution may entitle them.

6. Decides that the Board of Directors will have full authority, with the right to subdelegate under the conditions provided by French law, to implement this resolution, and in particular to:

- determine the characteristics, amount and terms and conditions of any issuance and of the securities issued, in particular, the category of the securities issued and set their subscription price, with or without premium, the terms and conditions for their payment in full (which may be achieved through cash settlement and/or offsetting liquid and due receivables or partly in cash and partly by incorporating reserves, earnings or premiums), the date of their entitlement to dividends, which may be retroactive, the terms and conditions under which the securities issued on pursuant to this resolution could give access to ordinary shares to be issued, the conditions under which such securities could also give access to existing shares or debt securities of the Company, the conditions of their redemption or possible cancellation as well as the possibility of suspending the exercise of the allotment rights attached to the securities to be issued; these issuances may be performed by subscription offer as well as by free allotment to the owners of existing shares, including share warrants, and that, in the event of a free allotment, the Board of Directors shall have the right to decide that allotment rights, forming fractions shall not be transferable and that the corresponding securities shall be sold;
- determine when the securities issued will consist of or be associated with debt securities, their fixed or indefinite term, their subordinated or non-subordinated form, and their interest rate;
- take all necessary measures to preserve the rights of the holders of securities or other rights giving access to the share capital of the Company, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment;
- charge, as the case may be, the fees and expenses related to the share capital increases against the related premiums, and, if it deems it appropriate, deduct from this amount the sums necessary to increase the legal reserve to one-tenth of the new total share capital resulting from each issuance;
- enter into any agreement, in particular to ensure the completion and proper execution, in the amount and on the dates it deems appropriate, in France and/or abroad, of the contemplated issuances, as well as defer them, where appropriate;
- have shares, securities to be issued or securities issued through the exercise of securities giving access to shares to be issued, admitted to trading on a regulated market or any other financial market located outside the European Economic Area; and
- record the completion of the capital increases performed in accordance with this resolution, amend accordingly the by-laws, performed any and all formalities and statements, and call for any authorizations that may be necessary to performed and complete these issuances successfully.

7. Decides that the aforementioned delegation is granted for a period of twenty-six (26) months as from the date of this General Meeting and terminates, with immediate effect, any previous delegation granted for the same purpose. It therefore supersedes, if any, for the remaining period and unused amounts, the delegation granted by the Combined General Meeting in its 24th resolution.

The Board of Directors will inform the general meeting of shareholders each year of the transactions performed in accordance with this resolution.

TWENTY-THIRD RESOLUTION (*Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders' preemptive subscription rights, by way of public offerings, excluding offers referred to in Article L.411-2 1° of the French Code monétaire et financier*)

The General Meeting, voting under the rules of quorum and majority required for extraordinary general meetings, having reviewed the management report of the Board of Directors and the special report of the Statutory Auditors and duly noting that the share capital has been fully paid up, and acting pursuant to the provisions of Articles L. 225-129 *et seq.* of the French Commercial Code, and in particular Article L. 225-129-2, L. 225-135 and L. 22-10-52, and Articles L. 228-91 *et seq.* of the French Commercial Code,

1. Delegates to the Board of Directors, with the right to subdelegate under the conditions provided by French law, the authority to proceed with, one or more issuances, by way of public offerings, excluding offers referred to in Article L. 411-2 1° of the French Commercial Code, in France and/or abroad, in euros or in any other currency or currency units established by reference to several currencies, without shareholders' preemptive

subscription rights, of ordinary shares of the Company and/or securities giving access, immediately or in the future, to ordinary shares to be issued by the Company, which may be subscribed for either in cash or by offsetting against claims, in the amount and at the times it deems appropriate.

Public offerings, performed pursuant to this resolution, may be combined, within one or several simultaneous issuances, with offerings pursuant to the provisions of Article L. 411-2 1° of the French *Code monétaire et financier*.

2. Decides that the maximum nominal amount of the share capital increases that may be performed, pursuant to this resolution shall not exceed two million euros (EUR 2,000,000), it being specified that this cap will count towards the overall cap of two million euros (EUR 2,000,000) stipulated in paragraph 3 of the 22nd resolution of this General Meeting. Added to those caps will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company.

3. Decides that securities giving access to ordinary shares to be issued by the Company may notably consist of debt securities or be associated with the issuance of such securities, or allow their issuance as intermediate securities, and that the debt securities issued pursuant to this resolution may take the form of subordinated or non-subordinated securities, for a fixed or indefinite term, and be issued in France and/or abroad, in euros, or in any other currency or currency units established by reference to several currencies.

The maximum nominal amount of such debt securities that may be issued pursuant to this resolution shall not exceed five hundred million euros (EUR 500,000,000) or the counter-value of this amount in another currency or in any currency units established by reference to several currencies, it being specified that the maximum par value of debt securities that may be issued pursuant to this resolution cannot exceed the overall cap stipulated in paragraph 4 of the 22nd resolution of this General Meeting. This cap is independent from the amount of debt securities whose issuance would be decided or authorized by the Board of Directors pursuant to Article L. 228-40 of the French Commercial Code.

4. Decides to waive the shareholders' preemptive subscription rights over ordinary shares and securities giving access to the capital of the Company that can be issued pursuant to this resolution.

5. Acknowledges that this resolution includes the waiver of the shareholders' preemptive subscription rights over ordinary shares of the Company to which any securities issued pursuant to this resolution may entitle them.

6. Decides that the Board of Directors may grant shareholders a priority right to subscribe to as irreducible and/or reducible amounts, during a period and on the terms set by it, for all or part of an issuance performed pursuant to this resolution. This priority right will be allocated in proportion to shareholders' existing interests in the share capital of the Company in accordance with applicable laws and regulations.

7. Decides that if subscriptions by shareholders do not absorb the entire issuance of ordinary shares or securities giving access to the share capital of the Company, the Board of Directors may use the options provided by Article L. 225-134 of the French Commercial Code in the order of its choice, or only some of them, and in particular the limitation of the issuance to the amount of subscriptions received, provided that such amount reaches at least three-quarters of the issuance decided upon.

8. Delegates full powers to the Board of Directors, pursuant to Article L. 22-10-52 of the French Commercial Code, with the right to subdelegate under the conditions provided by French law, to set the issue price of any securities to be issued under this authorization as follows:

- (i) the issue price of the ordinary shares to be issued will be at least equal either to:
- the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris for the last trading session preceding the pricing;
 - the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris on a period comprising between three (3) and seven (7) consecutive trading days, chosen from the thirty (30) trading days preceding the pricing date;
 - the last closing price of the share of the Company on the regulated market of Euronext Paris preceding the pricing date;

which may be reduced by maximum discount of 15%, the Board of Directors may freely choose any of the three

formulas set forth above, and

(ii) the issuance price of the securities to be issued pursuant to this resolution will at least be equal to the amount received immediately by the Company, plus any amount likely to be received later by the Company, where applicable, *i.e.* for each ordinary share issued as a result of these securities being issued, at least equal to the amount mentioned in paragraph (i) above.

9. Decides that the Board of Directors will have full authority, with the right to subdelegate under the conditions provided by French law, to implement this resolution, and in particular to:

- determine the characteristics, amount and terms and conditions of any issuance and of the securities issued, in particular, the category of the securities issued, and set, in the light of the information contained in its report, their subscription price, with or without premium, the terms and conditions for their payment in full (which may be achieved through cash settlement and/or offsetting liquid and due receivables or partly in cash and partly by incorporating reserves, earnings or premiums), the date of their entitlement to dividends, which may be retroactive, the terms and conditions under which the securities issued pursuant to this resolution could give access to ordinary shares to be issued, the conditions under which such securities could also give entitlement to existing shares or debt securities of the Company, the conditions of their redemption or possible cancellation as well as the possibility of suspending the exercise of the allotment rights attached to the securities to be issued;
- determine when the securities issued will consist of or be associated with debt securities, their fixed or indefinite term, their subordinated or non-subordinated form, and their interest rate;
- take all necessary measures to preserve the rights of the holders of securities or other rights giving access to the share capital of the Company, in accordance with applicable laws and regulations and, where applicable, other contractual provisions that provide for other cases of adjustment;
- charge, as the case may be, the fees and expenses related to the share capital increases against the related premiums, and, if it deems it appropriate, deduct from this amount the sums necessary to increase the legal reserve to one-tenth of the new total share capital resulting from each issuance;
- enter into any agreement, in particular to ensure the completion and proper execution, in the amount and on the dates it deems appropriate, in France and/or abroad, of the contemplated issuances, as well as defer them, where appropriate;
- have shares, securities to be issued or securities issued through the exercise of securities giving access to shares to be issued, admitted to trading on a regulated market or any other financial market located outside of the European Economic Area; and
- record the completion of the capital increases performed in accordance with this resolution, amend accordingly the by-laws and perform any and all formalities and statements, and call for any authorizations that may be necessary to perform and complete these issuances successfully.

10. Decides that the aforementioned delegation is granted for a period of twenty-six (26) months as from the date of this General Meeting and terminates, with immediate effect, any previous delegation granted for the same purpose. It therefore supersedes, if any, for the remaining period and unused amounts, the delegation granted by the Combined General Meeting in its 25th resolution.

The Board of Directors will inform the General Shareholders' Meeting each year of the final terms of the transactions performed in accordance with this resolution.

TWENTY-FOURTH RESOLUTION (*Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders' preemptive subscription rights, by way of public offerings referred to in Article L.411-2 1° of the French Code monétaire et financier*)

The General Meeting, voting under the rules of quorum and majority required for extraordinary general meetings, having reviewed the management report of the Board of Directors and the special report of the Statutory Auditors and duly noting that the share capital has been fully paid up, and acting pursuant to the provisions of Articles L. 225-129 *et seq.* of the French Commercial Code, and in particular Article L. 225-129-2, L. 22-10-51 and L. 22-10-52, and Articles L. 228-91 *et seq.* of the French Commercial Code,

1. Delegates to the Board of Directors, with the right to subdelegate under the conditions provided by French law,

the authority to proceed with, one or more issuances, in France and/or abroad, in euros in any other currency or currency units established by reference to several currencies, by way of offerings within the provisions provided for in Article L. 411-2 1° of the French *Code monétaire et financier* under the conditions and within the limits provided for by law, through the issuance, without shareholders' preemptive subscription rights, of ordinary shares of the Company and/or securities giving access, immediately or in the future, to ordinary shares to be issued by the Company, which may be subscribed for either in cash or by offsetting against claims, in the amount and at the times it deems appropriate.

2. **Decides** that the maximum nominal amount of the share capital increases that may be performed pursuant to this resolution shall not exceed one million euros (EUR 1,000,000), it being specified that this cap is common and will count towards the cap stipulated in paragraph 2 of the 23rd resolution of this General Meeting and that the maximum nominal amount of the share capital increases that may be performed pursuant to this resolution will count towards the overall cap of two million euros (EUR 2,000,000) stipulated in paragraph 3 of the 22nd resolution of this General Meeting. Added to those caps will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company. It is hereby specified that, in any event, the nominal amount of the capital increases performed pursuant to this resolution may not exceed the limit set by the legal and regulatory provisions applicable at the time of issue (i.e., for information purposes, as at the date of this General Meeting, 30% of the share capital per year as assessed on the date of implementation of the authorization by the Board of Directors in accordance with the provisions of Article L.225-136 and Article L.22-10-52 of the French Commercial Code).
3. **Decides** that securities giving access to ordinary shares to be issued by the Company may notably consist of debt securities or be associated with the issuance of such securities, or allow their issuance as intermediate securities, and that the debt securities issued pursuant to this resolution may take the form of subordinated or non-subordinated securities, for a fixed or indefinite term and be issued, in France and/or abroad, in euros, or in any other currency or currency units established by reference to several currencies.

The maximum nominal amount of such debt securities that may be issued pursuant to this resolution shall not exceed five hundred million euros (EUR 500,000,000) or the counter-value of this amount in another currency or in any currency units established by reference to several currencies, this amount being deducted from the ceiling stipulated in the paragraph 4 of the 22nd resolution of this General Meeting.

4. **Decides** that this resolution includes the waiver of the shareholders' preemptive subscription rights over ordinary shares and securities giving access to the share capital of the Company issued pursuant to this resolution.
5. **Decides** that if subscriptions by shareholders do not absorb the entire issuance of ordinary shares or securities giving access to the share capital of the Company, the Board of Directors may limit the issuance to the amount of subscriptions received provided that such amount reaches at least three-quarters of the issuance decided upon.
6. **Acknowledges** that this resolution includes the waiver of the shareholders' preemptive subscription rights over ordinary shares of the Company to which any securities issued pursuant to this resolution may entitle them.
7. **Delegates** full powers to the Board of Directors, pursuant to Article L. 22-10-52 of the French Commercial Code, with the right to subdelegate under the conditions provided by French law to be issued under this authorization as follows:

(i) the issue price of the ordinary shares to be issued will be at least equal either to:

- the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris for the last trading session preceding the pricing;
- the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris on a period comprising between three (3) and seven (7) consecutive trading days, chosen from the thirty (30) trading days preceding the pricing date;
- the last closing price of the share of the Company on the regulated market of Euronext Paris preceding the pricing date;

which may be reduced by maximum discount of 15%, the Board of Directors may freely choose any of the three formulas set forth above, and

(ii) the issuance price of the securities to be issued pursuant to this resolution will at least be equal to the amount received immediately by the Company, plus any amount likely to be received later by the Company, where applicable, *i.e.* for each ordinary share issued as a result of these securities being issued, at least equal to the amount mentioned in paragraph (i) above.

8. Decides that the Board of Directors will have full authority, with the right to subdelegate under the conditions provided by French law, to implement this resolution, and in particular to:

- determine the characteristics, amount and terms and conditions of any issuance and of the securities issued, in particular, the category of the securities issued, and will set, in the light of the information contained in its report, their subscription price, with or without premium, the terms and conditions for their payment in full (which may be achieved through cash settlement and/or offsetting liquid and due receivables or partly in cash and partly by incorporating reserves, earnings or premiums), the date of their entitlement to dividends, which may be retroactive, the terms and conditions under which the securities issued pursuant to this resolution could give access to ordinary shares to be issued, the conditions under which such securities could also give access to existing shares or debt securities of the Company, the conditions of their redemption or possible cancellation, as well as the possibility of suspending the exercise of the allotment rights attached to the securities to be issued;
- determine when the securities issued will consist of or be associated with debt securities, their fixed or indefinite term, their subordinated or non-subordinated form, and their interest rate;
- take all necessary measures to preserve the rights of the holders of securities or other rights giving access to the share capital of the Company, in accordance with applicable laws and regulations and, as the case may be, other contractual provisions that provide for other cases of adjustment;
- charge, as the case may be, the fees and expenses related to the share capital increases against the related premiums, and, if it deems it appropriate, deduct from this amount the sums necessary to increase the legal reserve to one-tenth of the new total share capital resulting from each issuance;
- enter into any agreement, in particular to ensure the completion and proper execution, in the amount and on the dates it deems appropriate, in France and/or abroad, of the contemplated issuances, as well as defer them, where appropriate;
- have shares, securities to be issued or securities issued through the exercise of securities giving access to shares to be issued, admitted to trading on a regulated market or any financial market located outside of the European Economic Area; and
- record the completion of the share capital increases performed in accordance with this resolution, amend accordingly the by-laws and, perform any and all formalities and statements, and call for any authorizations that may be necessary to perform and complete these issuances successfully.

9. Decides that the aforementioned delegation is granted for a period of twenty-six (26) months as from the date of this General Meeting and terminates, with immediate effect, any previous delegation granted for the same purpose. It therefore supersedes if any, for the remaining period and unused amounts, the delegation granted by the Combined General Meeting in its 26th resolution.

The Board of Directors will inform the general meeting of shareholders each year of the final terms of the transactions performed in accordance with this resolution.

TWENTY-FIFTH RESOLUTION (*Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders' preemptive subscription rights*)

The General Meeting, voting under the rules of quorum and majority required for extraordinary general meetings having reviewed the management report of the Board of Directors and the special report of the Statutory Auditors and duly noting that the share capital has been fully paid up, and acting pursuant to Articles L. 225-129 *et seq.* of the French Commercial Code, and in particular Articles L. 225-129-2, L.22-10-49, L. 22-10-51, L. 225-138 and Articles L. 228-91 *et seq.* of the French Commercial Code,

1. **Delegates** to the Board of Directors, with the right to subdelegate under the conditions provided by French law, the authority to proceed with, one or more issuances, in the amount and at the times it deems appropriate, in France and/or abroad, in euros or in any other currency or currency unit established by reference to several currencies, without shareholders' preemptive subscription rights, for the benefit of certain specific categories of beneficiaries, of ordinary shares of the Company and/or securities giving access, immediately and/or in the future, to ordinary shares to be issued by the Company, which may be subscribed for either in cash or by offsetting against claims.
2. **Decides** that the maximum nominal amount of the share capital increases that may be performed, immediately or in the future, pursuant to this resolution shall not exceed two million euros (EUR 2,000,000), it being specified that this cap will count towards the ceiling stipulated in paragraph 2 of the 23rd resolution of this General Meeting, and towards the overall cap of two million euros (EUR 2,000,000) stipulated in paragraph 3 of the 22nd resolution of this General Meeting. Added to those caps will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company.
3. **Decides** that securities giving access to ordinary shares to be issued by the Company may consist of debt securities or be associated with the issuance of such securities, or allow their issue as intermediated securities and that the debt securities issued pursuant to this resolution may take the form of subordinated or non-subordinated securities, for a fixed or indefinite term, and be issued, in France and/or abroad, in euros, or in any other currency or currency units established by reference to several currencies.

The maximum nominal amount of debt securities that may be issued pursuant to this resolution shall not exceed five hundred million euros (EUR 500,000,000) or the counter-value of this amount in another currency or in any currency units established by reference to several currencies, it being specified that this cap cannot exceed the overall cap stipulated in paragraph 4 of the 22nd resolution of this General Meeting.

4. **Decides** to waive the shareholders' preemptive subscription right to ordinary shares and securities that can be issued pursuant to this resolution, and to reserve the ordinary shares and securities to be issued pursuant to this resolution for certain specific categories of beneficiaries presenting any of the following characteristics:
 - i. natural or legal persons (including companies) trusts or investment funds, or other investment vehicles, in any form, established under French or foreign law, which regularly invest in the pharmaceutical, biotechnological or medical technology sectors; and/or
 - ii. companies, institutions or entities, in any form, French or foreign, exercising a significant part of its activities in the pharmaceutical, cosmetic or chemical sectors, or medical devices and/or technologies, or researching in such sectors; and/or
 - iii. French or foreign investment services companies, or any foreign establishment having an equivalent status, able to guarantee the completion of an issue intended to be placed with the persons referred to in (i) and/or (ii) above, and, in this context, to subscribe to the securities that are being issued.
5. **Decides** that the Board of Directors, with the right to subdelegate under the conditions provided by French law, will have full authority to implement this resolution, and in particular to determine the list of beneficiaries in accordance with the aforementioned categories of beneficiaries who will benefit from such capital increases and/or issuances of securities, as well as the number of securities to be allocated to each beneficiary.
6. **Decides** that if subscriptions by shareholders do not absorb the entire issuance of ordinary shares or securities giving access to the share capital of the Company pursuant to this resolution, the Board of Directors may limit the issuance to the amount of subscriptions received, provided that this amount reaches at least three-quarters of the issuance decided upon.
7. **Acknowledges** that this resolution includes the waiver of the shareholders' preemptive subscription rights to ordinary shares of the Company to which any securities issued pursuant to this resolution may entitle them.
8. **Decides** that the issuance price of the ordinary shares and securities to be issued pursuant to this resolution will be determined by the Board of Directors, with the right to subdelegate under the conditions provided by French law, pursuant to Articles L. 225-138 II of the French Commercial Code, and will at least be equal:
 - (i) for the ordinary shares, either to:

- the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris for the last trading session preceding the pricing;
- the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris on a period comprising between three (3) and seven (7) consecutive trading days, chosen from the thirty (30) trading days preceding the pricing date;
- the last closing price of the share of the Company on the regulated market of Euronext Paris preceding the pricing date;

which may be reduced by maximum discount of 15%, the Board of Directors may freely choose any of the three formulas set forth above, and

- (ii) (a) the issuance price of shares that may result from the exercise, conversion, exchange or redemption of securities giving access to the Company's capital issued under this authorization may be determined, at the discretion of the Board of Directors, by reference to a calculation formula defined by the Board of Directors and applicable after the issue of said securities (for example, on exercise, conversion, redemption or exchange), in which case the maximum discount referred to above may be determined, if the Board of Directors sees fit, on the date of application of said formula (and not on the date of the decision to issue the securities), and (b) the issuance price of the securities to be issued under this resolution, other than shares, will be such that the amount immediately received by the Company plus, where applicable, any amount that may subsequently be received by the Company, for each share issued as a result of the issue of such securities, is at least equal to the amount referred to in paragraph (i) above.

9. Decides that the Board of Directors will have full authority, with the right to subdelegate under the conditions provided by French law, to implement this resolution, and in particular to:

- determine the characteristics, amount and terms and conditions of any issue and of the securities issued, in particular, the category of the securities issued, and will set, in the light of the information contained in its report, their subscription price, with or without premium, the terms and conditions for their payment in full (which may be achieved through cash settlement and/or offsetting liquid and due receivables or partly in cash and partly by incorporating reserves, earnings or premiums), the date of their entitlement to dividends, which may be retroactive, the terms and conditions under which the securities issued pursuant to this resolution could give access to ordinary shares to be issued, the conditions under which such securities could also give entitlement to existing shares or debt securities of the Company, the conditions of their redemption or possible cancellation as well as the possibility of suspending the exercise of the allotment rights attached to the securities to be issued;
- determine when the securities issued will consist of or be associated with debt securities, their fixed or indefinite term, their subordinated or non-subordinated form, and their interest rate;
- take all necessary measures to preserve the rights of the holders of securities or other rights giving access to the share capital of the Company, in accordance with applicable laws and regulations and, as the case may be, other contractual provisions that provide for other cases of adjustment;
- charge, as the case may be, the fees and expenses related to the share capital increases against the related premiums, and, if it deems it appropriate, deduct from this amount the sums necessary to increase the legal reserve to one-tenth of the new total share capital resulting from each issuance;
- enter into any agreement, in particular to ensure the completion and proper execution, in the amount and on the dates it deems appropriate, in France and/or abroad, of the contemplated issuances, as well as defer them, where appropriate;
- have shares, securities to be issued or securities issued through the exercise of securities giving access to shares to be issued, admitted to trading on a regulated market or any financial market located outside the European Economic Area; and
- record the completion of the capital increases performed in accordance with this resolution, amend accordingly the by-laws and perform any and all formalities and statements, and call for any authorizations that may be necessary to perform and complete these issues successfully.

10. Decides that the aforementioned delegation is granted for a period of eighteen (18) months as from the date of this General Meeting and terminates, with immediate effect, any previous delegation granted for the same purpose. It therefore supersedes, if any, for the remaining period and unused amounts, the delegation granted by the Combined General Meeting in its 27th resolution.

The Board of Directors will prepare a report for the next ordinary general meeting of the final terms of the operations performed in accordance with this resolution.

TWENTY-SIXTH RESOLUTION (*Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in favor of one or more persons specifically designated by the Board of Directors, without shareholders' preemptive subscription rights*)

The General Meeting, voting under the rules of quorum and majority required for extraordinary general meetings having reviewed the management report of the Board of Directors and the special report of the Statutory Auditors and duly noting that the share capital has been fully paid up, and acting pursuant to Articles L. 225-129 *et seq.* of the French Commercial Code, and in particular Articles L. 225-129-2, L. 225-138, L. 22-10-49, L. 22-10-52-1 and Articles L. 228-91 *et seq.* of the French Commercial Code,

- 1. Delegates** to the Board of Directors, with the right to subdelegate under the conditions provided by French law, the powers to proceed with, one or more issuances, in the amount and at the times it deems appropriate, in France and/or abroad, in euros or in any other currency or currency unit established by reference to several currencies, without shareholders' preemptive subscription rights, for the benefit of certain specific categories of beneficiaries, of ordinary shares of the Company and/or securities giving access, immediately and/or in the future, to ordinary shares to be issued by the Company, which may be subscribed for either in cash or by offsetting against claims.
- 2. Decides** that the maximum nominal amount of the share capital increases that may be performed, immediately or in the future, pursuant to this resolution shall not exceed one million euros (EUR 1,000,000), it being specified that this cap will count towards the ceiling stipulated in paragraph 2 of the 23rd resolution of this General Meeting, and towards the overall cap of two million euros (EUR 2,000,000) stipulated in paragraph 3 of the 22nd resolution of this General Meeting. Added to those caps will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company. It is specified that, in any event, the total nominal amount of the capital increases that may be carried out under this delegation may not exceed the limit set by the legal and regulatory provisions applicable at the time of issue (i.e., for information purposes, as at the date of this General Meeting, 30% of the share capital per year as assessed on the date of implementation of the delegation by the Board of Directors in accordance with the provisions of Article L. 225-138 and Article L. 22-10-52-1 of the French Commercial Code).
- 3. Decides** that securities giving access to ordinary shares to be issued by the Company may consist of debt securities or be associated with the issuance of such securities, or allow their issue as intermediated securities and that the debt securities issued pursuant to this resolution may take the form of subordinated or non-subordinated securities, for a fixed or indefinite term, and be issued, in France and/or abroad, in euros, or in any other currency or currency units established by reference to several currencies.

The maximum nominal amount of debt securities that may be issued pursuant to this resolution shall not exceed five hundred million euros (EUR 500,000,000) or the counter-value of this amount in another currency or in any currency units established by reference to several currencies, it being specified that this cap cannot exceed the overall cap stipulated in paragraph 4 of the 22nd resolution of this General Meeting.

- 4. Decides** to waive the shareholders' preemptive subscription right to ordinary shares and securities that can be issued pursuant to this resolution, and to reserve the ordinary shares and securities to be issued pursuant to this resolution for one or more namely designated persons and to delegate to the Board of Directors the designation of such person(s).
- 5. Decides** that if the subscriptions do not absorb the entire issuance of shares or securities pursuant to this resolution, the Board of Directors may limit the amount of the issuance to the amount of subscriptions received, provided that such amount reaches at least three-quarters of the issuance decided.
- 6. Acknowledges** that this resolution includes the waiver of the shareholders' preemptive subscription rights to ordinary shares of the Company to which any securities issued pursuant to this resolution may entitle them.

7. **Decides**, in accordance with the provisions of Articles L. 22-10-52-1 and R. 22-10-32 of the French Commercial Code, the issuance price of the securities issued pursuant to this resolution will be set by the Board of Directors, in accordance with conditions provided for in applicable regulations on the date this delegation is used and shall be at least equal to the minimum provided for in applicable legal and regulatory provisions on the date this delegation is used (i.e., to date, an issue price at least equal to the last closing price of the last trading session preceding the decision of the Board of Directors to use this delegation, less a maximum discount of 10%).
8. **Decides** that that the Board of Directors will have full authority, with the right to subdelegate under the conditions provided by French law, to implement this resolution, and in particular to:
- determine the characteristics, amount and terms and conditions of any issue and of the securities issued, in particular, the category of the securities issued, and will set, in the light of the information contained in its report, their subscription price, with or without premium, the terms and conditions for their payment in full (which may be achieved through cash settlement and/or offsetting liquid and due receivables or partly in cash and partly by incorporating reserves, earnings or premiums), the date of their entitlement to dividends, which may be retroactive, the terms and conditions under which the securities issued pursuant to this resolution could give access to ordinary shares to be issued, the conditions under which such securities could also give entitlement to existing shares or debt securities of the Company, the conditions of their redemption or possible cancellation as well as the possibility of suspending the exercise of the allotment rights attached to the securities to be issued;
 - designate the person or persons for whom the issue is reserved;
 - determine the number of shares to be allotted to each beneficiary;
 - determine when the securities issued will consist of or be associated with debt securities, their fixed or indefinite term, their subordinated or non-subordinated form, and their interest rate;
 - take all necessary measures to preserve the rights of the holders of securities or other rights giving access to the share capital of the Company, in accordance with applicable laws and regulations and, as the case may be, other contractual provisions that provide for other cases of adjustment;
 - charge, as the case may be, the fees and expenses related to the share capital increases against the related premiums, and, if it deems it appropriate, deduct from this amount the sums necessary to increase the legal reserve to one-tenth of the new total share capital resulting from each issuance;
 - enter into any agreement, in particular to ensure the completion and proper execution, in the amount and on the dates it deems appropriate, in France and/or abroad, of the contemplated issuances, as well as defer them, where appropriate;
 - record the completion of the capital increases performed in accordance with this resolution, amend accordingly the by-laws and perform any and all formalities and statements, and call for any authorizations that may be necessary to perform and complete these issues successfully.
9. **Decides** that the aforementioned delegation is granted for a period of eighteen (18) months as from the date of this General Meeting. It therefore supersedes, if any, for the remaining period and unused amounts, the delegation granted by the Combined General Meeting in its 28th resolution

The Board of Directors will prepare a report for the next ordinary general meeting of the final terms of the operations performed in accordance with this resolution.

TWENTY- SEVENTH RESOLUTION (*Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares, immediately or in the future, reserved for certain specific categories of beneficiaries meeting specific characteristics within the framework of an equity financing agreement on the U.S. market called "At-the-market" or "ATM", without shareholders' preemptive subscription rights*)

The General Meeting, voting under the rules of quorum and majority required for extraordinary general meetings, having reviewed the management report of the Board of Directors and the special report of the Statutory Auditors and acting pursuant to Articles L. 225-129 *et seq.* of the French Commercial Code, and in particular Articles L. 225-129-2, L. 225-135, L. 225-138 and L. 228-91 *et seq.* of the French Commercial Code, and Article L. 22-10-49 of the French Commercial Code,

1. **Delegates** to the Board of Directors, with the right to subdelegate under the conditions provided by French law, the authority to proceed with, one or more issuances, in the amount and at the times it deems appropriate, in France and/or abroad, in euros or in any other currency or currency unit established by reference to several currencies, without shareholders' preemptive subscription rights, of ordinary shares in the form of American Depositary Shares or American Depositary Receipts of the Company, which may be subscribed for either in cash or by offsetting against claims.
2. **Decides** that the maximum total nominal amount of the share capital increases that may be performed, pursuant to this delegation shall not exceed one million euros (EUR 1,000,000), it being specified, on the one hand that this cap is common to the ceiling stipulated in paragraph 2 of the 23rd resolution of this General Meeting and is to be deducted from the latter, and on the other hand, that the maximal nominal amount of the capital increases that may result from this resolution is to be deducted from the overall ceiling of two million euros (EUR 2,000,000) stipulated in paragraph 3 of the 22nd resolution of this General Meeting. Added to those caps will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company.
3. **Decides** to waive the shareholders' preemptive subscription rights to shares that can be issued pursuant to this resolution, and to reserve the shares to be issued pursuant to this resolution for specific category of beneficiaries as follows:
 - French or foreign credit institution or investment services companies, or any foreign establishment having an equivalent status, intervening within the framework of an ATM program set up by the Company (or any equity financing program of the same nature that may be substituted for it) and providing, within this framework, for the subscription of securities issued by the Company.
4. **Decides** that the Board of Directors, with the right to subdelegate under the conditions provided by French law, shall determine the precise list of beneficiaries of this or these reserved capital increase(s) within this category of persons and the number of securities to be allocated to each beneficiary.
5. **Decides** that if subscriptions by shareholders do not absorb the entire issuance of shares pursuant to this resolution, the Board of Directors may limit the issuance to the amount of subscriptions received, provided that this amount reaches at least three-quarters of the issuance decided upon.
6. **Decides** that the issuance price of the ordinary shares to be issued pursuant to this resolution will be determined by the Board of Directors, with the right to subdelegate under the conditions provided by French law, pursuant to Articles L. 225-138 II of the French Commercial Code, and will at least be equal either to:
 - the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris for the last trading session preceding the pricing;
 - the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris on a period comprising between three (3) and seven (7) consecutive trading days, chosen from the thirty (30) trading days preceding the pricing date;
 - the last closing price of the share of the Company on the regulated market of Euronext Paris preceding the pricing date;which may be reduced by maximum discount of 15%, the Board of Directors may freely choose any of the three formulas set forth above, and
7. **Decides** that the Board of Directors will have full authority, with the right to subdelegate under the conditions provided by French law, to implement this resolution, and in particular to:
 - determine the characteristics, amount and terms of any issue and of the securities issued, in particular, the category of the securities issued, and will set, in the light of the information contained in its report, their subscription price, with or without premium, the terms for their payment in full (which may be achieved through cash settlement and/or offsetting liquid and due receivables or partly in cash and partly by incorporating reserves, earnings or premiums), the date of their entitlement to dividends, which may be retroactive;
 - charge, as the case may be, the fees related to the share capital increases against the related premiums,

and, if it deems it appropriate, deduct from this amount the sums necessary to increase the legal reserve to one-tenth of the new total share capital resulting from each issuance;

- enter into any agreement, in particular to ensure the completion execution, in order to carry out the aforementioned issues on one or more occasions, in the amount and on the dates it deems appropriate, in France and/or where applicable abroad, of the contemplated issuances, as well as defer them, where appropriate;
- proceed, as the case may be, giving access to ordinary shares admitted to trading on a regulated market and/or any financial market located outside the European Economic Area; and
- record the completion of the capital increases performed in accordance with this resolution, amend accordingly the by-laws and perform any and all formalities and statements, and call for any authorizations that may be necessary to perform and complete these issues successfully.

8. Decides that the aforementioned delegation is granted for a period of eighteen (18) months as from the date of this General Meeting and supersedes, with immediate effect, any previous authorization for the same purpose. It therefore supersedes, if any, for the remaining period and unused amounts, the delegation granted by the Combined General Meeting in its 29th resolution.

The Board of Directors will prepare a report for the next ordinary general meeting of the final terms of the operations performed in accordance with this resolution.

TWENTY-EIGHTH RESOLUTION (*Delegation of authority to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders' preemptive subscription rights*)

The General Shareholders' Meeting, voting under the rules of quorum and majority required for Extraordinary General Shareholders' Meetings, having reviewed the management report of the Board of Directors and the special report of the Statutory Auditors, and acting pursuant to the provisions of Articles L. 225-135-1 and R. 225-118 of the French Commercial Code,

- 1. Delegates** to the Board of Directors, with the right to subdelegate under the conditions provided by French law, the authority to decide, within thirty (30) days following the closing of the subscription, up to a maximum of fifteen percent (15%) of the initial issuance and at the same price as the initial issuance), for each issuance decided pursuant to resolutions 22 to 27 of this General Meeting, to increase the number of shares to be issued as part of share capital increases within the ceiling provided for in the resolution pursuant to which the issue is decided upon.
- 2. Decides** that the aforementioned delegation is granted for a period of twenty-six (26) months as from the date of this General Meeting (except for resolutions 25 to 27 of this General Meeting, for which this delegation is valid for an 18-months period) and terminates, with immediate effect, any previous delegation granted for the same purpose. It therefore supersedes, if any, for the remaining period and unused amounts, the delegation granted by the Combined General Meeting in its 30th resolution.

The Board of Directors will inform the general meeting of shareholders each year of the final terms of the transactions performed in accordance with this resolution.

TWENTY-NINTH RESOLUTION (*Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares and securities giving access to the share capital of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company*)

The General Meeting, voting under the rules of quorum and majority required for extraordinary general meetings, having reviewed the management report of the Board of Directors and the special report of the Statutory Auditors, duly noting that the share capital has been fully paid up, and acting pursuant to the provisions of Articles L. 225-129 *et seq.* of the French Commercial Code, in particular Articles L. 225-129-2, L. 22-10-54, and L. 228-91 *et seq.* of the French Commercial Code,

- 1. Delegates** to the Board of Directors, with the right to subdelegate under the conditions provided by French law, the authority to proceed with, one or more issuances, in France and/or abroad, in euros or in any other currency

or currency units established by reference to several currencies, of ordinary shares of the Company and/or securities giving access, immediately and/or in the future, to ordinary shares to be issued by the Company, in consideration for the securities contributed to a public exchange offer including an exchange component (on a principal or subsidiary basis) initiated by the Company, in France and/or abroad, in accordance with local regulations on the securities of a company whose shares are admitted to trading on one of the regulated markets listed in Article L. 22-10-54 of the French Commercial Code.

2. **Decides**, as necessary, to the benefit of these securities' holders, to waive shareholders' preemptive subscription rights over ordinary shares and/or securities to be issued.
3. **Decides** that the maximum nominal amount of the share capital increases that may be performed pursuant to this resolution shall not exceed one million euros (EUR 1,000,000), it being specified that this cap will count towards the cap stipulated in paragraph 2 of the 23rd resolution of this General Meeting and towards the overall cap of two million euros (EUR 2,000,000) stipulated in paragraph 3 the 22nd resolution of this General Meeting. Added to those caps will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company.
4. **Decides** that securities giving access, immediately or in the future, to ordinary shares to be issued by the Company may notably consist of debt securities or be associated with the issuance of such securities, or allow their issuance as intermediate securities, and that the debt securities issued pursuant to this resolution may take the form of subordinated or non-subordinated securities with a fixed or indefinite term and be issued, in France and/or abroad, in euros, or in any other currency or currency units established by reference to several currencies.

The maximum nominal amount of debt securities that may be issued pursuant to this resolution shall not exceed five hundred million euros (EUR 500,000,000) or the counter-value of this amount in another currency or in any currency units established by reference to several currencies, it being specified that this cap cannot exceed the overall cap stipulated in paragraph 4 of the 22nd resolution of this General Meeting. This cap is independent from the debt securities whose issue would be decided on or authorized by the Board of Directors in accordance with Article L. 228-40 of the French Commercial Code.

5. **Acknowledges** that this resolution includes the waiver of the shareholders' preemptive subscription rights over ordinary shares of the Company to which any securities issued pursuant to this resolution may entitle them.
6. **Decides** that the Board of Directors will have full authority, with the right to subdelegate under the conditions provided by French law, to implement this resolution, and in particular to:
 - set the exchange ratio as well as, were applicable, the amount of the balance in cash to be paid;
 - determine the terms and conditions of the securities that may be issued pursuant to this resolution;
 - record the number of securities contributed to the exchange;
 - determine the dates, terms and conditions of the issuance, and in particular the price and the date of their entitlement to dividends, which may be retroactive, of the new ordinary shares or securities giving access, immediately and/or in the future, to the share capital of the Company and as the case may be amend the terms and conditions of the securities issued pursuant to this resolution during the duration of the relevant securities and in accordance with the applicable laws and regulations;
 - take all necessary measures to preserve the rights of the holders of securities or other rights giving access to the share capital of the Company, in accordance with applicable laws and regulations and, as the case may be, other contractual provisions that provide for other cases of adjustment;
 - record among the liabilities the contribution share premium, relating to the rights of the shareholders, the difference between the issuance price and of the new shares and their nominal value;
 - charge, as the case may be, the fees and expenses related to the share capital increases against the related premiums, and, if it deems it appropriate, deduct from this amount the sums necessary to increase the legal reserve to one-tenth of the new total share capital resulting from each issuance;
 - have shares, securities to be issued or securities issued through the exercise of securities giving access to shares to be issued, admitted to trading on a regulated market for ordinary shares or on any other financial market located outside the European Economic Area;
 - take all necessary steps and enter into any agreements to successfully complete the authorized transaction,

record the resulting increase(s), and amend the by-laws; and

- record the completion of the capital increases performed pursuant to this resolution, amend accordingly the by-laws and, perform any and all formalities and statements, and call for any authorizations that may be necessary to perform and complete these issuances successfully.

7. **Decides** that the aforementioned delegation is granted for a period of twenty-six (26) months as from the date of this General Meeting and terminates, with immediate effect, any previous delegation granted for the same purpose. It therefore supersedes, if any, for the remaining period and unused amounts, the delegation granted by the Combined General Meeting in its 31st resolution.

The Board of Directors may, within the limits it has previously set, subdelegate the power granted to it under this resolution.

The Board of Directors will inform the general meeting of shareholders each year of the final terms of the transactions performed in accordance with this resolution.

THIRTIETH RESOLUTION (*Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in consideration for contributions in kind within the limits set by legal and regulatory provisions, excluding the case of a public exchange offer initiated by the Company*)

The General Meeting, voting under the rules of quorum and majority required for extraordinary general meetings, having reviewed the management report of the Board of Directors and the special report of the Statutory Auditors, duly noting that the share capital has been fully paid up, and acting pursuant to the provisions of Articles L. 225-129 *et seq.* of the French Commercial Code, in particular Articles L. 225-129-2, L. 22-10-53, and L. 228-91 *et seq.* of the French Commercial Code,

1. **Delegates** to the Board of Directors, with the right to subdelegate under the conditions provided by French law, the authority to proceed, on the basis of the report of the Statutory Auditors, with, one or more issuances, in France and/or abroad, in euros or in any other currency or currency units established by reference to several currencies, of ordinary shares of the Company and/or securities giving access, immediately and/or in the future, to ordinary shares to be issued by the Company, in order to remunerate contributions in kind granted to the Company and consisting of equity securities or securities giving access to the share capital, when the provisions of Article L. 22-10-54 of the French Commercial Code are not applicable.
2. **Decides** that the maximum nominal amount of the share capital increases that may be performed pursuant to this resolution shall not exceed the limit set by the laws and regulations in force at the time this authorization is used (currently 20% of the share capital of the Company at the date of the transaction), it being specified that this cap will count towards the ceiling set out in paragraph 2 of the 23rd resolution of this General Meeting and towards the overall cap of two million euros (EUR 2,000,000) stipulated in paragraph 3 of the 22nd resolution of this General Meeting. Added to those caps will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company.
3. **Decides** that securities giving access, immediately or in the future, to ordinary shares to be issued by the Company may notably consist of debt securities or be associated with the issuance of such securities, or allow their issuance as intermediate securities, and that the debt securities issued pursuant to this resolution may take the form of subordinated or non-subordinated securities with a fixed or indefinite term and be issued, in France and/or abroad, in euros, or in any other currency or currency units established by reference to several currencies.

The maximum nominal amount of debt securities that may be issued pursuant to this resolution shall not exceed five hundred million euros (EUR 500,000,000) or the counter-value of this amount in another currency or in any currency units established by reference to several currencies, it being specified that this cap cannot exceed the overall cap stipulated in paragraph 4 of the 22nd resolution of this General Meeting. This cap is independent from the debt securities whose issuance would be decided on or authorized by the Board of Directors in accordance with Article L. 228-40 of the French Commercial Code.

4. **Acknowledges** that this resolution includes the waiver of the shareholders' preemptive subscription rights over ordinary shares of the Company to which any securities issued pursuant to this resolution may entitle them.

5. Decides that the Board of Directors will have full authority, with the right to subdelegate under the conditions provided by French law, to implement this resolution, and in particular to:

- decide, pursuant to the special report of the Statutory Auditors, referred to in the 1st and 2nd paragraphs of Article L. 22-10-53 of the French Commercial Code, on the valuation of the contributions and the granting of any special benefits;
- draw up a list of the shares or the securities brought to the exchange, set the exchange parity and, as the case may be, the amount of the cash balance to be paid;
- determine the dates, terms and conditions of the issuance, and in particular the price and the date of their entitlement to dividends, which may be retroactive, of the new ordinary shares or securities giving access, immediately and/or in the future, to the share capital of the Company;
- charge, as the case may be, the fees and expenses related to the share capital increases against the related premiums, and, if it deems it appropriate, deduct from this amount the sums necessary to increase the legal reserve to one-tenth of the new total share capital resulting from each issuance;
- take all necessary measures to preserve the rights of the holders of securities or other rights giving access to the share capital of the Company, in accordance with applicable laws and regulations and, as the case may be, contractual provisions that provide for other cases of adjustment;
- have shares, securities to be issued or securities issued through the exercise of securities giving access to shares to be issued, admitted to trading on a regulated market for ordinary shares or on any other financial market located outside the European Economic Area; and
- record the completion of the share capital increases performed pursuant to this resolution, amend accordingly the by-laws and, perform any and all formalities and statements, and call for any authorizations that may be necessary to perform and complete these issuances successfully.

6. Decides that the aforementioned delegation is granted for a period of twenty-six (26) months as from the date of this General Meeting and terminates, with immediate effect, any previous delegation granted for the same purpose. It therefore supersedes, if any, for the remaining period and unused amounts, the delegation granted by the Combined General Meeting in its 32nd resolution.

The Board of Directors may, within the limits it has previously set, subdelegate the power granted to it under this resolution.

The Board of Directors will inform the general meeting of shareholders each year of the final terms of the transactions performed in accordance with this resolution.

THIRTY-FIRST RESOLUTION (*Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, by the Company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French Code de travail, without shareholders' preferential subscription rights*)

The General Meeting, voting under the rules of quorum and majority required for extraordinary meetings, and having reviewed the management report of the Board of Directors and the special report of the Statutory Auditors prepared in accordance with applicable laws and pursuant to the provisions of Articles L. 225-129 *et seq.* of the French Commercial Code, Articles L. 225-129-2, L. 225- 129-6, L. 225-138 I of the French Commercial Code, and Article L.3332-18 *et seq.* of the French *Code du Travail*.

1. Delegates to the Board of Directors, with the right to subdelegate under the conditions provided by French law, the authority to proceed with, one or more issuances, in the amount and at the times it deems appropriate, on its own initiative, of ordinary shares of the Company and/or securities giving access immediately and/or in the future, to ordinary shares to be issued by the Company, reserved for employees of the Company and its affiliates pursuant to Article L. 225-180 of the French Commercial Code, who are members of a company savings plan, to be instituted at the initiative of the Company and/or any mutual funds through the intermediary from which the new shares thus issued would be subscribed by them.

2. Decides that the maximum nominal amount of the share capital increases that may be performed, immediately

or in the future, pursuant to this resolution shall not exceed four thousand three hundred euros (EUR 4,300), it being specified that this cap will count towards the overall cap of two million euros (EUR 2,000,000) stipulated in paragraph 3 the 22nd resolution of this General Meeting. Added to those caps will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company.

3. **Decides** to waive shareholders' preemptive rights to ordinary shares of the Company and/or securities to be issued, where applicable freely granted, pursuant to this resolution which includes the waiver of the shareholders' preemptive subscription rights to the ordinary shares of the Company to which the securities that would be issued pursuant to this resolution entitle them.
4. **Acknowledges** that this resolution includes the waiver of the shareholders' preemptive subscription rights over ordinary shares of the Company shares to which any securities issued pursuant to this resolution may entitle them.
5. **Decides** that the issuance price for new shares or securities to be issued pursuant to this resolution shall be set in accordance with Article L. 3332-19 of the French *Code du travail*, and decide to set the maximum discount at 20%. However, this General Meeting expressly authorizes the Board of Directors to reduce this discount or not to grant it, in particular in accordance with the regulations applicable in the countries where the new shares or securities to be issued will be offered.
6. **Decides**, pursuant to the provisions of Article L.3332-21 of the French *Code du travail*, that the Board of Directors may freely grant to the beneficiaries, as defined above, newly issued shares or shares to be issued or other securities giving access to the Company's share capital to be issued or already issued in respect of (i) the contribution that may be paid pursuant to the regulations governing company savings plans, and/or (ii) where applicable, the discount.
7. **Decides** that, in the event that the beneficiaries as defined above have not subscribed to the entire share capital increase within the time limit allotted, the share capital increase would only be performed for the amount of the shares subscribed, and that the unsubscribed shares may be offered again to the said beneficiaries within the scope of a subsequent capital increase.
8. **Decides** that the Board of Directors will have full authority, within the limits and conditions specified above, to determine the terms and conditions of share capital increases, defer them, and in particular to:
 - establish a savings plan, in accordance with Articles L. 3332-1 et seq. of the French Code du travail;
 - decide that the issuances may be performed directly to the advantage of the beneficiaries or through collective securities investment funds (UCITS);
 - determine the terms and conditions of the issuances, to be made pursuant to this resolution and in particular dividend rights, the terms and conditions for paying up, the subscription price of ordinary shares or securities giving access to the capital under the legal conditions;
 - determine the opening and closing dates of subscriptions;
 - set the timeframe allotted to subscribers for the payment of their ordinary shares or securities giving access to the share capital of the Company;
 - take all due measures to preserve the rights of the holders of securities or other rights giving access to the share capital of the Company, in accordance with applicable laws and regulations and, as the case may be, other contractual provisions that provide for other cases of adjustment;
 - record the completion of the share capital increases performed pursuant to this resolution and amend the by-laws accordingly, perform any and all formalities and statements, and call for any authorizations;
 - charge, as the case may be, the fees and expenses related to the share capital increases against the related premiums, and, if it deems it appropriate, deduct from this amount the sums necessary to increase the legal reserve to one-tenth of the new total share capital resulting from each issuance;
 - have shares, securities to be issued or shares to be issued by the exercise of the right attached to the securities giving access to the share capital, admitted to trading on a regulated market or any other financial market located outside the European Economic Area; and
 - perform any and all formalities and statements, and call for any authorizations that may be necessary to

perform and complete these issuances successfully.

- 9. Decides** that the aforementioned delegation is granted for a period of twenty-six (26) months as from the date of this General Meeting and terminates, with immediate effect, any previous delegation granted for the same purpose.

THIRTY-SECOND RESOLUTION (Delegation of authority to the Board of Directors to increase the share capital of the Company by incorporating reserves, profits or premiums)

The General Meeting, voting under the rules of quorum and majority required for extraordinary general meetings, having reviewed the management report of the Board of Directors and in accordance with the provisions of Articles L. 225-129-2 and L. 22-10-50, of the French Commercial Code,

- 1. Delegates** to the Board of Directors, with the right to subdelegate under the conditions provided by French law, the authority to proceed with, one or more issuances, in the amount and at the times it deems appropriate, by incorporation, successive or simultaneous, into the share capital of reserves, profits, premiums or any other sums whose capitalization may be allowed, to be realized by increasing the par value of existing ordinary share and/or by granting new ordinary shares free of charge.
- 2. Decides** that the maximum nominal amount of the share capital increases that may be performed, immediately or in the future, pursuant to this resolution shall not exceed forty thousand euros (EUR 40,000) it being specified that this cap is set independently and separately from the caps for share capital increases resulting from issuances of ordinary shares or securities authorized by the other resolutions submitted to this General Meeting and by the resolutions adopted, and still in force, at any previous general meeting of shareholders, and that added to those caps will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company.
- 3. Decides** that the Board of Directors will have full authority, with the right to subdelegate under the conditions provided by French law, to implement this resolution, and in particular to:
 - determine the amount and nature of the sums to be incorporated into the share capital of the Company;
 - determine the number of new ordinary shares to be issued and/or the amount by which the nominal value of the existing shares composing of the share capital will be increased;
 - determine the date of their entitlement to dividends, which may be retroactive, or from which the increase in the par value of existing equity securities will take effect;
 - decide, where applicable, that fractional rights will be neither negotiable nor transferable and that the corresponding shares will be sold, the sums resulting from the sale being allocated to the holders of the rights within the period provided for by the applicable regulations;
 - take all necessary measures to protect the rights of holders of securities or other rights giving access to the share capital of the Company, in accordance with applicable laws and regulations and, contractual provisions providing for other cases of adjustment;
 - charge, as the case may be, the fees and expenses related to the share capital increases against the related premiums, and, if it deems it appropriate, deduct from this amount the sums necessary to increase the legal reserve to one-tenth of the new total share capital resulting from each issuance;
 - have shares admitted to trading on a regulated market or any other financial market located outside the European Economic Area; and
 - record the completion of the capital increases performed pursuant to this resolution, amend accordingly the by-laws and, perform any and all formalities and statements, and call for any authorizations that may be necessary to perform and complete these issuances successfully.
- 4. Decides** that the aforementioned delegation is granted for a period of twenty-six (26) months as from the date of this General Meeting and terminates, with immediate effect, any previous delegation granted for the same purpose. It therefore supersedes, if any, for the remaining period and unused amounts, the delegation granted by the Combined General Meeting in its 34th resolution.

THIRTY-THIRD RESOLUTION (Authorization to the Board of Directors to grant free shares to employees)

and/or certain corporate officers)

The General Meeting, voting under the rules of quorum and majority required for extraordinary general meetings, having reviewed the management report of the Board of Directors and the special report of the Statutory Auditors, duly noting that the share capital has been fully paid up, and pursuant to in accordance with the provisions of Articles L. 225-197-1 and L. 225-197-2 of the French Commercial Code,

1. **Authorizes** the Board of Directors to proceed with, on one or more occasions, the allocation of free ordinary shares of the Company, existing or to be issued, to the benefit of:
 - employees of the Company or of companies directly or indirectly related to it, to the within the meaning of Article L.225-197-2 of the French Commercial Code, and/or
 - corporate officers who meet the conditions set out in Article L.225-197-1, II of the French Commercial Code,

the identity of which shall be determined by the Board of Directors in accordance with the allocation criteria and conditions defined by it, it being reminded (i) that no shares may be allocated to employees and corporate officers each holding more than 10% of the Company's share capital and (ii) that a free allocation may not have the effect of conferring on any employee or corporate officer more than 10% of the Company's share capital. Only Company shares held directly by an employee or corporate officer for less than seven years are included in this percentage.

2. **Decides** that the total number of free shares granted may not exceed (i) 8.1% of the share capital on the date of the decision of their grant by the Board of Directors, it being specified that the aggregate nominal amount of all capital increases that may be carried out pursuant to this resolution may not exceed (ii) a ceiling of 8.1% of the fully-diluted share capital as recorded on the date of this General Meeting (the ceiling referred to in (ii), the "**Common Ceiling**").
3. **Decides** that the Board of Directors shall have the power to adjust the number of free shares granted, within the limit of the aforementioned ceiling, in the event of transactions affecting the Company's share capital that may be carried out, in order to preserve the rights of the beneficiaries. In the event of an adjustment, the shares granted will be deemed to have been granted on the same day as the shares initially granted.
4. **Decides** that free shares granted to a given beneficiary by the Board of Directors which would not give rise to a definitive grant at the end of the Vesting Period (as defined below) may be the subject of a new grant and will then no longer be taken into account for the calculation of the ceiling defined above.
5. **Decides**, in accordance with the wording of Article L.225-197-1 of the French Commercial Code, that the granting of free shares to their beneficiaries will be definitive at the end of a vesting period, the duration of which will be set by the Board of Directors, but may not be less than one (1) year from the date of the Board of Director's decision to grant (the "**Vesting Period**"), which may be subject to a lock-up obligation for the shares that runs from the date of the definitive grant of the shares (the "**Retention Period**"), it being specified that the cumulative period of the Vesting Period and the Retention Period may not be less than two (2) years.

As an exception, the definitive grant will take place before the end of the Vesting Period in the event of the death of the beneficiary and in the event of disability of the beneficiary corresponding to the classification in the second and third of the categories provided in Article L.341-4 of the French *Code de la Sécurité Sociale*.

6. **Acknowledges** that this authorization automatically entails the waiver by the shareholders of their preferential subscription rights to the ordinary shares to be issued on the basis of this authorization.
7. **Decides** that the Board of Directors will have full authority, with the right to subdelegate under the conditions provided by French law, to implement this resolution, and in particular to:
 - set, in accordance with the legal conditions and limits, the dates on which the allocations will be made;
 - set the conditions and criteria for the allocation of free shares and, in particular, determine whether the free shares allocated are shares to be issued or existing shares, it being specified that the Board of Directors may defer its choice until the day before the end of the Vesting Period;

- in the event of the issuance of new shares, charge, if necessary, the sums required to pay up the said shares to reserves, profits or issue premiums, record the completion of the capital increases carried out pursuant to this authorization, make the corresponding amendments to the bylaws and accomplish all necessary acts and formalities;
 - determine, in accordance with these conditions and criteria, the identity of the beneficiaries of the bonus share allocation and the number of shares allocated to each of them, as well as the terms and conditions for the allocation of the shares, and in particular the duration of the Vesting Period and the Retention Period for the shares thus allocated within the following limits fixed;
 - subject, where applicable, the definitive acquisition of all or part of the shares, to the achievement of one or more of the following conditions of performance that it will determine, it being specified that the allocations to the benefit of the executives corporate officers may only act (i) under the conditions provided for in Article L.22-10-60 of the French Commercial Code, or (ii) under the conditions provided for in Article L.225-197-6 of the French (ii) subject to the fulfillment of performance conditions that the Board of Directors may set determine and in compliance with the conditions of Article L. 225-197-1 II of the French Commercial Code;
 - decide on the number of shares to be issued or existing shares;
 - adjust the number of free shares granted during the Vesting Period, if necessary, to take into account any transactions affecting the Company's share capital in order to preserve the rights of the beneficiaries under the terms and conditions that it may freely determine; and
 - record the completion of the capital increases up to the amount of shares that will actually be issued allocated free of charge to persons designated by the Board of Directors, amend the bylaws, deduct the sums necessary to increase the legal reserve to one-tenth of the new share capital after each increase, and to proceed with all formalities and declarations, to request any authorizations that may be necessary for the completion and successful completion of this issuance, enter into any agreement, in particular to reach the completion of the planned issues, take all measures and carry out all formalities necessary for the issuance, the listing and to the financial service of the securities issued pursuant to this delegation, as well as to the exercise of the rights which are attached to it, and generally do what is necessary.
- 8. Decides** that the aforementioned delegation is granted for a period of thirty-eight (38) months as from the date of this General Meeting and terminates, with immediate effect, any previous delegation granted for the same purpose. It therefore supersedes, if any, for the remaining period and unused amounts, the delegation granted by the general shareholders' meeting of December 11, 2024 in its 60th resolution.

THIRTY-FOURTH RESOLUTION (Authorization to the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies of the group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options)

The General Meeting, voting under the rules of quorum and majority required for extraordinary general meetings, having reviewed the management report of the Board of Directors and the special report of the Statutory Auditors, duly noting that the share capital has been fully paid up, and acting pursuant to the provisions of Article L. 225-177 and seq. of the French Commercial Code,

- 1. Authorizes** the Board of Directors to grant, on one or more occasions, share subscription or share purchase options to employees or corporate officers of the Company or French or foreign companies or groups related to it within the meaning of Article L.225-180 of the French Commercial Code, or certain categories of them.
- 2. Decides** that the total number of options that may be granted under this resolution may not entitle their holders to subscribe for or acquire a total number of new or existing shares representing more than 8.1% of the share capital on the date of the decision to grant them by the Board of Directors, it being specified that the nominal amount of all capital increases that may be carried out pursuant to this resolution shall be charged against the Common Ceiling set in point 2) of the thirty-third (33rd) resolution of this General Meeting.

3. **Resolves** that the shares that may be obtained by exercising the share purchase options granted under this resolution may be acquired by the Company, as the case may be, under the share buyback program covered by the 20th resolution of this General Meeting pursuant to Article L.22-10-62 of the French Commercial Code or any share buyback program previously or subsequently applicable.
4. **Acknowledges** that this resolution includes the waiver of the shareholders' preemptive subscription rights over ordinary shares of the Company shares to which any securities issued pursuant to this resolution may entitle them.
5. **Decides** that the exercise price of the options granted under this resolution will be set by the Board of Directors as follows:
 - the exercise price of the share subscription option shall not be less than 80% of the average purchase price of the Company's shares on Euronext Paris regulated market during the twenty (20) trading sessions preceding the day on which the options are granted,
 - in addition, the exercise price of the share purchase options shall not be less than 80% of the average purchase price of the shares held by the Company under the share buyback program authorized according to the 20th resolution of this General Meeting pursuant to Article L.22-10 62 of the French Commercial Code or any share buyback program previously or subsequently applicable.
6. **Decides** that the options granted must be exercised within a period of 10 years from the date of their grant by the Board of Directors.
7. **Decides** that the Board of Directors will have full authority, with the right to subdelegate under the conditions provided by French law, to implement this resolution, and in particular to:
 - set, in accordance with the legal conditions and limits, the dates on which the options will be granted;
 - determine the list of beneficiaries, the number of options granted to each of them and the terms and conditions for granting and exercising of the options;
 - set the conditions for exercising the options and, in particular, limit, restrict or prohibit (a) the exercise of the options (including, as the case may be, performance conditions to be met) or (b) the sale of the shares obtained by exercising the options, during certain periods or following certain events, and its decision may (i) relate to all or part of the options and (ii) concern all or part of the beneficiaries;
 - decide the conditions under which the price and/or the number of shares to be subscribed or acquired will be adjusted in the cases provided for by French law; and
 - more generally, enter into all agreements, draw up all documents, record capital increases following the exercise of the options, amend the bylaws accordingly if necessary, carry out all formalities and make all declarations to all authority and do all that would otherwise be necessary.
8. **Decides** that the aforementioned delegation is granted for a period of thirty-eight (38) months as from the date of this General Meeting and terminates, with immediate effect, any previous delegation granted for the same purpose. It therefore supersedes, if any, for the remaining period and unused amounts, the delegation granted by the general shareholders' meeting of December 11, 2024 in its 61st resolution.

The Board of Directors will inform the general meeting of shareholders each year of the operations carried out in the context of this resolution.

THIRTY-FIFTH RESOLUTION (*Delegation of authority to the Board of Directors to decide on the issuance of share subscription warrants, without shareholders' preemptive subscription rights, to the benefit of categories of persons*)

The General Meeting, voting under the rules of quorum and majority required for extraordinary general meetings, having reviewed the management report of the Board of Directors and the special report of the Statutory Auditors,

and in accordance with the provisions of Article L. 225-138, L. 225-129-2, L. 228-91 and seq. of the French Commercial Code,

1. **Delegates** to the Board of Directors its authority to issue, on one or more occasions, ordinary share subscription warrants (the "**2026 BSAs**"), without shareholders' preferential subscription right to the said 2026 BSAs, each 2026 BSAs giving the right to subscribe for one ordinary share of the Company with a par value of 0.01 euro.
2. **Decides** that the total number of 2026 BSAs granted under this resolution may not entitle their holders to subscribe for or acquire a total number of new or existing shares representing more than 8.1% of the share capital on the date of the decision of their grant by the Board of Directors, to which may, where applicable, be added the nominal amount of the shares to be issued in order to preserve the rights of the holders of the 2026 BSAs, should such preservation be required, it being specified that this limit shall be charged against the Common Ceiling as set out in point 2) of the thirty-third (33rd) resolution of this General Meeting.
3. **Decides** to cancel the shareholders' preferential subscription right to the 2026 BSAs and to reserve the subscription of the said 2026 BSAs in favor of natural or legal entities meeting one of the following:
 - executive employees or executive officers or members of the Company's management team who are not corporate officers, or
 - members of the Board of Directors (including members of any research committee or those serving as censor) in office on the date of grant of the warrants, who are not executive officers of the Company or one of its subsidiaries, or consultants, managers or partners of companies providing services to the Company that have entered into a consulting or service agreement with the Company in force at the time of use of this delegation by the Board of Directors, or
 - employees of the Company or a subsidiary of the Company,(together, the "**Beneficiaries**").
4. **Specifies** that pursuant to the provisions of Articles L.228-91 and L.225-132 of the French Commercial Code, this decision entails, in favor of the holders of 2026 BSAs, the waiver by the shareholders of their preferential subscription right to the ordinary shares to which the 2026 BSAs entitle them.
5. **Decides** that:
 - the 2026 BSAs will not be the subject of a request for admission to trading on any market. They will be transferable. They will be issued in registered form and will be registered in an account;
 - the 2026 BSAs must be exercised within the exercise period determined by the Board of Directors, which may not exceed ten (10) years from their issuance and those that have not been exercised at the end of this period will automatically become null and void;
 - the issue price of a 2026 BSA will be determined by the Board of Directors on the day of the issuance of the said 2026 BSA in the light of the report of an independent expert appointed by the Board of Directors, depending on the characteristics of the latter;
 - the issue price of the 2026 BSAs must be paid up in full at the time of subscription, by cash settlement or by offsetting against liquid and due receivables;
 - the issue price of one ordinary share to be subscribed for pursuant to the exercise of the 2026 BSAs shall be determined by the Board of Directors at the time of the grant of the 2026 BSAs and shall be equal to the volume-weighted average share price of the last twenty (20) trading days preceding the date of grant of the 2026 BSAs by the Board of Directors as long as the Company's shares are admitted to trading on the regulated market of Euronext Paris (the "**Exercise Price**"); and
 - the ordinary shares thus subscribed shall be fully paid up at the time of their subscription, either by cash payment or by offsetting against liquid and payable debts.

6. Decides that in the event that, as long as the 2026 BSAs have not been fully exercised, the Company will proceed with one of the transactions mentioned below:

- issue of securities with preferential subscription rights for shareholders; or
- capital increase by incorporation of reserves, profits or share premiums; or
- distribution of reserves in cash or securities,

the rights of the holders of the 2026 BSA would be reserved under the conditions provided for in Article L.228-98 of the French Commercial Code.

7. Authorizes the Company to modify its purpose, amortize its capital, modify the distribution of profits or distribute reserves in accordance with the provisions of Article L.228-98 of the French Commercial Code.

8. Authorizes the Company to require the holders of the 2026 BSAs to buy back or reimburse their rights as provided for in Article L.228-102 of the French Commercial Code.

9. Decides that the Board of Directors will have full authority, with the right to subdelegate under the conditions provided by French law, to implement this resolution, and in particular to:

- to establish the list of beneficiaries among the persons fulfilling the characteristics specified above and to set the number of 2026 BSAs allocated to each of them;
- issue and allocate the 2026 BSAs and set the subscription price, the exercise conditions and the final terms of the 2026 BSAs, in particular the exercise schedule and the cases of acceleration of the exercise conditions in accordance with the provisions of this resolution and within the limits set in this resolution;
- set the price of the ordinary share that may be subscribed for upon exercise of a 2026 BSAs under the aforementioned conditions;
- determine the dates and terms of the issuance of ordinary shares to be carried out pursuant to this delegation of authority in accordance with the legal and statutory requirements;
- receive the subscription to the said 2026 BSAs and record the completion of the definitive issuance of the 2026 BSAs under the conditions set out above and their allocation;
- record the number of ordinary shares issued following the exercise of the 2026 BSAs, carry out the formalities following the corresponding capital increases and make the corresponding amendments to the bylaws, and have the ordinary shares thus issued admitted to trading on Euronext Paris regulated market, as the case may be;
- to take all measures to ensure the protection of the holders of the 2026 BSAs in the event of a financial transaction concerning the Company, in accordance with the legal and regulatory provisions in force; and
- in general, to take any measure and carry out any formality useful to this issuance.

9. Decides that the aforementioned delegation is granted for a period of eighteen (18) months as from the date of this General Meeting and terminates, with immediate effect, any previous delegation granted for the same purpose. It therefore supersedes, if any, for the remaining period and unused amounts, the delegation granted by the general shareholders' meeting of December 11, 2024 in its 62nd resolution.

The Board of Directors will inform the general meeting of shareholders each year of the operations carried out in the context of this resolution.

THIRTY-SIXTH RESOLUTION (Decision to be taken in application of Article L. 225-248 of the French Commercial Code (shareholders' equity less than half the share capital))

The General Meeting, voting under the rules of quorum and majority required for extraordinary general shareholders' meetings, having reviewed the management report of the Board of Directors and in accordance with Article L. 225-248 of the French Commercial Code,

Acknowledges that the losses recorded in the Company's annual financial statements show that shareholders' equity is less than half the share capital, and that it is therefore incumbent on the Board to decide whether to dissolve the Company early,

Acknowledges that if dissolution is ruled out, the Company will have a period of time, in accordance with the provisions of Article L 225-248 paragraph 2 of the French Commercial Code, expiring at the latest at the close of the second financial year following that in which the losses were recognized, to regularize the situation, in accordance with the conditions laid down by the legal and regulatory provisions in force,

Resolves, in view of the foregoing, not to dissolve the Company early and to continue its operations,

Acknowledges that this decision will be subject to the publicity measures provided for by the legal and regulatory provisions in force, and that the Company will be required to reconstitute its shareholders' equity within the aforementioned timeframe.

THIRTY-SEVENTH RESOLUTION *(Harmonization of the articles of association of the Company with applicable laws and regulations, resulting from the French Decree no. 2026-94 of February 13, 2026 relating to the modernization of communication means with their shareholders of some commercial companies)*

The General Meeting, voting under the rules of quorum and majority required for extraordinary general shareholders' meetings, having reviewed the management report of the Board of Directors,

Decides to harmonize the articles of association of the Company with legal and regulatory provisions resulting from the French Decree no. 2026-94 of February 13, 2026 relating to the modernization of communication means with their shareholders of some commercial companies,

Decides to amend article 26 (*Convening of general meetings*) of the articles of associations as follows:

Curent version	New version
[...] If the Board of Directors decides, at the time the General Meeting is called, to allow proxy forms to be submitted electronically, the electronic signature on such forms may be generated by a reliable shareholder identification process that ensures the shareholder's connection to the remote form to which the signature is attached. Votes cast in this manner prior to the General Meeting via this electronic means, as well as the acknowledgment of receipt provided, shall be considered irrevocable written documents enforceable against all parties. The proxy is, however, revocable in the same manner as that required for the appointment of the proxy holder. In the event of a transfer of ownership of shares occurring before midnight (Paris time) on the second business day preceding the General Meeting, the company will invalidate or modify accordingly, as the case may be, the proxy or the vote cast prior to the General Meeting by this electronic means. [...]	[...] If the Board of Directors decides, at the time the General Meeting is called, to allow proxy forms to be submitted electronically, the electronic signature on such forms may be generated by a reliable shareholder identification process that ensures the shareholder's connection to the remote form to which the signature is attached. Votes cast in this manner prior to the General Meeting via this electronic means, as well as the acknowledgment of receipt provided, shall be considered irrevocable written documents enforceable against all parties. The proxy is, however, revocable in the same manner as that required for the appointment of the proxy holder. In the event of a transfer of ownership of shares occurring before midnight (Paris time) on the fifth business day preceding the General Meeting, the company will invalidate or modify accordingly, as the case may be, the proxy or the vote cast prior to the General Meeting by this electronic means. [...]

THIRTY-EIGHTH RESOLUTION (*Amendment of article 23 (censor) of the articles of association of the Company*)

The General Meeting, voting under the rules of quorum and majority required for extraordinary general shareholders' meetings, having reviewed the management report of the Board of Directors, decides to grant the option to the Board of Directors to appoint up to three (3) censors, and decide, accordingly, to amend article 23 (*Censors*) of the articles of associations as follows:

Curent version	New version
[...] The Board of Directors may appoint, upon proposal of the Chairman, censors which number shall not exceed two (2). The censors shall be appointed for a period of three (3) years. They may be renewed. They may be removed at any time upon decision of the Board of Directors. [...]	[...] The Board of Directors may appoint, upon proposal of the Chairman, censors which number shall not exceed three (3) . The censors shall be appointed for a period of three (3) years. They may be renewed. They may be removed at any time upon decision of the Board of Directors. [...]

THIRTY-NINTH RESOLUTION (*Decision to issue share subscription warrants of the Company without shareholders' preferential subscription rights to the benefit of the European Investment Bank and delegation of authority to the Board of Directors*)

The General Meeting, acting in accordance with the quorum and majority requirements for extraordinary general meetings, having reviewed the report of the Board of Directors and the special report of the Statutory Auditors, and having verified that the share capital has been fully paid up, in accordance with the provisions of Articles L. 225-129 et seq. of the French *Code de commerce*, and in particular Articles L. 225-129-2, L. 225-135, L. 225-138, L. 22-10-49, L. 22-10-52-1, and the provisions of Articles L. 228-91 et seq. of said French *Code de commerce*,

In the context of the financing entered into with the European Investment Bank (the "**EIB**") on May 16, 2022 for a maximum amount in principal of €50 million (the "**EIB Loan**"), the Company issued two tranches of share subscription warrants to subscribe for new ordinary shares of the Company to the EIB, including constraining contractual mechanisms, such as anti-dilution and a put option provisions (the "**2022 EIB Warrants**"). As part of a plan to fully refinance the EIB Loan as well as to rationalise the Company's share capital structure announced on in June 1st 2026, it has been decided to (i) on the one hand, to repurchase and cancel a significant portion of these 2022 EIB Warrants, together with the early repayment of the outstanding EIB Loan (in principal and accrued interests), and, (ii) on the other hand, to substitute the remaining 2022 EIB Warrants with the issuance of new share subscription warrants giving the right to subscribe to new ordinary shares of the Company to the EIB, without certain specific rights awarded to the EIB in respect of the 2022 EIB Warrants (notably the anti-dilution mechanisms or put option), subject to the approval of the shareholders' general meeting of the Company.

This resolution therefore aims to authorize the issuance of such new share subscription warrants to the EIB in connection with this restructuring.

- 1. Resolves** to issue, with the exclusion of shareholders' preferential subscription rights in favor of the European Investment Bank, whose registered office is located at 98-100, boulevard Konrad Adenauer L-2950 Luxembourg Grand Duchy of Luxembourg, number of fifteen million six hundred seventy-seven thousand five hundred seventy-three (15,677,573) new share subscription warrants (the "**EIB Warrants**"), to be issued at a subscription price of one euro cent (€0.01) per EIB Warrant, each entitling the holder, upon payment of an exercise price of one euro cent (€0.01), to subscribe for one ordinary share of the Company with a par value of one euro cent (€0.01), up to a maximum of fifteen million six hundred seventy-seven thousand five hundred seventy-three (15,677,573) ordinary shares (without prejudice to any subsequent adjustments made to preserve the rights of the holders of EIB Warrants, in accordance with applicable law and regulations and the terms and conditions of the EIB Warrants).
- 2. Resolves** accordingly that the nominal amount of the capital increase that may be carried out in the future pursuant to this resolution shall correspond to the issuance of fifteen million six hundred seventy-seven thousand five hundred seventy-three (15,677,573) ordinary shares with a par value of 0.01 euro each, to which

Translation for information purpose only

may be added the nominal amount of shares to be issued to preserve the rights of the EIB in accordance with applicable laws and regulations and the terms and conditions of the EIB Warrants, it being specified that said nominal amount shall not be counted toward the maximum nominal amount of capital increases of two million euros (€2,000,000) set forth in paragraph 3) of the 22nd resolution of this General Meeting.

3. **Resolves** that the subscription price of the EIB Warrants issued pursuant to this resolution shall be paid in full upon subscription, by payment in cash and/or by set-off against liquid and due receivables, at the time of their subscription.
4. **Takes note**, in accordance with the provisions of Article L. 225-132, paragraph 6, of the French *Code de commerce*, that this resolution entails the shareholders' waiver, in favor of the EIB, of their preferential subscription rights to the Company's shares to which the EIB Warrants issued pursuant to this delegation entitle them.
5. **Resolves** to establish the main provisions of the terms and conditions of the EIB Warrants as follows:

General	The EIB Warrants are securities giving access to the capital (<i>valeurs mobilières donnant accès au capital</i>) within the meaning of Article L. 228-91 et seq. of the French <i>Code de commerce</i> . They will not be admitted to trading on the regulated market Euronext Paris.
Exercise Period	<p>The EIB Warrants shall be exercisable as of the end of the 90-day lock-up period beginning on the date of execution of the Master Agreement, which is expected to occur around June 1, 2026 and until the maturity date of the EIB Warrants which will be January 4, 2036.</p> <p>EIB Warrants not exercised within this period shall lapse and shall be deemed automatically null and void and irrevocably cease to be exercisable.</p>
Exchange Ratio	Each EIB Warrant shall entitle the holder to one new ordinary share of the Company, subject to adjustments as provided in applicable laws and regulations and the terms and conditions of the EIB Warrants.
Subscription price, payment terms and exercise price	<p>The subscription price of each EIB Warrant, i.e., one euro cent (€0.01), is payable upon subscription by payment in cash and/or by set-off against liquid and due receivables held by the subscriber.</p> <p>The exercise price of each EIB Warrant shall be one euro cent (€0.01).</p>
Gross proceeds upon exercise of all subscription warrants	In the event of the exercise of all fifteen million six hundred seventy-seven thousand five hundred seventy-three (15,677,573) EIB Warrants, the gross proceeds from the exercise of the EIB Warrants will total of one hundred fifty-six thousand seven hundred seventy-five euros and seventy-three cents (156,775.73) euros, representing a capital increase with a total nominal amount of one hundred fifty-six thousand seven hundred seventy-five euros and seventy-three cents (€156,775.73) (without prejudice to any adjustment in accordance with applicable laws and regulations and in the terms and conditions of the EIB Warrants).

Rights attached to shares resulting from the exercise of subscription warrants and dividend entitlement date	The ordinary shares to be issued upon exercise of the EIB Warrants will be ordinary shares of the same class as the Company's existing ordinary shares and shall be issued with the same rights as all Company's existing ordinary shares. They will carry full dividend rights and will be subject to all provisions of the Company's articles of association as well as to the resolutions of the shareholders' meetings as of their date of issuance.
Listing of shares resulting from the exercise of subscription warrants	The ordinary shares to be issued upon exercise of the EIB Warrants will be subject to an application for admission to trading on the regulated market Euronext Paris on the same mnemonic as the Company's existing shares.
Preservation of the rights of subscription warrant holders	The preservation of the rights of subscription warrant holders in the event of financial transactions will be ensured by adjusting the exercise conditions pursuant to the legal provisions of the French <i>Code de commerce</i> and the terms and conditions of the EIB Warrants.

6. **Resolves** that in the event of a capital increase, a merger by absorption, a merger, a demerger, or the issuance of new equity securities or new securities giving access to the capital, or other financial transactions involving a preferential subscription right or reserving a priority subscription period for the benefit of the Company's shareholders, the Company shall be entitled to suspend the exercise of the EIB Warrants for a period not exceeding three months or any other period set by applicable regulations (the exercise period being extended by the same period).
7. **Resolves** that the Board of Directors shall have full authority, with the power to subdelegate under the conditions provided by law, to implement this resolution, and in particular to:
- determine the fulfilment of any applicable conditions precedent relating to the implementation of this resolution, or, where applicable, the waiver of certain thereof;
 - determine the terms and conditions of the issuance of the EIB Warrants;
 - finalize the terms and conditions of the EIB Warrants in accordance with the terms set forth by this General Meeting;
 - determine the final number of EIB Warrants to be issued;
 - take all necessary or useful steps for the final issuance of the EIB Warrants (including, in particular, obtaining the EIB's subscription, confirming the receivables to be used for the set-off of the subscription price of the EIB Warrants and acknowledging receipt of the payment of the subscription price);
 - take all necessary or useful steps to carry out the capital increases resulting from the exercise of the EIB Warrants (including, in particular, receiving the subscription price for the Company's new ordinary shares issued upon exercise of the EIB Warrants);
 - where applicable, make any deduction from the issue premium(s) resulting from the issuance of the EIB Warrants;
 - arrange for the admission to trading on Euronext Paris of the new ordinary shares issued upon exercise of the EIB Warrants;
 - to record the capital increases resulting from the exercise of the EIB Warrants, and if it deems it appropriate, (i) to charge, where applicable, the costs of the capital increases against the amount of the premiums related to such increases and (ii) to deduct from this amount the sums necessary to bring the legal reserve to one-tenth of the new capital after each increase;

- to record the completion of the capital increases resulting from this resolution and to make the corresponding amendments to the articles of association, as well as to carry out all formalities and filings and to seek all authorizations that may prove necessary for the completion and successful conclusion of this issuance;
- determine the terms and conditions under which, if applicable, the rights of holders of the EIB Warrants will be preserved;
- take all necessary measures to protect the rights of the holders of the EIB Warrants, in accordance with legal and regulatory provisions and the terms and conditions of the EIB Warrants; and
- more generally, to take all necessary or useful actions and steps to carry out the issuance of the EIB Warrants and of the ordinary shares resulting from their exercise, to manage the financial aspects of the securities issued pursuant to this resolution, and to exercise the rights attached thereto, to comply with and implement the terms and conditions of the EIB Warrants, and to complete all resulting formalities.

8. Resolves that this decision shall be implemented by the Board of Directors within eighteen (18) months from the date of this General Meeting.

The Board of Directors shall, in accordance with the law and regulations, prepare a report for the next Ordinary General Meeting describing the use made of the delegation granted pursuant to this resolution.

For the avoidance of doubt, this delegation of authority shall supersede and render void any prior delegation of authority having the same purpose.

ORDINARY RESOLUTION

FORTIETH RESOLUTION (Power for formalities)

The General Meeting, deliberating in accordance with the quorum and majority requirements for ordinary general meetings,

Grants full powers to the bearer of an original, copy or extract of the minutes of this General Meeting to carry out all publication and filing formalities, and generally to do whatever is necessary.

INFORMATION

Shareholder status

Pursuant to Article R. 22-10-28 of the French Commercial Code, will be able to participate in the General Meeting, the shareholders who will justify:

- In the case of registered shares: of an account registration of said shares in the Company's registered share accounts by Tuesday June 23, 2026, zero hour, Paris time;
- In the case of bearer shares: of an account registration of said shares (if applicable, in the name of the intermediary registered on behalf of the shareholder concerned in accordance with the legal and regulatory requirements) in the bearer securities accounts held by their intermediary by Tuesday June 23, 2026, zero hour, Paris time. The authorized intermediaries will deliver a certificate of securities ownership, as an appendix to the remote voting form or proxy form filled by the shareholder or on behalf of the shareholder represented by the registered intermediary.

Only those shareholders who can prove their status by or before Tuesday June 23, 2026, zero hour, Paris time, under the conditions set out above, will be able to participate in this General Meeting.

Method of participation in the Shareholders' Meeting

Shareholders have several options for participating in the General Meeting. They can (1) vote while physically attending the General Meeting or (2) vote remotely or by proxy (a) by mail or (b) via Internet.

Pursuant to the provisions of Article R. 22-10-28, III, of the French Commercial Code, once a shareholder votes remotely, sends a proxy or asks for an admission card or a certificate to participate in the General Meeting, he or she will not be able to choose another method of participation.

1. Vote by physically attending the General Meeting

The shareholders wishing to personally attend the General Meeting must request an admission card as soon as possible to receive the card in a timely manner:

- For registered shareholders: either by returning the single form duly completed and signed using the pre-paid reply envelope enclosed with the invitation received by post mail; by logging in on the website www.sharinbox.societegenerale.com using their usual access codes or their login e-mail (if they have already activated their Sharinbox by SG Markets account), together with the password already in their possession. The password was sent to them by post when they contacted Société Générale Securities Services. It can be re-sent by clicking on "Get your codes" on the home page of the website. Once connected, shareholders should follow the on-screen instructions to access the VOTACCESS platform and request their admission card; the registered shareholder who has not received their admission card may spontaneously attend the General Meeting with a proof of identity document.
- For holders of bearer shares: either by asking the authorized intermediary managing their share-accounts to send them an admission card. Should the admission card not be received by Tuesday June 23, 2026, zero hour, Paris time, the shareholder shall ask the authorized intermediary managing their share-accounts to issue a certificate of participation in order to prove their status as shareholders; or by logging in on the Internet portal of their account holder with their usual access codes. The shareholder will then have to click on the icon that will appear on the line corresponding to their Inventiva shares to access the Votaccess website and follow the procedure described on the screen. Only the bearer shareholder whose account holder has subscribed to the Votaccess website will be able to fulfil their request for admission card via Internet.

On the day of the General Meeting, each shareholder will have to prove his or her quality during the registration process.

2. Vote remotely or by proxy

The shareholders not physically attending the General Meeting will be able to vote remotely or to give proxy to the President of the General Meeting, to their spouse, to their partner with whom a *pacte civil de solidarité* has been made, to another shareholder or to any other individual or legal entity of their choosing, subject to the conditions set forth in Articles L. 225-106 and L. 22-10-39 of the French Commercial Code.

Pursuant to the provisions of Article R. 225-79 of the French Commercial Code, the proxy given by a shareholder to be represented must be signed by the shareholder. The proxy will specify his/her last name, first name and address, and will designate a proxy, including his/her last name, first name and address or for a legal entity, its corporate name and registered office. The proxy does not have the right to delegate its duties to another individual or legal entity.

It is specified that, for any proxy without indication of an agent, the President of the General Meeting will vote in favor of adopting the draft resolutions presented or approved to by the Board of Directors and vote against adopting all other draft resolutions. To vote otherwise, the shareholders will have to designate an agent who will accept to vote as provided by the principal.

a. To vote remotely or by proxy by mail:

For registered shareholders: a postal voting form or proxy form will be sent directly to them. This form should be returned in the prepaid T envelope enclosed with the notice of meeting.

For holders of bearer shares: from this day, the postal voting form or proxy form can be requested from the intermediaries managing their shares. Each demand must be addressed by the financial intermediary to the *Services des Assemblées* of Société Générale, 32, rue du Champs de Tir, CS 30812, 44308 Nantes Cedex 3 at the latest six days before the date of the General Meeting (Article R. 225-75 of the French Commercial Code). The single postal voting form or proxy form must be submitted with a certificate of securities ownership drawn up by the financial intermediary who will have to forward these documents to the *Services des Assemblées* of Société Générale, 32, rue du Champs de Tir, CS 30812, 44308 Nantes Cedex 3.

In any case, the postal voting form or proxy voting form duly filled and signed (and accompanied by the certificate of securities ownership for the bearer shares) must be returned in such a way that the *Services des Assemblées* of Société Générale or the Company can receive it at least 3 days before the date of the General Meeting (that is Saturday June 27, 2026).

b. To vote or give proxy via Internet

Shareholders also have the option of transmitting their voting instructions and giving or revoking a proxy via Internet before the General Meeting, on the website Votaccess, under the following conditions:

- For registered shareholders: they will be able to access Votaccess to vote or give proxy via Internet by logging on to www.sharinbox.societegenerale.com, using their usual access codes or their login e-mail (if they have already activated their Sharinbox by SG Markets account), together with the password already in their possession. The password was sent to them by post when they contacted Société Générale Securities Services. It can be re-sent by clicking on "Get your codes" on the home page of the website. Once connected, follow the on-screen instructions to access the VOTACCESS platform.

they may also appoint or revoke a proxy by sending an e-mail bearing an electronic signature, obtained by them from an authorized third-party certifier under the legal and regulatory conditions in force, to the e-mail address agiva30062026@inventivapharma.com, specifying their surname, first name, address and Société Générale identifier for pure registered shareholders (information available at the top left of their account statement) or their identifier with their authorized intermediary for administered registered shareholders, as well as the surname, first name and address of the appointed or revoked proxy;

SGSS is available to answer shareholder queries from 9:30 a.m. to 6:00 p.m. on the following telephone number: + 33 (0)2 51 85 67 89;

- For holders of bearer shares: they will have to log in on the Internet portal of their account holders with their usual access codes. They will then have to click on the icon that will appear on the line corresponding to their Inventiva shares to access the Votaccess website and follow the procedure described on the screen.

Translation for information purpose only

Beware, only those shareholders whose account holder has subscribed to Votaccess will be able to vote, give or revoke a proxy via Internet.

If the account holder of the shareholder has not subscribed to Votaccess, the notice of appointment and revocation of a proxy can nevertheless be effectuated by electronic means in accordance with the provisions of Articles R. 22-10-24 and R. 225-79 of the French Commercial Code according to the following procedures: by sending an e-mail with an electronic signature, obtained by them from a third party certifier duly authorized pursuant to legal and regulatory provisions in force, to the electronic address agiva30062026@inventivapharma.com specifying their last name, first name, address, and their share-account's full bank references, as well as the last name, first name and address of the appointed or revoked agent, and then by asking imperatively to the authorized intermediary managing their share-accounts to send a written confirmation to the *Services des Assemblées* of Société Générale.

In order for the duly signed and completed appointments or revocations of proxy to be validly taken into account, they must reach the Company no later than Saturday June 27, 2026.

The revocation of a proxy is carried out under the same conditions of form as those used for its appointment.

The secured platform Votaccess will be open as of Friday June 12, 2026, 9 a.m., Paris time. The ability to vote, give or revoke a proxy via Internet prior to the General Meeting will end on Monday June 29, 2026, 3 p.m., Paris time. Shareholders are advised not to wait until the last days before the General Meeting to enter their instructions.

You are reminded that, in accordance with the provisions of Article R. 22-10-28 of the French Commercial Code:

- Any shareholder who has carried out any of the above formalities may sell all or part of his shares. However, if the sale is carried out before the fifth (5th) business day preceding the General Meeting at zero hour, Paris time, that is Tuesday June 23, 2026 the Company or its proxy cancels or modifies accordingly, depending on the case, the vote or proxy. To this end, the authorized intermediary holding the account notifies the Company or its authorized representative of the transfer and provides it with the necessary information;
- If the sale occurs after this period, it does not have to be notified by the authorized intermediary or taken into consideration by the Company, notwithstanding any agreement to the contrary.

Submission of written questions

In accordance with the provisions of Article R. 225-84 of the French Commercial Code, each shareholder will have the right to submit written questions to the Board of Directors no later than the fourth (4th) business day preceding the date of the Shareholders' Meeting, i.e. Wednesday June 24, 2026.

Requests for the submissions of written questions must be sent to the Company's registered office by registered letter with acknowledgement of receipt. They must be accompanied by a certificate of account registration.

Right of communication

All the documents and information provided for in Article R. 22-10-23 of the French Commercial Code (in particular the text of the draft resolutions presented to the General Meeting by the Board of Directors) can be consulted on the Company's website (www.Inventivapharma.com) as of the twenty first day preceding the Meeting, that is Tuesday June 9, 2026.

All the documents referred to in Articles R. 225-89 seq. of the French Commercial Code will be made available to shareholders at the Company's registered office as of the publication of the notice of meeting or on the fifteenth day preceding the General Meeting at the latest, depending on the document concerned.

As from the notice of meeting, shareholders may ask the Company to send them the documents and information mentioned in Articles R. 225-81 and R. 225-83 of the French Commercial Code, up to and including the fifth day, preferably by email (agiva30062026@inventivapharma.com) or at the head office by registered letter with acknowledgment of receipt. To this end, the shareholder shall indicate one's e-mail address in the request so that the Company can validly send him said documents in return. Bearer shareholders must provide proof of this status by sending a certificate of registration.

Audiovisual broadcasting

In accordance with Article R. 22-10-29-1 of the French Commercial Code, the General Meeting will be broadcast live in its entirety via the following link: <https://inventivapharma.com/fr/investisseurs/assemblees-generales/>. A recording of the General Meeting will be available for consultation on the Company's website no later than seven (7) working days after the date of the General Meeting and for at least two (2) years from the date it goes online.

The Board of Directors

INVENTIVA

Société anonyme with a Board of Directors
With a share capital of EUR 2,090,074.75
Registered office: 50, Rue de Dijon, 21121 Daix, France
537 530 255 Trade and Companies Registry of Dijon

**REPORT OF THE BOARD OF DIRECTORS
TO THE ORDINARY AND EXTRAORDINARY GENERAL MEETING
OF SHAREHOLDERS OF JUNE 30, 2026**

Madams and Sirs,

We have convened this General Meeting to submit for your approval decisions that fall within the competence of the Ordinary General Meeting, on the one hand, and the Extraordinary General Meeting, on the other hand.

The purpose of this report is to present the draft resolutions submitted by the Board of Directors to the General Meeting. It is intended to present the main points of the draft resolutions, in accordance with current regulations. It does not, therefore, claim to be exhaustive. Thus, it is essential that you read the text of the draft resolutions carefully before exercising your voting rights.

A summary of the Company's financial position, activity and earnings during the past fiscal year, as well as the various information required by the applicable laws and regulations, is included in the universal registration document, which includes the 2025 annual financial report, available on the Company's website (<http://inventivapharma.com>), to which you are invited to refer.

You are hereby called to rule on the following agenda:

AGENDA

Reading of the reports of the Board of Directors and the Statutory Auditors;

Ordinary items

1. Approval of the statutory financial statements for the financial year ended December 31, 2025;
2. Approval of the consolidated financial statements for the financial year ended December 31, 2025;
3. Appropriation of profit/loss for the financial year ended December 31, 2025;
4. Approval of the expenses and charges referred to in Article 39(4) of the French General Tax Code;
5. Approval of the subscription agreement for new shares with warrants issued by the Company signed on May 2, 2025 between the Company and Samsara BioCapital L.P., in accordance with Articles L.225-38 et seq. of the French Commercial Code;

6. Final approval of the fixed and variable compensation paid or awarded to Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors for the financial year ended December 31st, 2025;
7. Final approval of the fixed and variable compensation paid or awarded to Mr. Frédéric Cren in his capacity as Chief Executive Officer until September 30, 2025 for the financial year ended December 31st, 2025;
8. Final approval of the fixed and variable compensation paid or awarded to Mr. Andrew Obenshain in his capacity as Chief Executive Officer from October 1st, 2025 for the financial year ended December 31st, 2025;
9. Final approval of the fixed and variable compensation paid or awarded to Mr. Pierre Broqua in his capacity as Deputy Chief Executive Officer until June 30, 2025 for the financial year ended December 31st, 2025;
10. Approval of the information on corporate officers' compensation included in the corporate governance report and referred to in Article L.22-10-9 I. of the French Commercial Code;
11. Approval of the compensation policy for Mr. Mark Pruzanski in his capacity as Chairman of the Board of Directors;
12. Approval of the compensation policy for Mr. Andrew Obenshain in his capacity as Chief Executive Officer;
13. Total compensation paid to members of the Board of Directors;
14. Approval of the compensation policy of the Company's directors;
15. Renewal of the Director's mandate of Ms. Renée Aguiar-Lucander;
16. Renewal of the Director's mandate of Mr. Heinz Maeusli.
17. Appointment of Ms. Camilla Soenderby, as Director of the Company;
18. Appointment of Ms. Anne Prener, as Director of the Company;
19. Appointment of Ms. Barbara Krebs-Pohl, as Director of the Company;
20. Authorization granted to the Board of Directors to buyback the Company's shares;

Extraordinary items

21. Authorization to the Board of Directors to reduce the share capital by cancellation of shares;
22. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, with shareholders' preemptive subscription rights maintained;
23. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders' preemptive subscription rights, by way of public offerings, excluding offers referred to in Article L.411-2- 1° of the French *Code monétaire et financier*;

24. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders' preemptive subscription rights, by way of public offerings referred to in Article L.411-2 1° of the French *Code monétaire et financier*;
25. Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders' preemptive subscription rights;
26. Delegation of powers to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in favor of one or more persons specifically designated by the Board of Directors, without shareholders' preemptive subscription rights;
27. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares, immediately or in the future, reserved for certain specific categories of beneficiaries meeting specific characteristics within the framework of an equity financing agreement on the US market called "At-the-market" or "ATM", without shareholders' preemptive subscription rights;
28. Authorization to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders' preemptive subscription rights;
29. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares and securities giving access to the share capital of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company;
30. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in consideration for contributions in kind within the limits set by legal and regulatory provisions, excluding the case of a public exchange offer initiated by the Company;
31. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company immediately or in the future by the company reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Article L.3332-18 et seq. of the French *Code du travail*, without shareholders' preferential subscription rights;
32. Delegation of authority to the Board of Directors to increase the share capital of the Company by incorporating reserves, profits or premiums;
33. Authorization to the Board of Directors to grant free shares to employees and/or certain corporate officers;
34. Authorization to the Board of Directors to grant share subscription and/or share purchase options to corporate officers and employees of the Company or companies of the group, entailing the waiver by shareholders of their preferential rights to subscribe for shares issued following the exercise of stock options;
35. Delegation of authority to the Board of Directors to decide on the issuance of share subscription warrants, without shareholders' preemptive subscription rights, to the benefit of categories of persons;
36. Decision to be taken in application of article L. 225-248 of the French Commercial Code (shareholders' equity less than half the share capital);

37. Harmonization of the articles of association of the Company with applicable laws and regulations, resulting from the French Decree no. 2026-94 of February 13, 2026 relating to the modernization of communication means with their shareholders of some commercial companies;
38. Amendment of article 23 (censor) of the articles of association of the Company;
39. Decision to issue warrants, without shareholders' preemptive subscription rights, to the benefit of the European Investment Bank and delegation of power to the Board of Directors.

Ordinary item

40. Power for formalities.

We propose to examine hereafter each of the above proposals submitted for your approval.

1. APPROVAL OF BOTH THE STATUTORY AND CONSOLIDATED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED DECEMBER 31, 2025 - APPROPRIATION OF PROFIT/LOSS (*FIRST TO FOURTH RESOLUTIONS*)

You are invited to refer to the management report of the Boards of Directors and to the reports of the Statutory Auditors, including the universal registration document, which includes the 2025 annual financial report, both made available under the conditions provided by laws and regulations.

Concerning the state of business since the beginning of the current fiscal year, once again, you are invited to refer to the management report of the Boards of Directors.

2. APPROVAL OF RELATED-PARTY AGREEMENT IN ACCORDANCE WITH ARTICLES L.225-38 ET SEQ. OF THE FRENCH COMMERCIAL CODE (*FIFTH RESOLUTION*)

The 5th resolution submits for your approval a related-party agreement authorized by the Board of Directors in 2025 and covered by the Statutory Auditors' special report, in accordance with Articles L. 225-38 et seq. of the French Commercial Code.

Please refer to the Statutory Auditors' special report on agreements governed by Articles L. 225-38 et seq. of the French Commercial Code, which also describes agreements entered into in previous years which are still in force.

The purpose of the agreement submitted for your approval is to define terms and conditions of the subscription by Samsara BioCapital L.P. ("**Samsara**") for new shares with warrants issued by the Company in the context of the issuance of the second tranche of structured financing announced on October 14, 2024.

Mr. Srinivas Akkaraju, being a member of the Board of Directors of the Company and one of the corporate officers of Samsara, the subscription agreement constitutes a related-party agreement within the meaning of Articles L.225-38 et seq. of the French Commercial Code.

In consideration of the payment of an amount of EUR 8,959,999.95, Samsara has subscribed for 6,637,037 new shares with warrants potentially giving right to subscribe for 5,973,333 other new shares in the context of the issuance of the third tranche of structured financing announced on October 14, 2024.

The Company's Board of Directors authorized the conclusion of this agreement at its meeting of May 2, 2025, in accordance with Article L. 225-38 of the French Commercial Code. Mr. Srinivas Akkaraju did not participate in

the deliberations or the vote. The Company then entered into this related-party agreement with Samsara on May 2, 2025.

3. COMPENSATION OF CORPORATE OFFICERS (EX POST VOTES) FOR THE FINANCIAL YEAR ENDED DECEMBER 31, 2025 (SIXTH TO TENTH RESOLUTIONS)

The say on pay process regarding the compensation of corporate officers of listed companies provides that the annual ordinary general meeting is called to rule on:

an "individual" *ex post* vote: on the fixed, variable and exceptional items making up the total compensation and benefits of any kind paid or granted in respect of the previous financial year for the Chairman of the Board of Directors, Chief Executive Officer and the Deputy Chief Executive Officer, and

a "general" *ex post* vote: on the information relating to the compensation of all corporate officers (including directors) mentioned in I of Article L. 22-10-9 of the French Commercial Code (general *ex post* vote) as presented in the corporate governance report.

You are therefore invited to refer (i) to section 3.5.1.5 of the corporate governance report included in the universal registration document, itself including the 2025 annual financial report, which presents the compensation paid or granted in respect of financial year 2025 to the Chairman of the Board of Directors, Chief Executive Officer and the Deputy Chief Executive Officer, and (ii) to section 3.5.1.6 of the same report for information on the compensation of corporate officers mentioned in section I of article L. 22-10-9 of the French Commercial Code.

Will be subject to your approval:

as part of the individual *ex post* vote: the compensation paid or granted for the financial year 2025 to the Chairman of the Board of Directors, Chief Executive Officer and the Deputy Chief Executive Officer, as set out in section 3.5.1.5 of the corporate governance report, and

in the context of the general *ex post* vote: the information on the compensation of corporate officers mentioned in I of Article L. 22-10-9 of the French Commercial Code, as set out in section 3.5.1.6 of the corporate governance report.

4. APPROVAL OF THE COMPENSATION POLICIES FOR THE CHAIRMAN AND THE CHIEF EXECUTIVE OFFICER - TOTAL COMPENSATION PAID TO MEMBERS OF THE BOARD OF DIRECTORS - APPROVAL OF THE COMPENSATION POLICY OF THE COMPANY'S DIRECTORS (ELEVENTH TO FOURTEENTH RESOLUTIONS)

The say on pay process regarding the compensation of corporate officers also provides that the annual ordinary general meeting is called to vote *ex ante*, on the compensation policy applicable to all corporate officers, including the directors.

The compensation policy, in its common aspects as well as in those aspects specific to each of the corporate officers and as determined by your Board of Directors, is described in sections 3.5.1.1, 3.5.1.2 and 3.5.1.3 of the corporate governance report, included in the 2025 annual financial report, which is itself part of the universal registration document.

On March 27, 2026, the Board of Directors decided, on the recommendation of the Remuneration and Appointments Committee to adopt the terms of:

- a remuneration policy for the Chairman for the 2026 financial year;
- a remuneration policy for the Chief Executive Officer for the 2026 financial year;

in terms that are substantially equivalent to those of the policies submitted for your approval on May 22, 2025, and November 27, 2025, respectively.

At its meeting on May 1, 2026, the Board of Directors decided, however, to amend the compensation policy for the Chairman of the Board of Directors as set forth in the corporate governance report included in the universal registration document dated April 8, 2026, and where relevant, in the universal registration document dated April 15, 2025. The main change consists of removing the adjustment mechanism under which the Chairman of the Board of Directors would ultimately hold 5% of the Company's share capital on a fully diluted basis, as provided for in the 2024 compensation policy set out in the 2024 universal registration document dated April 15, 2025, and consequently amending the 2026 compensation policy described under the paragraph "Long-term compensation: grant of stock options or subscription rights" on page 135 of the 2025 universal registration document, published on April 8, 2026.

In this context, the Board of Directors has decided that, in addition to the grant of up to 12,898,116 stock options or subscription rights approved on December 20, 2024, it may grant to the Chairman of the Board of Directors an additional 3,000,000 stock options or subscription rights. This additional grant will result in the termination of the anti-dilution mechanism referred to above.

The amended version of the remuneration policy for the Chairman of the Board of Directors, which replaces the one presented in paragraph 3.5.1.2.1 "Remuneration Policy for the Chairman of the Board of Directors (ex-ante vote)" on page 135 and following of the 2025 Universal Registration Document, is included in the Appendix to this report.

At its meeting on March 27, 2026, the Board of Directors also decided to establish the terms of a director compensation policy tailored to the total annual amount to be distributed among the members of the Board of Directors.

Four resolutions will therefore be submitted for your approval, concerning the compensation plan as applied, respectively, to the Chairman, the Chief Executive Officer and the Directors, as well as a resolution to set at one million five hundred thousand euros (EUR 1,500,000) the total annual amount to be distributed among the members of the Board of Directors as remuneration for their work, as provided for in Article L. 225-45 of the French Commercial Code. The increase in this total annual amount is justified in light of the proposed appointment of three new directors to the Board of Directors, as detailed in section 6 below.

5. RENEWAL OF THE EXPIRING DIRECTOR MANDATES (*FIFTEENTH TO SIXTEENTH RESOLUTIONS*)

The terms as director of the Company of Ms. Renée Aguiar-Lucander and Mr. Heinz Maeusli, are coming to an end after your General Meeting.

Through the 15th and 16th resolutions, we invite you to renew respectively:

- The term as director of Ms. Renée Aguiar-Lucander for a period of three (3) years, ending after your annual ordinary general meeting called to rule on the financial statements for the financial year ended December 31, 2028;
- The terms as directors of Mr. Heinz Maeusli for a period of three (3) years, ending after your annual ordinary general meeting called to rule on the financial statements for the financial year ended December 31, 2028.

6. APPOINTMENT OF NEW DIRECTORS OF THE COMPANY (SEVENTEENTH TO NINETEENTH RESOLUTIONS)

The 17th to 19th resolutions propose that shareholders to as Directors of your Company:

- Ms. Camilla Soenderby, for a period of three (3) years, ending after your annual ordinary general meeting called to rule on the financial statements for the financial year ended December 31, 2028.
- Ms. Anne Prener, for a period of three (3) years, ending after your annual ordinary general meeting called to rule on the financial statements for the financial year ended December 31, 2028.
- Ms. Barbara Krebs-Pohl, for a period of three (3) years, ending after your annual ordinary general meeting called to rule on the financial statements for the financial year ended December 31, 2028.

Biography of Camilla Soenderby

Camilla Soenderby brings 25 years of international leadership experience gained within major biopharmaceutical companies across Europe, the United States and Asia.

Ms. Soenderby currently serves on the boards of directors of BB Biotech, a publicly listed investment company, the publicly listed biotechnology company Abivax, and the biotechnology company F2G. She previously served on the board of directors of Affibody. In addition, she is a member of Novo Holdings' Advisory Group and serves as an Industry Advisor to the private equity firm EQT.

Previously, Ms. Soenderby held executive leadership positions at Takeda, where she led the commercialization of the global portfolio. Prior to that, she served as Senior Vice President and Head of Global Product Strategy at Shire, following regional and general management leadership roles at Roche Pharma, Abbott (now AbbVie), and Schering-Plough (now Merck & Co.).

She began her career as a strategy consultant at McKinsey & Company and holds a Master's degree from the University of Copenhagen.

Biography of Anne Prener

Senior biotech executive with more than 20 years of international large pharma experience, Anne Prener has a proven track record of building and leading high-performing global teams for both preclinical and clinical stage biotech companies. Her 25+ years of experience across several therapeutic areas has focused on cardiovascular diseases, gene therapy and rare diseases.

Currently, Anne serves as an independent Director of the Board of XSpray Pharma, having previously served on numerous publicly-listed and privately held biotech boards (Galecto, Kaleido Biosciences, Rubius Therapeutics, Swanbio).

Prior, Anne Prener served as CEO of Freeline Therapeutics, Ltd., where she scaled the company from the preclinical stage to a fully-integrated biotechnology organization, which included a broad, internally developed pipeline, two programs in clinical development and a commercial-scale, high-quality CMC and manufacturing platform.

Prior to that, Dr. Prener was CEO for Gyroscope, a gene therapy company focused on addressing important retinal diseases with novel approaches. She helped build the company from start, including hiring the clinical, regulatory and scientific teams, developed medical and commercial strategy and served as a leading board director of the company. Overall, Dr. Prener has been instrumental in bringing six biologics through development, approval and launch preparations, of which one new treatment for hemophilia took only 4.5 years from first human dose to approval.

Biography of Barbara Krebs-Pohl

Barbara Krebs-Pohl is a highly respected biotechnology industry executive with more than 30 years of experience, particularly in business development, corporate strategy and alliance management.

She has held key leadership positions at leading companies, notably at MorphoSys, where she served as Chief Business Officer and negotiated transactions generating \$2.9 billion in value. Her expertise in strategic partnerships and post-acquisition integration, including the integration of Constellation Pharmaceuticals, Inc., played a pivotal role in strengthening MorphoSys's leadership position in oncology and contributed to its recent acquisition by Novartis.

Barbara has also served on the board of directors of HI-Bio, which was acquired by Biogen in 2024, and currently serves as chief executive officer of the Foundation for stem cell research and regenerative medicine. In addition, she is Partner and Managing Director at Viopas Venture Consulting, where she advises emerging biotechnology companies on growth strategies and strategic partnerships.

She currently serves as Chair of the Board of Directors of OneChain Immunotherapeutics (private company based in Spain) and Nykode Therapeutics (company listed on the Oslo Stock Exchange).

Her scientific background includes a Ph.D. focused on antibody technologies, together with substantial early-career experience in immunology, oncology, and drug discovery and development.

7. AUTHORIZATION TO IMPLEMENT A SHARE REPURCHASE PLAN, AND CONCOMITANTLY TO AUTHORIZE THE BOARD TO REDUCE THE SHARE CAPITAL BY CANCELLING TREASURY SHARES (*TWENTIETH AND TWENTY-FIRST RESOLUTIONS*)

We propose that you renew, in advance, the authorization granted to the Board of Directors, for a period of 18 months, by the ordinary and extraordinary general meeting of May 22, 2025, in its 22nd resolution, to implement a buyback program.

During previous fiscal years, this buyback program has been exclusively used within the framework of a liquidity agreement initially entered into with Oddo BHF (which was succeeded by an identical agreement with Kepler Cheuvreux), to meet the objective of allowing the liquidity of the Company's share through an investment services provider. The Company announced that it has terminated the liquidity agreement entered into on February 1, 2018, with Kepler Cheuvreux, with effect as of February 27, 2026.

The resolution that we submit to you aims at continuing the implementation of said liquidity agreement, within the limit of 10% of the shares composing the share capital, at any moment, the Board of Directors being able to lower this ceiling when implementing this resolution.

The maximum purchase price by share (excluding fees and commissions) would be set at forty euros (EUR 40). We also submit to your approval the authorization to be granted to the Board of Director to cancel, if applicable, the treasury shares obtained while implementing the share repurchase plan and to reduce the share capital correlatively.

Once again, this involves the anticipatory renewal of the authorization granted to the Board of Directors, for a period of 18 months, by the 23rd resolution of the combined general meeting of May 22, 2025; to avoid having a period not covered by this authorization.

In all circumstances, the Company has currently no intention to repurchase its shares as part of its buyback program.

8. FINANCIAL DELEGATIONS TO THE BOARD OF DIRECTORS (*TWENTY-SECOND TO THIRTY-SECOND RESOLUTIONS*)

We propose that you renew, in advance, the current financial delegations granted to the Board of Directors by the extraordinary and ordinary general meetings dated May 22, 2025.

These delegations would give the Board of Directors the authority to carry out various transactions on the share capital and thus to give the Company the necessary flexibility and reactivity to strengthen its capital base by implementing various financing options, without having to consult again the shareholders' general meeting. The Company could thus have the necessary resources, as the case may be, by calling on markets in order to accelerate and complete its development programs.

The Company is regularly studying various financing options in order to meet its cash requirements, in particular to finance the filing of marketing authorization applications in the United States and Europe and to prepare for commercialization in the event of positive results from the NATiV3 phase III trial in NASH ("**NATiV3 Phase III**") In view of the financing requirements, at the General Meeting to be held on June 30, 2026, shareholders will be asked to set the maximum aggregate nominal amount of the capital increase under several of the existing financial delegations at EUR 2,000,000. This amount is higher than that of the financial delegations adopted at the combined general meeting of May 22, 2025, in order to take into account changes in the Company's capital structure, in particular following the November 2025 fundraising, while providing the Company with the necessary flexibility to anticipate and support its future financing needs. This is particularly the case in the event of favorable outcomes from the NATiV3 study, with a view to supporting key milestones such as the filing of marketing authorization applications in the United States and Europe and, if applicable, the launch of initial pre-commercialization phases.

This amount is intended to enable the Board of Directors to have sufficient financial authorizations to deal with fluctuations in the share price and a difficult financial environment in which non-dilutive transactions are not always possible, and to raise one or more funds from investors in Europe and/or outside Europe (particularly in the United States), if it considers this necessary or useful. Other non-dilutive options are being evaluated in parallel by the Board to finance key milestones of the Company.

The Board points out that if an offer intended to be placed mainly outside France were to be made under the 22nd, 23rd, 24th, 25th, 26th and 29th resolutions, shareholders would be unlikely to be able to take part, given the characteristics and constraints of such an offer, particularly as regards the form of the securities, the timetable for the offer and the investors concerned.

The Board notes that the French Law no. 2024-537 of June 13, 2024 aimed at increasing the financing of businesses and the attractiveness of France, known as the "Attractiveness" Act, introduced a new article L. 22-10-52-1 of the French Commercial Code, particularly for companies whose shares are admitted to trading on a regulated market. This article gives the extraordinary general meeting the power to delegate to the Board of Directors, up to a limit of 30% of the share capital per year, the power to increase the share capital in favor of named persons whose designation is granted to the Board. In accordance with the provisions of this new article L. 22-10-52-1 and Article R.22-10-32 of the French Commercial Code, the issue price of the shares issued under this authorization will be set by the Board of Directors and shall be at least equal to the last closing price of the last trading session preceding the decision of the Board of Directors to use this delegation, less a maximum discount of 10%.

In this regard, we would like to point out that:

- The maximal global nominal amount of any share capital increase with shareholders' preemptive subscription rights that may be carried out pursuant to the delegation granted under the terms of the resolution 22 (*with shareholders' preemptive subscription rights maintained*) hereunder is set at 2,000,000 euros, corresponding to 200,000,000 shares, representing approximately 96% of the share capital as of May 1st, 2026,
- The maximal global nominal amount of any share capital increase without shareholders' preemptive subscription rights that may be carried out pursuant to the delegations granted under the terms of the

resolutions 23 (*public offerings excluding offers referred to in Article L.411-2 1° of the French Code monétaire et financier*) and 25 (*categories of beneficiaries*) hereunder, is set at 2,000,000 euros (said cap would count towards the overall cap of 2,000,000 euros referred to above), corresponding to 200,000,000 shares, representing approximately 96% of the share capital as of May 1st, 2026,

- The maximal global nominal amount of any share capital increase without shareholders' preemptive subscription rights that may be carried out pursuant to the delegations granted under the terms of the resolutions 24 (*public offerings referred to in Article L.411-2 1° of the French Code monétaire et financier*), 26 (*in favor of one or more persons specifically designated by the Board of Directors*) and 27 (*categories of beneficiaries meeting specific characteristics within the framework of an equity financing agreement on the US market called "At-the-market" or "ATM"*) hereunder, is set at 1,000,000 euros (said cap would count towards the overall cap of 2,000,000 euros referred to above), corresponding to 100,000,000 shares, representing approximately 48% of the share capital as of May 1st, 2026,
- The maximal global nominal amount of any capital increase without shareholders' preemptive subscription rights that may be carried out pursuant to the delegation granted under the terms of the resolution 29 (*public exchange offer initiated by the Company*) hereunder, is set at 1,000,000 euros (said cap would count towards the overall cap of 2,000,000 euros referred to above), corresponding to 100,000,000 shares, representing approximately 48% of the share capital as of May 1st, 2026,
- The maximal global nominal amount of any capital increase without shareholders' preemptive subscription rights that may be carried out pursuant to the delegation granted under the terms of the resolution 30 (*in consideration for contributions in kind, excluding the case of a public exchange offer initiated by the Company*) may not exceed the applicable legal and regulatory provisions on the date the delegation is implemented (*i.e.* to date, 20% of the share capital existing on the date of the transaction) (said cap would count towards the overall cap of 2,000,000 euros referred to above),
- The maximum global nominal amount of any share capital increase that may be carried out pursuant to the delegation granted under the terms of the resolution 31 hereunder as regards the Company saving plan is set at 4,300 euros (said amount will count towards the overall cap of 2,000,000 euros referred to above), corresponding to 430,000 shares, representing approximately 0.2% of the share capital as of May 1st, 2026,
- The maximum global nominal amount of any share capital increase that may be carried out pursuant to the delegation granted under the terms of the resolution 32 hereunder as regards incorporation of reserves, profits or premiums, is set at 40,000 euros (said cap being independently fixed and distinct from the caps referred to above), corresponding to 4,000,000 shares, representing approximately 2% of the share capital as of May 1st, 2026,
- The maximum global nominal amount of debt securities that may be carried out pursuant to these delegations would be set at 500,000,000 euros,
- The delegations requested could not be used during the period of a public offering for the Company's shares,
- These delegations would put an end on the delegations, having the same object, granted previously.

All of these delegations would be granted for a period of twenty-six (26) months, with the exception of the delegations referred to in resolutions 25, 26 and 27 (*delegations for the purpose of increasing the share capital of the company by issuance of ordinary shares or securities giving access to ordinary shares of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, or without shareholders' preemptive subscription rights or in favor of one or more persons specifically designated by the Board of Directors or in favor of categories of beneficiaries meeting specific characteristics within the framework of an equity*

financing agreement on the US market called "At-the-market" or "ATM"), which would be granted for a period of eighteen (18) months, as well as the delegation referred to in the resolution 28 (authorization to increase the number of securities to be issued), which would be granted for a period of eighteen (18) months if used in the context of resolutions 25, 26 and 27.

The Board of Directors would have full powers, with the right to subdelegate such powers in accordance with French law, to implement the delegations granted to it. Should the Board of Directors use the delegations of authority thus granted, it would report thereon to the following ordinary general meeting, in accordance with the law and regulations.

You will read the reports prepared by the Statutory Auditor on these delegations and authorizations.

We therefore propose that you review hereinafter each of the delegations and authorizations that you are being asked to grant your Board of Directors.

8.1. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to ordinary shares of the Company, immediately or in the future, with shareholders' preemptive subscription rights maintained, up to the global limit of 2,000,000 euros (*Twenty-second resolution*)

This delegation would grant the Board of Directors, with the right to sub-delegate under the conditions provided by French law, the authority to proceed with, one or more issuances, in France and/or abroad, in euros or in any other currency or currency units established by reference to several currencies, with maintenance of the shareholders' preemptive subscription rights, of ordinary shares of the Company and/or any securities giving access, immediately or in the future, to ordinary shares to be issued by the Company, including through the free allocation of share subscription warrants, which may be subscribed for either in cash or by offsetting against claims, in the amount and at the times it deems appropriate.

The shareholders shall have, proportionally to the amount of their shares, preemptive subscription rights over the ordinary shares and securities giving access to the share capital of the Company to be issued. The Board of Directors may grant shareholders excess subscription rights for ordinary shares or securities issued, to be exercised in proportion to their subscription rights and within the limit of their requests.

If the subscriptions on an irreducible basis and, as the case may be, on a reducible basis, do not absorb the entire issuance of shares or securities giving access to the share capital of the Company pursuant to this resolution, the Board of Directors may use the options provided by Article L. 225-134 of the French *Code de commerce*, in the order of its choice, or only some of them, and in particular the limitations of the issuance to the amount of subscriptions received, provided that such amount reaches at least three-quarters of the issuance decided upon, or decides to offer to the public all or part of the securities not subscribed.

The maximum nominal amount of the share capital increases that may be performed, pursuant to this resolution shall not exceed two million euros (EUR 2,000,000), consisting of 200,000,000 shares, representing approximately 96% of the share capital as of May 1st, 2026 and it being specified that the maximum nominal amount of the share capital increases that may be performed pursuant to this resolution and the resolutions 22 to 31 of this General Meeting, would be deducted from the overall ceiling capital increases that may be carried out under the resolutions presented to you. Added to this cap would be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company.

Securities giving access, immediately or in the future, to ordinary shares to be issued by the Company may notably consist of debt securities or be associated with the issuance of such securities, or allow their issuance as intermediate securities. The debt securities issued pursuant to this resolution may take the form of subordinated or non-subordinated securities, for a fixed or indefinite term, and be issued in euros, or in any other currency or currency units established by reference to several currencies.

The maximum nominal amount of such debt securities that may be issued pursuant to this resolution shall not exceed five hundred million euros (EUR 500,000,000) (or the counter-value of this amount in another currency or in any currency units established by reference to several currencies). This amount is a global cap which applies to all of the debt securities whose issuance is provided for pursuant to this resolution and resolutions 22 to 30 of this General Shareholders' Meeting. This cap is independent from the debt securities whose issuance would be decided or authorized by the Board of Directors pursuant to Article L. 228-40 of the French *Code de commerce*.

This resolution entails the waiver of the shareholders' preemptive subscription rights over the ordinary shares of the Company to which any securities issued pursuant to this resolution may entitle them.

The Board of Directors will have full authority, with the right to sub-delegate under the conditions provided by French law, to implement this resolution.

The aforementioned delegation would be granted for a period of 26 months and would terminate, with immediate effect, for the unused fraction, the delegation granted by the Combined General Meeting dated May 22, 2025 in its 24th resolution.

8.2. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to ordinary shares of the Company, immediately or in the future, without shareholders' preemptive subscription rights, by way of public offerings, excluding offers referred to in Article L.411-2- 1° of the French *Code monétaire et financier* (Twenty-third resolution)

This delegation would grant the Board of Directors, with the right to sub-delegate under the conditions provided by French law, the authority to proceed with one or more issuances, on one or more occasions, by way of public offerings, excluding offers referred to in article L. 411-2 1° of the French *Code monétaire et financier*, in France and/or abroad, in euros or in any other currency or currency units established by reference to several currencies, without shareholders' preemptive subscription rights, of ordinary shares of the Company and/or securities giving access, immediately or in the future, to ordinary shares to be issued by the Company, in the amount and at the times it deems appropriate.

Public offerings, performed pursuant to this resolution, may be combined, within one or several simultaneous issuances, with offerings pursuant to the provisions of Article L. 411-2 1° of the French *Code monétaire et financier*.

The Board of Directors may grant shareholders a priority right to subscribe to as irreducible and/or reducible amounts, during a period and on the terms set by it for all or part of an issuance performed, pursuant to the provisions of Article L. 225-135 of the French *Code de commerce*. This priority right will be allocated in proportion to shareholders' existing interests in the share capital of the Company in accordance with applicable laws and regulations.

If subscriptions by shareholders do not absorb the entire issuance of ordinary shares or securities giving access to the share capital of the Company, the Board of Directors may use the options provided by Article L. 225-134 of the French *Code de commerce* in the order of its choice, or only some of them, and in particular the limitation of the issuance to the amount of subscriptions received, provided that such amount reaches at least three-quarters of the issuance decided upon.

The maximum nominal amount of the share capital increases that may be performed, pursuant to this resolution shall not exceed two million euros (EUR 2,000,000), consisting of 200,000,000 shares, representing approximately 96% of the share capital as of May 1st, 2026, it being specified that this cap would count towards the overall cap of two million euros (EUR 2,000,000) stipulated in paragraph 8.1 above. Added to those caps would be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities or other rights giving access to the share capital of the Company.

Securities giving access to ordinary shares to be issued by the Company may notably consist of debt securities or be associated with the issuance of such securities, or allow their issuance as intermediate securities. The debt securities may take the form of subordinated or non-subordinated securities, for a fixed or indefinite term, and be

issued in France and/or abroad, in euros, or in any other currency or currency units established by reference to several currencies.

The maximum nominal amount of such debt securities that may be issued pursuant to this resolution shall not exceed five hundred million euros (EUR 500,000,000) (or the counter-value of this amount in another currency or in any currency units established by reference to several currencies), it being specified that this amount would count towards the overall cap stipulated in paragraph 8.1 above. This cap is independent from the amount of debt securities whose issuance would be decided or authorized by the Board of Directors pursuant to Article L. 228-40 of the French *Code de commerce*.

This resolution entails the waiver of the shareholders' preemptive subscription rights over the ordinary shares of the Company to which any securities issued pursuant to this resolution may entitle them.

We remind you that the issuance price of the ordinary shares and securities to be issued pursuant to this resolution will be determined by the Board of Directors, in accordance with the provisions of Article L.22-10-52 of the French Commercial Code, with the right to subdelegate under the conditions provided by law, and will be at least either equal to:

- (i) for the shares:
 - the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris for the last trading session preceding the pricing;
 - the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris on a period comprising between three (3) and seven (7) consecutive trading days, chosen from the thirty (30) trading days preceding the pricing date;
 - the last closing price of the share of the Company on the regulated market of Euronext Paris preceding the pricing date;

which may be reduced by maximum discount of 15%, any of the three formulas set forth above may be freely used.

- (ii) The issue price of the securities to be issued in the context of the present delegation other than shares would at least be equal to the amount received immediately by the Company, plus any amount likely to be received later by the Company, where applicable, i.e. for each ordinary share issued as a result of these securities being issued, at least equal to the amount mentioned above.

Full powers would be granted to the Board of Directors, with the right to subdelegate such powers in accordance with the law, for implementing this resolution.

The delegation presented would be granted for a period of 26 months and would terminate, with immediate effect, the unused portion of the delegation granted by the Combined General Meeting of May 22, 2025 in its 25th resolution.

8.3. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to ordinary shares of the Company, immediately or in the future, without shareholders' preemptive subscription rights, by way of public offerings referred to in Article L.411-2 1° of the French *Code monétaire et financier* (Twenty-fourth resolution)

This delegation is in all respects identical to the delegation described in the paragraph above, with the difference that the issues decided pursuant to this delegation would be carried out in the context of an offer to qualified investors or a restricted circle of investors referred to in 1° of Article L. 411-2 of the French *Code monétaire et financier*, it being specified that the total nominal amount of the share capital increases that may be carried out pursuant to this delegation may not exceed EUR 1,000,000 (representing 100,000,000 shares or 48% of the share capital as at May 1st, 2026), nor, in any event, exceed the limit set by the legal and regulatory provisions applicable at the time of issue (*i.e.* for information purposes, as at the date of this General Meeting, 30% of the share capital

per year as assessed on the date the delegation is implemented by the Board of Directors), maximum amount to which would be added, where applicable, the additional amount of shares to be issued to preserve, in accordance with the law and, where applicable, contractual stipulations providing for other cases of adjustment, the rights of holders of securities and other rights giving access to ordinary shares, it being specified, on the one hand, that this cap will count towards the cap of EUR 2,000,000 ceiling stipulated in point 8.2 above and would be deducted from the latter on the other hand, that the maximum nominal amount of the share capital increases that may be performed pursuant to this resolution will count towards the overall cap of EUR 2,000,000 stipulated in point 8.1 above.

Securities giving access to ordinary shares to be issued by the Company may notably consist of debt securities or be associated with the issuance of such securities, or allow their issuance as intermediate securities, and that the debt securities issued pursuant to this resolution may take the form of subordinated or non-subordinated securities, for a fixed or indefinite term and be issued in euros, or in any other currency or currency units established by reference to several currencies.

The total nominal amount of debt securities that may be issued under this delegation may not exceed EUR 500,000,000 (or the equivalent of this amount in foreign in any other currency or currency units established by reference to several currencies), this amount being included in the global ceiling stipulated in point 8.1 above.

We remind you that the issuance price of the ordinary shares and securities to be issued pursuant to this resolution will be determined by the Board of Directors, in accordance with the provisions of Article L.22-10-52 of the French Commercial Code, with the right to subdelegate under the conditions provided by law, and will be at least either equal to:

- (i) for the shares:
 - the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris for the last trading session preceding the pricing;
 - the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris on a period comprising between three (3) and seven (7) consecutive trading days, chosen from the thirty (30) trading days preceding the pricing date;
 - the last closing price of the share of the Company on the regulated market of Euronext Paris preceding the pricing date;

which may be reduced by maximum discount of 15%, any of the three formulas set forth above may be freely used.

- (ii) The issue price of the securities to be issued in the context of the present delegation other than shares would at least be equal to the amount received immediately by the Company, plus any amount likely to be received later by the Company, where applicable, i.e. for each ordinary share issued as a result of these securities being issued, at least equal to the amount mentioned above.

Full powers would be granted to the Board of Directors, with the right to subdelegate such powers in accordance with the law, for implementing this resolution.

This delegation would be granted for a period of 26 months and would terminate, with immediate effect, for the unused portion of the delegation granted by the Combined General Meeting of May 22, 2025, in its 26th resolution.

8.4. Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to ordinary shares of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders' preemptive subscription rights (*Twenty-fifth resolution*)

This delegation would enable the Board to proceed with, with the right to subdelegate under the conditions provided for by law, in France or abroad, one or more issuances, in the amount and at the times it deems

appropriate, in France and/or abroad, in euros or in any other currency or currency unit established by reference to several currencies, without shareholders' preemptive subscription rights, for the benefit of certain specific categories of beneficiaries, of ordinary shares of the Company and/or securities giving access, immediately and/or in the future, to ordinary shares to be issued by the Company, with cancellation of shareholders' preemptive subscription right in favor of categories of beneficiaries with one of the following characteristics:

- (i) natural or legal persons (including companies) trusts or investment funds, or other investment vehicles, in any form, established under French or foreign law, which regularly invest in the pharmaceutical, biotechnological or medical technology sectors; and/or
- (ii) companies, institutions or entities, in any form, French or foreign, exercising a significant part of its activities in the pharmaceutical, cosmetic or chemical sectors, or medical devices and/or technologies, or researching in such sectors; and/or
- (iii) French or foreign investment services companies, or any foreign establishment having an equivalent status, able to guarantee the completion of an issue intended to be placed with the persons referred to in (i) and/or (ii) above, and, in this context, to subscribe to the securities that are being issued.

The sole purpose of the latter paragraph is to enable investment service providers who are likely to guarantee the realization of an issue intended to be placed with the persons referred to in the first two paragraphs to subscribe to the securities issued in the event that the guarantee is activated.

The total nominal amount of the share capital increases that may be carried out pursuant to this delegation may not exceed EUR 2,000,000, which represents 200,000,000 shares, *i.e.* approximately 96% of the share capital as of May 1st, 2026, it being specified, firstly, that this ceiling would count towards the overall cap of EUR 2,000,000 stipulated in point 8.2 above and would be deducted from the latter and, secondly, that the nominal amount of the capital increases likely to result from this resolution would be deducted from the overall cap of EUR 2,000,000 stipulated in point 8.1 above. Added to those caps will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company.

The total nominal amount of the debt securities that may be issued under this delegation may not exceed EUR 500,000,000 (or the equivalent of this amount in foreign in any other currency or currency units established by reference to several currencies), this amount being included in the overall cap stipulated in point 8.1 above.

If the subscriptions have not fully absorbed an issue of shares or securities giving access to the capital issued pursuant to this resolution, the Board of Directors may limit the issue to the amount of subscriptions provided that this amount reaches at least three-quarters of the issue decided.

The issuance price of the ordinary shares and securities to be issued pursuant to this resolution will be determined by the Board of Directors, with the right to subdelegate under the conditions provided by French law, pursuant to Articles L. 225-138 II of the French *Code de commerce*, and will at least be equal:

- (i) for the ordinary shares, either to:
 - the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris for the last trading session preceding the pricing, or
 - the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris on a period comprising between three (3) and seven (7) consecutive trading days, chosen from the thirty (30) trading days preceding the pricing date; or
 - the last closing price of the share of the Company on the regulated market of Euronext Paris preceding the pricing date;

which may be reduced by maximum discount of 15%, any of the three formulas set forth above may be freely used;

- (ii) (a) the issuance price of shares that may result from the exercise, conversion, exchange or redemption of securities giving access to the Company's capital issued under this authorization may be determined, at the discretion of the Board of Directors, by reference to a calculation formula defined by the Board of Directors and applicable after the issue of said securities (for example, on exercise, conversion, redemption or exchange), in which case the maximum discount referred to above may be determined, if the Board of Directors sees fit, on the date of application of said formula (and not on the date of issue of the securities), and (b) the issuance price of the securities to be issued under this resolution, other than shares, will be such that the amount immediately received by the Company plus, where applicable, any amount that may subsequently be received by the Company, for each share issued as a result of the issue of such securities, is at least equal to the amount referred to in paragraph (i) above; and

Full powers would be granted to the Board of Directors to implement this resolution.

This delegation, together with the proposed discount, would enable the Company to call on specialist investors and, once again, give it greater flexibility in raising funds in the form of equity securities (ordinary shares represented or not by ADS and securities giving access to capital) necessary to finance its activity.

Lastly, this resolution may be used for issuances reserved for specialized investors falling within the above-mentioned categories in particular following solicitations by such investors to the Company or the Sales Agent (so-called "reverse inquiries"), within the framework of the equity financing At the market program ("the **ATM Program**"), which has been reactivated by the Company on the US market and registered with the Securities Commission Exchange (the "**SEC**") by the Company in October 2024.

This delegation would be granted for a period of 18 months and would terminate, with immediate effect, for the unused portion of the delegation granted by the combined general meeting of May 22, 2025, in its 27th resolution.

8.5. Delegation of powers to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in favor of one or more persons specifically designated by the Board of Directors, without shareholders' preemptive subscription rights (*Twenty-sixth resolution*)

This delegation would enable the Board to proceed with, with the right to subdelegate under the conditions provided for by law, one or more issuances, in the amount and at the times it deems appropriate, in France and/or abroad, in euros or in any other currency or currency unit established by reference to several currencies, for the benefit of certain specific categories of beneficiaries, of ordinary shares of the Company and/or securities giving access, immediately and/or in the future, to ordinary shares to be issued by the Company, with cancellation of shareholders' preemptive subscription right of one or more persons specifically designated by the Board.

The total nominal amount of the share capital increases that may be carried out pursuant to this delegation may not exceed EUR 1,000,000, which represents 100,000,000 shares, i.e. approximately 48% of the share capital as of May 1st, 2026, it being specified, firstly, that this ceiling would count towards the overall cap of EUR 2,000,000 stipulated in point 8.2 above and would be deducted from the latter and, secondly, that the nominal amount of the capital increases likely to result from this resolution would be deducted from the overall cap of EUR 2,000,000 stipulated in point 8.1 above. Added to those caps will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company.

It being specified that in any event, the total nominal amount of the share capital increases that may be carried out pursuant to this delegation may not exceed the limit set by the legal and regulatory provisions applicable at the time of issue (*i.e.* for information purposes, as at the date of this General Meeting, 30% of the share capital per year as assessed on the date the delegation is implemented by the Board of Directors in accordance with Articles L. 225-138 and L. 22-10-52-1 of the French Commercial Code).

The total nominal amount of the debt securities that may be issued under this delegation may not exceed EUR 500,000,000 (or the equivalent of this amount in foreign in any other currency or currency units established by reference to several currencies), this amount being included in the overall cap stipulated in point 8.1 above.

If subscriptions by shareholders do not absorb the entire issuance of ordinary shares or securities giving access to the share capital of the Company, the Board of Directors may use the options provided by Article L. 225-134 of

the French Commercial Code in the order of its choice, or only some of them, and in particular the limitation of the issuance to the amount of subscriptions received, provided that such amount reaches at least three-quarters of the issuance decided upon.

We remind you that, in accordance with Article L. 22-10-52-1 of the French Commercial Code, the issuance price of the ordinary shares and securities to be issued pursuant to this resolution will be determined by the Board of Directors according to the regulatory provisions applicable on the date this delegation would be used and, in consequence, in accordance with Article R. 22-10-32 of the French Commercial Code currently applicable, the issue price would be at least equal to the last closing price of the last trading session preceding the decision of the Board of Directors to use this delegation, less a maximum discount of 10%.

This delegation would be granted for a period of 18 months and would terminate, with immediate effect, for the unused portion of the delegation granted by the combined general meeting of May 22, 2025, in its 28th resolution.

8.6. Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries meeting specific characteristics within the framework of an equity financing agreement on the US market called "At-the-market" or "ATM", without shareholders' preemptive subscription rights (Twenty-seventh resolution)

This resolution would enable the Board of Directors to carry out, with the right to subdelegate under the conditions provided for by law its authority to proceed, on one or more occasions, in France or abroad, in the proportions and at the times it deems appropriate, to the issue, in euros or in foreign currency, or in any other monetary unit established by reference to several currencies, without shareholders' preemptive subscription rights, of ordinary shares of the Company in the form of American Depositary Shares or American Depositary Receipts, which may be subscribed either in cash or by set-off of receivables, reserved for the following category of beneficiaries:

- any French or foreign credit institution or investment service provider, or any foreign institution with an equivalent status, intervening within the framework of an ATM program set up by the Company (or any similar equity financing program that replaces it) and providing, in this context, for the subscription of securities issued by the Company.

This authorization is intended to allow the extension of the ATM Program, to investment transactions carried out by the bank in charge of the ATM Program (or "Sales Agent"), of new shares in the form of ADSs sold directly on the US market, according to the trading procedures market (an investment technique known as "dribble out").

Such sales would be made at the market price, in as many transactions as necessary, during one or more trading days, at the request of the Company, within the limit of the overall amount, the duration and the minimum price indicated by the Company to the Sales Agent and within the limits provided for in this resolution.

The use of this resolution, which remains subject to obtaining the necessary regulatory approvals, would allow the Company to issue to the Sales Agent the number of shares sold by the latter during the envisaged period (for instance, one trading day), at a subscription price corresponding to their weighted average price on the market. The Company would retain full control over the activation or deactivation of the ATM Program, including during its execution.

The total nominal amount of the share capital increases that may be carried out pursuant to this delegation may not exceed 1,000,000 euros, which represents 100,000,000 shares, *i.e.* approximately 48% of the share capital as of May 1st, 2026), it being specified, firstly, that this cap will count towards the cap of EUR 2,000,000 stipulated to in point 8.2 above and would be deducted from the latter and, secondly, that the nominal amount of the capital increases that may result from this resolution would be deducted from the overall cap of EUR 2,000,000 referred to in point 8.1 above.

Furthermore, the issues carried out under the ATM Program, in the form of "reverse enquiries" (under the 25th resolution) as well as "dribble outs" (under the present resolution) would not be subject to a Prospectus and therefore would remain limited to the legal constraint of 30% of the share capital per 12-month period (cumulatively with the other eligible issues that would be carried out by the Company, if any) assessed on the date of implementation of the delegation by the Board of Directors in accordance with point 5 of Article 1 of Regulation (EU) 2017/1129 dated June 14th, 2017.

Should subscriptions not absorb the entire issue of shares or securities giving access to the capital issued pursuant to this resolution, the Board of Directors may limit the issue to the amount of subscriptions, provided that this amount reaches at least three-quarters of the issue decided.

The issue price of the ordinary shares to be issued under this resolution shall be set by the Board of Directors, with the right to sub delegate under the conditions provided for by law, in accordance with the provisions of Articles L. 225-138 II of the French Commercial Code, and shall be at least equal to:

- the volume-weighted average price of the Company's shares on the regulated market of Euronext Paris during the last trading session preceding the pricing date; or
 - the volume-weighted average price of the share of the Company on the regulated market of Euronext Paris on a period comprising between three (3) and seven (7) consecutive trading days, chosen from the thirty (30) trading days preceding the pricing date; or
 - the last closing price of the share of the Company on the regulated market of Euronext Paris preceding the pricing date;
- which may be reduced by maximum discount of 15%, any of the three formulas set forth above may be freely used.

All powers would be granted to the Board of Directors to implement this resolution.

This delegation, the proposed discount, and the proposed period for determining the weighted average price would enable the Company to capitalize on opportune market windows, engage specialized investors, and, once again, benefit greater flexibility when raising capital in the form of equity securities (in the form of American Depositary Shares representing the Company's common stock) necessary to finance its operations.

This delegation would be granted for a period of 18 months and cancel, with immediate effect, for the unused portion, the delegation granted by the Combined General Meeting of May 22, 2025, in its 29th resolution.

8.7. Authorization to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders' preemptive subscription rights (*Twenty-eighth resolution*)

We ask you to authorize your Board of Directors, with the right to subdelegate under the conditions provided by law, for each of the issues decided pursuant to the 22nd to 27th resolutions above, to decide, within the periods and limits provided for by the law and regulations applicable on the date of the relevant issue (on the date of this meeting, within thirty (30) days following the closing of the subscription, up to a maximum of fifteen percent (15%) of the initial issuance and at the same price as the initial issuance), to increase the number of shares to be issued as part of share capital increases within the ceiling provided for in the resolution pursuant to which the issue is decided upon.

This authorization would notably enable the Board to provide for an additional capital increase, if necessary, to facilitate any over-allotments and stabilization measures on the Company's share price.

This authorization would be granted for a period of 26 months and would terminate, with immediate effect, for the unused portion of the authorization granted by the Combined General Meeting of May 22, 2025, in its 30th resolution. By exception, the present delegation would be granted for a period of 18 months as regards the 25th to 27th resolutions.

8.8. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares and securities giving access to the share capital of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company (*Twenty-ninth resolution*)

We suggest you, in accordance, in particular, with the provisions of Articles L. 225-129-2 and 22-10-54 of the French *Code de commerce*, to delegate to the Board of Directors, with the right to subdelegate under the conditions

provided by law, the authority to proceed with, one or more issuances, in France and/or abroad, in euros or in any other currency or currency units established by reference to several currencies, of ordinary shares of the Company and/or securities giving access, immediately and/or in the future, to ordinary shares to be issued by the Company, in consideration for the securities contributed to a public exchange offer including an exchange component (on a principal or subsidiary basis) initiated by the Company, in France and/or abroad, in accordance with local regulations on the securities of a company whose shares are admitted to trading on one of the regulated markets listed in Article L. 22-10-54 of the French *Code de commerce*, with cancellation of shareholders' preemptive subscription rights over these shares and/or securities to be issued in favor of the holders of such securities.

The total nominal amount of the share capital increases that may be carried out pursuant to this delegation may not exceed EUR 1,000,000 (which represents 100,000,000 shares, i.e. approximatively 48% of the share capital as of May 1st, 2026), it being specified that this cap will count towards the cap of EUR 2,000,000 stipulated to in point 8.2 above and would be deducted from the latter and, secondly, that the nominal amount of the capital increases that may result from this resolution would be deducted from the overall cap of EUR 2,000,000 referred to in point 8.1 above. Added to those caps will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company.

Securities giving access to ordinary shares to be issued by the Company may notably consist of debt securities or be associated with the issuance of such securities, or allow their issuance as intermediate securities, and that the debt securities issued pursuant to this resolution may take the form of subordinated or non-subordinated securities with a fixed or indefinite term, in France and/or abroad, and be issued in euros, or in any other currency or currency units established by reference to several currencies.

The total nominal amount of the debt securities that may be issued under this delegation may not exceed EUR 500,000,000 (or the counter-value of this amount in another currency or in any currency units established by reference to several currencies), it being specified that this amount would be deducted from the overall cap stipulated in section 8.1 above, it being specified that this amount does not include the redemption premium(s) above par, if any. It would be independent from the debt securities whose issue would be decided on or authorized by the Board of Directors in accordance with Article L. 228-40 of the French *Code de commerce*.

This delegation would entail a waiver of the shareholders' preemptive subscription rights over ordinary shares of the Company to which any securities issued pursuant to this resolution may entitle them.

All powers would be granted to the Board of Directors, with the option of sub-delegation, to implement this resolution.

This delegation would be granted for a period of 26 months and would terminate, with immediate effect, for the unused portion of the delegation granted by the Combined General Meeting of May 22, 2025, in its 31st resolution.

8.9. Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, in consideration for contributions in kind within the limits set by legal and regulatory provisions , excluding the case of a public exchange offer initiated by the Company (*Thirtieth resolution*)

We suggest you, in accordance, in particular, with the provisions of Articles L. 225-129-2 and 225-147 of the French *Code de commerce*, to delegate to the Board of Directors, with the right to subdelegate under the conditions provided by law, the authority to proceed, on the basis of the report of the Contribution Auditor(s), with, one or more issuances, in France and/or abroad, in euros or in any other currency or currency units established by reference to several currencies, of ordinary shares of the Company and/or securities giving access, immediately and/or in the future, to ordinary shares to be issued by the Company, in order to remunerate contributions in kind granted to the Company and consisting of equity securities or securities giving access to the share capital, when the provisions of Article L. 22-10-54 of the French *Code de commerce* are not applicable, for example in connection with the acquisition of assets.

The securities so issued may notably consist of debt securities or be associated with the issuance of such securities, or allow their issuance as intermediate securities, and that the debt securities issued pursuant to this resolution may take the form of subordinated or non-subordinated securities with a fixed or indefinite term and be issued in France and/or abroad in euros, or in any other currency or currency units established by reference to several currencies.

The total nominal amount of the share capital increases that may be carried out under this delegation may not exceed the legal limit provided for by the laws and regulations in force at the time this delegation is used (currently twenty (20)% of the share capital existing on the date of the transaction), it being specified, firstly, that this cap would be common to the cap of EUR 2,000,000 set in point 8.2 above, and would be deducted from the latter, and, secondly, that the nominal amount of the capital increases that may result from this resolution would count towards the overall cap of EUR 2,000,000 stipulated in point 8.1 above. Added to those caps will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company.

The total maximum nominal amount of debt securities that may be issued pursuant to this resolution shall not exceed EUR 500,000,000 (or the counter-value of this amount in another currency or in any currency units established by reference to several currencies), this amount being deducted from the overall ceiling referred to in point 8.1 above, it being specified that this amount does not include the redemption premium(s) above par, if any. This cap is independent from the debt securities whose issuance would be decided on or authorized by the Board of Directors in accordance with Article L. 228-40 of the French *Code de commerce*.

Full powers would be granted to the Board of Directors, with the right to subdelegate, to implement this resolution.

This delegation would be granted for a period of 26 months and would terminate, with immediate effect, for the unused portion of the delegation granted by the Combined General Meeting of May 22, 2025, in its 32nd resolution.

8.10. Delegation of authority to the Board of Directors to increase the share capital reserved for employees of the Company (*Thirty-first resolution*)

We remind you that pursuant to Article L. 225-129-6 of the French *Code de commerce*, when making any decision to increase the share capital, the Extraordinary Shareholders' Meeting must vote on a draft resolution to carry out a capital increase reserved for employees under the conditions provided for in Articles L. 3332-18 et seq. of the French *Code du Travail*, i.e. those who are members of a company savings plan (*Plan d'Épargne d'Entreprise*).

Under these conditions, we are submitting to you a resolution to delegate to the Board of Directors, with the right to subdelegate under the conditions provided by law, the powers of the Extraordinary General Meeting to carry out a capital increase, on one or more occasions, in the proportions and at the times it deems appropriate, based on its deliberations alone, within a period of twenty-six (26) months from the date of this meeting, up to a maximum nominal amount of EUR 4,300, by issuing 430,000 shares, to be paid up in cash, with cancellation of the shareholders' preemptive subscription right over cash shares to be issued to the *Fonds Commun de Placement d'Entreprise* to be set up as part of a Company Savings Plan to be created, in the event of completion of the capital increase(s) provided for above.

The nominal amount of the capital increases that may result from this resolution would be deducted from the overall ceiling of EUR 2,000,000 stipulated in 8.1 above. Added to those caps will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company.

We remind you, however, that there is no company savings plan in existence now to which our Company's employees could subscribe and that the Company has always favored employee access to its capital through its policy of directly granting securities giving access to the capital.

We would like to inform you that we are not in favor of such an authorization as we believe that the proposal to set up free share allocation plans that have been submitted to you in advance are more in line with the Company's current social policy, which is designed to strengthen the direct participation of the Company's employees in its capital.

This authorization would be granted for a period of 26 months, with right to subdelegate, and would terminate, with immediate effect, the delegation granted by the Combined General Meeting of May 22, 2025, in its 33rd resolution.

8.11. Delegation of authority to the Board of Directors to increase the share capital of the Company by incorporating reserves, profits or premiums (*Thirty-second resolution*)

We suggest you, in accordance, in particular, with the provisions of Articles L. 225-129-2 and L. 225-130 of the French *Code de commerce*, to delegate to the Board of Directors, with the right to subdelegate under the conditions provided by law, the authority to proceed with, one or more issuances, in the amount and at the times it deems appropriate, by incorporation, successive or simultaneous, into the share capital of reserves, profits, premiums or any other sums whose capitalization may be allowed, to be realized by increasing the par value of existing ordinary share and/or by granting new ordinary shares free of charge.

The total nominal amount of the capital increases that may be carried out under this delegation may not exceed EUR 40,000, it being specified that this cap is set independently and separately from the caps for share capital increases resulting from issuances of ordinary shares or securities authorized by the other resolutions submitted to this Meeting and stipulated to in points 8.1 and 8.2 above, by the resolutions adopted, and still in force, at any previous General Meeting, and that added to those caps will be, as the case may be, the aggregate par value of any additional shares to be issued in order to preserve, in accordance with applicable laws and regulations, and, as the case may be, other contractual provisions that provide for other cases of adjustment, the rights of holders of securities giving access to the share capital of the Company.

This authorization would be granted for a period of 26 months, with the option of sub-delegation, and would terminate, with immediate effect, for the unused portion of the authorization granted by the Combined General Meeting of May 22, 2025, in its 34th resolution.

9. DELEGATIONS AND AUTHORIZATIONS TO THE BOARD OF DIRECTORS WITHIN THE FRAMEWORK OF THE INTEREST POLICY FOR CORPORATE OFFICERS AND EMPLOYEES OF THE COMPANY (*THIRTY-THIRD TO THIRTY-FIFTH RESOLUTIONS*)

As part of its remuneration and/or motivational policy for its employees, corporate officers and consultants, the Company has implemented successive plans to grant warrants to entrepreneurs, free shares or authorized the subscription of share warrants.

In this context, the Company's Board of Directors, anxious to be able to continue to motivate and retain the Company's employees and managers, the members of the Company's Board of Directors and their consultants, in line with the interests of the shareholders, wishes to continue the system of granting stock options, the free allocation of shares, the issuance of share warrants and the allocation of warrants for business creator shares, in accordance with good governance practices. In this respect, as with the financial delegations, it is proposed that you renew, in advance, the authorization granted to the Board of Directors for the allocation of free shares and the granting of stock options, for a period of 38 months, respectively granted by Combined General Meeting of December 11, 2024 in its 60th resolution and by the one of November 27, 2025 in its 4th resolution.

We inform you that the nominal amount of the capital increases resulting from the exercise of share subscription options and/or the free allocation of shares and/or the exercise of warrants that may be granted under the terms of resolutions 33 to 35 submitted for your approval may not exceed, with respect to each such resolution, a number of shares representing more than 8.1% of the share capital on the date of the Board of Directors' decision to grant them.

The nominal amount of any capital increases that may be carried out pursuant to these resolutions 33 to 35 is, in addition, capped at 8.1% of the Company's share capital on a fully diluted basis as at the date of this General Meeting, it being understood that this limit is common to all three resolutions (the "**Common Ceiling**").

These percentages do not take into account the nominal amount of the equity securities to be issued, if any, in respect of adjustments made in accordance with the law and, where applicable, contractual stipulations providing for other cases of adjustment.

The Board of Directors would have full authority to implement the authorizations and delegations thus granted to it.

In the event that the Board of Directors were to use these delegations of authority, it would report to the next ordinary general meeting on the transactions carried out under these authorizations, in accordance with the law and regulations.

Please note that these authorizations may not be used during a public offer for the Company's shares.

For information purposes, the dilutive instruments allocated and not yet acquired or subscribed for and not yet exercised, benefiting employees, officers, directors, and/or consultants represented 37,222,080 shares, representing a potential dilution of approximately 17.92% of the share capital based on a share capital of EUR 2,077,074.75.

We suggest that you review each of the authorizations that we are asking you to grant your Board of Directors.

9.1. Authorization to the Board of Directors to grant free shares to employees and/or certain corporate officers (*Thirty-third resolution*)

We suggest that you authorize your Board of Directors, for a period of 38 months, to proceed, on one or more instalments, the allocation of free ordinary shares of the Company, existing or to be issued, to the benefit of:

- employees of the Company or of companies directly or indirectly related to it, to the within the meaning of Article L.225-197-2 of the French Code de commerce, and/or
- corporate officers who meet the conditions set out in Article L.225-197-1, II of the French Code de commerce.

The total number of free shares granted may not exceed 8.1% of the share capital on the date of the grant decision by the Board of Directors, it being specified that the nominal amount of any capital increases that may be carried out pursuant to this resolution would be deducted from the Common Ceiling.

9.2. Authorization to the Board of Directors to grant share subscriptions and/or shares purchase options to corporate officers and employees of the Company (*Thirty-fourth resolution*)

We ask that you authorize the Board of Directors to grant, for a period of 38 months, on one or more occasions, options to subscribe for or purchase shares in the Company, under the following conditions:

- the total number of options that may be granted may not entitle the holder to subscribe for or acquire a total number of shares representing more than 8.1% of the share capital on the date of the Board of Directors' decision to grant them, it being specified that the amount of any capital increases that may be carried out pursuant to this resolution would be deducted from the Common Ceiling;
- the options would be granted to members of the salaried employees and/or corporate officers (or some of them) of the Company and of companies and economic interest groups linked to the Company under the conditions defined in Article L. 225-180-I of the French Commercial Code;
- the shares that may be obtained through the exercise of stock options may be acquired by the Company, either under Article L. 225-208 of the French Commercial Code, or, as the case may be, under the share buyback program subject to resolution 20 of this General Meeting pursuant to Article L. 225-209 of the French Commercial Code or under any share buyback program applicable prior or subsequent to the date of this resolution;
- the exercise price of the options granted under this resolution would be set by the Board of Directors, as follows:

- in the case of options to subscribe for new ordinary shares, the exercise price of the share subscription option shall not be less than 80% of the average purchased price of the Company's shares on the regulated market Euronext Paris during the twenty (20) trading sessions preceding the day on which the option is granted;
- in the case of options to purchase existing shares, the exercise price of the share purchase options shall not be less than 80% of the average purchase price of the shares held by the Company pursuant to Article L. 225-208 of the French Commercial Code, or, as the case may be, under the share buyback program authorized according to resolution 20 of this General Meeting pursuant to Article L. 225-209 of the French Commercial Code or any share buyback program previously or subsequently applicable;

each option should be exercised at the latest within 10 years from the date of their grant by the Board of Directors.

9.3. Delegation of authority to the Board of Directors to decide on the issuance of warrants, without shareholders' preemptive subscription rights, to the benefit of categories of persons (*Thirty-fifth resolution*)

We suggest that you delegate to the Board of Directors the authority to issue, on one or more occasions, ordinary share subscription warrants (the "**2026 BSAs**"), without shareholders' preemptive subscription rights over the said 2026 BSAs, each 2026 BSA giving the right to subscribe for one ordinary share of the Company with a par value of 0.01 euro.

The total number of 2026 BSAs granted under this resolution may not entitle the right to subscribe for or to acquire a total number or new or existing shares representing more than 8.1%, to which would be added, where applicable, the nominal amount of the shares to be issued in order to preserve the rights of the holders of the 2026 BSAs, if such reservation would be necessary, it being specified that this limit would be deducted from the Common Ceiling.

The shareholders' preemptive subscription rights over the 2026 BSAs would be cancelled and the subscription of said 2026 BSAs would be reserved in favor of individuals or legal entities meeting one of the following characteristics:

- executive employees or executive officers or members of the Company's management team who are not corporate officers, or
- members of the Board of Directors (including members of any research committee or those serving as censor) in office on the date of grant of the warrants, who are not executive officers of the Company or one of its subsidiaries, or
- consultants, managers or partners of companies providing services to the Company that have entered into a consulting or service agreement with the Company in force at the time of use of this delegation by the Board of Directors, or
- employees of the Company,

(together, the "**Beneficiaries**").

Pursuant to the provisions of Articles L. 228-91 and L. 225-132 of the French Commercial Code, this decision would entail in favor of the holders of 2026 BSAs, the waiver by the shareholders of their preemptive subscription right over the ordinary shares to which the 2026 BSAs entitle them.

It would be decided that:

- the 2026 BSAs would not be the subject of an application for admission to any market. They would be transferable. They would be issued in registered form and would be entered in an account;

- the 2026 BSAs must be exercised during the exercise period determined by the Board of Directors, provided that such period may not exceed 10 years from their issuance, and the 2026 BSAs that have not been exercised at the end of this period would automatically lapse;
- the issuance price of a 2026 BSA would be determined by the Board of Directors on the date of issuance of the said 2026 BSA in the light of the report of an independent expert appointed by the Board of Directors, according to the characteristics of the latter;
- the issuance price of 2026 BSA must be paid up in full at the time of subscription, by cash settlement or by offsetting against liquid and due receivables;
- the issuance price of one ordinary share to be subscribed for pursuant to the exercise of the 2026 BSAs should be determined by the Board of Directors at the time of the grant of the 2026 BSAs and shall be equal to the volume-weighted average of the prices of the last twenty (20) trading days preceding the date of grant of the 2026 BSA by the Board of Directors as long as the Company's shares are admitted to trading on the regulated market of Euronext Paris (the "**Exercise Price**"); and
- the ordinary shares thus subscribed should be fully paid up at the time of their subscription, either by cash payment or by offsetting against liquid and payable receivables.

In the event that the 2026 BSA have not been fully exercised, the Company would proceed with one of the transactions mentioned below:

- issuance of securities with shareholders' preemptive subscription rights; or
- capital increase by incorporation of reserves, profits or share premiums; or
- distribution of reserves in cash or securities,

the rights of the holders of the 2026 BSAs would be reserved under the conditions provided for in Article L. 228-98 of the French Commercial Code.

The Company would be authorized to change its purpose, amortize its capital, modify the distribution of profits or distribute reserves in accordance with the provisions of Article L. 228-98 of the French Commercial Code.

The Company would be authorized to require holders of the 2026 BSAs to repurchase or redeem their rights as provided for in Article L. 228-102 of the French Commercial Code.

Lastly, we request that you grant full authority to the Board of Directors, with the possibility of sub-delegation under the conditions provided for by law, to implement this delegation.

This delegation would be granted for a period of 18 months from the date of this Meeting and would terminate, with immediate effect, for the unused portion, the delegation granted by the Combined General Meeting of December 11, 2024, in its 62nd resolution.

In the event that the Board of Directors were to use this delegation of authority, it would report thereon to the next ordinary general meeting, in accordance with the law and regulations.

10. DECISION TO BE TAKEN IN APPLICATION OF ARTICLE L. 225-248 OF THE FRENCH COMMERCIAL CODE - SHAREHOLDERS' EQUITY LESS THAN HALF THE SHARE CAPITAL (THIRTY-SIXTH RESOLUTION)

The year ended December 31, 2025 showed a loss of (207,965,630.56) euros. The shareholders' equity is less than half the share capital. In accordance with article L. 225-248 of the French Commercial Code, you are asked to decide whether the Company should be wound up early.

Under the terms of the 36th resolution, you are therefore asked not to dissolve the Company and to continue the Company's operations.

11. HARMONIZATION OF THE ARTICLES OF ASSOCIATION OF THE COMPANY WITH APPLICABLE LAWS AND REGULATIONS (THIRTY-SEVENTH RESOLUTION)

We propose you to harmonize the articles of association of the Company with legal and regulatory provisions resulting from the French Decree no. 2026-94 of February 13, 2026 relating to the modernization of communication means with their shareholders of some commercial companies.

We propose you to amend article 26 (*Convening of general meetings*) of the articles of associations as follows:

Curent version	New version
<p>[...]</p> <p>If the Board of Directors decides, at the time the General Meeting is called, to allow proxy forms to be submitted electronically, the electronic signature on such forms may be generated by a reliable shareholder identification process that ensures the shareholder's connection to the remote form to which the signature is attached. Votes cast in this manner prior to the General Meeting via this electronic means, as well as the acknowledgment of receipt provided, shall be considered irrevocable written documents enforceable against all parties. The proxy is, however, revocable in the same manner as that required for the appointment of the proxy holder. In the event of a transfer of ownership of shares occurring before midnight (Paris time) on the second business day preceding the General Meeting, the company will invalidate or modify accordingly, as the case may be, the proxy or the vote cast prior to the General Meeting by this electronic means.</p> <p>[...]</p>	<p>[...]</p> <p>If the Board of Directors decides, at the time the General Meeting is called, to allow proxy forms to be submitted electronically, the electronic signature on such forms may be generated by a reliable shareholder identification process that ensures the shareholder's connection to the remote form to which the signature is attached. Votes cast in this manner prior to the General Meeting via this electronic means, as well as the acknowledgment of receipt provided, shall be considered irrevocable written documents enforceable against all parties. The proxy is, however, revocable in the same manner as that required for the appointment of the proxy holder. In the event of a transfer of ownership of shares occurring before midnight (Paris time) on the fifth business day preceding the General Meeting, the company will invalidate or modify accordingly, as the case may be, the proxy or the vote cast prior to the General Meeting by this electronic means.</p> <p>[...]</p>

12. AMENDMENT OF ARTICLE 23 (CENSOR) OF THE ARTICLES OF ASSOCIATION OF THE COMPANY (THIRTY-EIGHTH RESOLUTION)

We propose you to amend article 23 (*Censor*) of the articles of associations as follows:

Curent version	New version
<p>[...]</p> <p>The Board of Directors may appoint, upon proposal of the Chairman, censors which number shall not exceed two (2). The censors shall be appointed for a period of three (3) years. They may be renewed. They may be</p>	<p>[...]</p> <p>The Board of Directors may appoint, upon proposal of the Chairman, censors which number shall not exceed three (3). The censors shall be appointed for a period of three (3) years. They may be renewed. They may be</p>

removed at any time upon decision of the Board of Directors. [...]	removed at any time upon decision of the Board of Directors. [...]
---	---

13. ISSUANCE OF SHARE SUBSCRIPTION WARRANTS OF THE COMPANY WITHOUT SHAREHOLDERS' PREEMPTIVE SUBSCRIPTION RIGHTS, FOR THE BENEFIT OF THE EUROPEAN INVESTMENT BANK (*THIRTY-NINTH RESOLUTION*)

The issuance contemplated under this resolution would take place within the framework of a comprehensive and integrated refinancing project of the Company, aimed at anticipating the upcoming maturity of the existing financing entered into with the European Investment Bank (the “**EIB**”) on May 16, 2022, the repayment of which is scheduled between December 2026 and January 2027 (the “**EIB Loan**”). This financing, in an initial amount of EUR 50 million, is accompanied by share subscription warrants (*bons de souscription d'actions* – BSA) issued in a specific historical context and including mechanisms that have become complex and highly dilutive (the “**Existing EIB Warrants**”).

In order to secure its financial trajectory and simplify its capital structure, the Company announced on June [2], 2026 that it had implemented a transaction comprising three indivisible components:

- The first component aims at the restructuring of the Existing EIB Warrants and the repayment of the EUR 50 million loan. To this end, the Company intends to repurchase a significant portion of the outstanding Existing EIB Warrants for an amount of approximately EUR 50 million, thereby eliminating the most constraining contractual mechanisms and reducing the complexity of the instruments. This repurchase was financed through a capital increase announced on June 1, 2026;
- The second component consisted in entering into a bond financing arrangement for a maximum aggregate amount of EUR 150 million, notably to finance the Company's general corporate purposes and to refinance the EIB Loan;
- Finally, in consideration for the early repayment of the EIB Loan, the repurchase of the Existing EIB Warrants and the removal of certain associated protective rights (in particular the put option), the Company plans to issue approximately 15.7 million new warrants for the benefit of the EIB, with simplified terms and conditions aligned with market practice.

Accordingly, we propose that you approve and proceed with the issuance, without shareholders' preemptive subscription rights, for the benefit of the EIB, of fifteen million six hundred seventy-seven thousand five hundred seventy-three (15,677,573) share subscription warrants (the “**EIB Warrants**”), to be issued at a subscription price of EUR 0.01 per warrant, each warrant entitling its holder, upon payment of an exercise price of EUR 0.01, to subscribe for one ordinary share of the Company.

All powers would be delegated by you to the Board of Directors to determine the terms and conditions of the issuance of the EIB Warrants. The EIB Warrants issued under the proposed resolution shall be fully paid in cash at the time of their subscription, which would be carried out by way of set-off against liquid and payable receivables.

The main characteristics of the EIB Warrants would be as follows:

General	The EIB Warrants are securities giving access to the share capital within the meaning of Articles L. 228-91 et seq. of the French Commercial Code. They will not be admitted to trading on the regulated market of Euronext Paris or any other market.
----------------	--

<p>Exercise period</p>	<p>The EIB Warrants will be exercisable from the end of the 90-day restriction period starting from the execution of the Master Agreement, around June 1, 2026, until the maturity date of the EIB Warrants, i.e., January 4, 2036.</p> <p>Any EIB Warrants not exercised within this period shall automatically lapse, be deemed null and void, and irrevocably cease to be exercisable.</p>
<p>Parity</p>	<p>Each EIB Warrant shall entitle its holder to subscribe for one new ordinary share of the Company, subject to customary adjustments in accordance with applicable laws and regulations and the terms and conditions of the EIB Warrants.</p>
<p>Subscription and exercise price</p>	<p>The subscription price of each EIB Warrant, i.e., one euro cent (EUR 0.01), shall be payable upon subscription, either in cash and/or by set-off against liquid and payable receivables held by the subscriber.</p> <p>The exercise price of each EIB Warrant shall be one euro cent (EUR 0.01).</p>
<p>Gross proceeds in the event of full exercise of the warrants</p>	<p>In the event of exercise of all fifteen million six hundred seventy-seven thousand five hundred seventy-three (15,677,573) EIB Warrants, the gross proceeds from such exercise would amount to one hundred fifty-six thousand seven hundred seventy-five euros and seventy-three cents (EUR 156,775.73), corresponding to a share capital increase of the same nominal amount (without prejudice to adjustments provided for under applicable laws and regulations and the terms and conditions of the EIB Warrants).</p>
<p>Rights attached to the shares issued upon exercise of the warrants and dividend rights</p>	<p>The ordinary shares to be issued upon exercise of the EIB Warrants shall be ordinary shares of the same class as the existing ordinary shares of the Company. They shall carry full dividend rights and shall be subject to all provisions of the Company's by-laws and to the resolutions of general meetings from their date of issuance.</p>
<p>Admission to trading of the shares issued upon exercise of the warrants</p>	<p>The ordinary shares issued upon exercise of the EIB Warrants will be the subject of an application for admission to trading on the regulated market of Euronext Paris under the same ticker as the Company's existing shares.</p>
<p>Protection of the rights of warrant holders</p>	<p>The rights of holders of the EIB Warrants in the event of financial transactions shall be preserved by adjusting the exercise conditions in accordance with applicable legislative and regulatory provisions and the terms and conditions of the EIB Warrants.</p>

In the event of a capital increase, merger, demerger, contribution, issuance of new equity securities or securities giving access to the share capital, or any other financial transaction involving preemptive subscription rights or granting a priority subscription period to shareholders, the Company shall be entitled to suspend the exercise of the EIB Warrants for a period not exceeding three months (or any other period provided for by applicable regulations), it being specified that the exercise period shall be extended accordingly.

The issuance shall be carried out without shareholders' preemptive subscription rights over the ordinary shares to which the EIB Warrants entitle, for the exclusive benefit of the EIB.

Lastly, you are requested to grant full powers to the Board of Directors, with the right to subdelegate under the conditions provided for by law and regulations, within the limits and subject to the conditions set forth above, to implement this decision and to take all necessary or useful actions for the completion of the issuance.

This delegation shall be granted for a period of eighteen (18) months from the date of this Meeting.

The Board of Directors shall prepare, in accordance with applicable laws and regulations, a report to the next ordinary general meeting describing the use made of the delegation granted pursuant to this resolution.

It is under these conditions that we ask you to vote on the resolutions proposed to you by your Board of Directors.

The Board of Directors

APPENDIX

Compensation Policy for the Chairman of the Board of Directors (ex-ante vote)

The compensation of the Chairman of the Board of Directors, detailed below, consists of (i) fixed compensation and (ii) long-term compensation in the form of stock options and/or bonus shares.

The structure of the Chairman of the Board of Directors' compensation is determined by the Board, which sets the various components based on the recommendations of the Compensation Committee:

Fixed Compensation

The gross annual amount is USD 250,000, paid in four installments, in arrears at the end of each calendar quarter.

Remuneration for the role of director (formerly attendance fees)

The Chairman of the Board of Directors does not receive compensation for serving as a director.

Long-term compensation: grant of stock options or stock subscription options The paragraphs below supersede the terms of the Chairman's compensation policy as described in paragraphs 3.5.1.2.1 of the universal registration document published on April 8, 2026, and, as applicable, in the universal registration document dated April 15, 2025.

- i. Stock Option Plan of December 20, 2024 (together with the Stock Option Grant Agreement, the "**2024 Plan**")

In accordance with the compensation policy adopted by the Combined General Meeting of December 11, 2024, the Chairman of the Board of Directors was granted a maximum of 12,898,116 stock options (the "**Options**") on December 20, 2024.

The Options become exercisable in three tranches, each comprising a maximum of 4,299,372 Options, at the end of three periods of one, two, and three years, respectively, from the date of grant of the Options, subject to the fulfillment of attendance requirements and, for 25% of them, performance requirements.

It is specified that the final number of granted Options eligible for exercise may not exceed the ratio of the maximum number of granted Options (i.e., 12,898,116 Options) to the percentage of the €348 million financing announced on October 14, 2024, that has been achieved. Fulfilment of this final condition will be known on the date of completion of the third tranche of said financing.

- ii. Supplementary Stock Option Plan

The Chairman will also be granted 3,000,000 stock options (the "**Supplementary Options**") under a stock option plan to be implemented in 2026 (the "**2026 Plan**"). This supplemental grant has the effect of terminating, going forward, the adjustment mechanism that would have resulted in the Chairman of the Board of Directors holding 5% of the fully diluted share capital, as mentioned in the 2025 compensation policy included in the 2024 Universal Registration Document dated April 15, 2025.

The acquisition of the Additional Options will take place in two tranches, which will also be subject to attendance and performance conditions:

- The Tranche 1 Supplementary Options, representing 50% of all Supplementary Options, will be subject to the same attendance and performance conditions (*Continuous Presence Condition* and *Performance Conditions* as defined in the 2024 Plan) as those applicable to the Tranche 2 Options under the 2024 Plan (as defined by the 2024 Plan), conditions that will be incorporated into the 2026 Plan; and
- the Tranche 2 Supplementary Options, representing the remaining 50% of the Supplementary Options, will be subject to the same attendance and performance conditions (*Continuous Presence Condition* and *Performance Conditions* as defined in the 2024 Plan) applicable to the Tranche 3 Options of the 2024 Plan (as defined by the 2024 Plan), conditions that will be incorporated into the 2026 Plan.

Any other compensation component attributable to the term of office

The Chairman is entitled to reimbursement of reasonable and necessary expenses incurred in the performance of his duties as Chairman of the Board of Directors.

He is also covered by directors' and officers' liability insurance to protect him and, if necessary, indemnify him against claims arising from the performance of his duties as a director and Chairman of the Board of Directors of the Company.

Term of Office – Duration – Termination

The Chairman has been appointed for the term of his directorship, which will expire at the Annual General Meeting called to approve the financial statements for the 2026 fiscal year. The Board of Directors may remove him at any time.

Important : Avant d'exercer votre choix, veuillez prendre connaissance des instructions situées au verso - Important : Before selecting please refer to instructions on reverse side
Quelle que soit l'option choisie, noircir comme ceci ■ la ou les cases correspondantes, dater et signer au bas du formulaire - Whichever option is used, shade box(es) like this ■, date and sign at the bottom of the form

JE DÉSIRE ASSISTER À CETTE ASSEMBLÉE et demande une carte d'admission : dater et signer au bas du formulaire // **WISH TO ATTEND THE SHAREHOLDER'S MEETING** and request an admission card: date and sign at the bottom of the form



50 rue de dijon
21121 DAIX

Société anonyme au capital de 2 090 074,75 €
537 530 255 R.C.S. DIJON

**ASSEMBLEE GENERALE
ORDINAIRE ET EXTRAORDINAIRE
Mardi 30 juin 2026 à 14h**

Hôtel Villa M
24-30 Boulevard Pasteur
75015 PARIS

CADRE RÉSERVÉ À LA SOCIÉTÉ - FOR COMPANY'S USE ONLY

Identifiant - Account
 Nominatif Registered
 Porteur Bearer
 Vote simple Single vote
 Vote double Double vote
 Nombre d'actions Number of shares
 Nombre de voix - Number of voting rights

JE VOTE PAR CORRESPONDANCE // I VOTE BY POST
Cf. au verso (2) - See reverse (2)

Je vote **OUI** à tous les projets de résolutions présentés ou agréés par le Conseil d'Administration ou le Directoire ou la Gérance, à l'EXCEPTION de ceux que je signale en noircissant comme ceci ■ l'une des cases "Non" ou "Abstention". // I vote **YES** all the draft resolutions approved by the Board of Directors, EXCEPT those indicated by a shaded box, like this ■, for which I vote "No" or "I abstain".

Sur les projets de résolutions non agréés, je vote en noircissant la case correspondant à mon choix. On the draft resolutions not approved, I cast my vote by shading the box of my choice.

	1	2	3	4	5	6	7	8	9	10	A	B
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Oui / Yes	<input type="checkbox"/>
Abs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Non / No	<input type="checkbox"/>
	11	12	13	14	15	16	17	18	19	20	C	D
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Oui / Yes	<input type="checkbox"/>
Abs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Non / No	<input type="checkbox"/>
	21	22	23	24	25	26	27	28	29	30	E	F
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Oui / Yes	<input type="checkbox"/>
Abs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Non / No	<input type="checkbox"/>
	31	32	33	34	35	36	37	38	39	40	G	H
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Oui / Yes	<input type="checkbox"/>
Abs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Non / No	<input type="checkbox"/>
	41	42	43	44	45	46	47	48	49	50	J	K
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Oui / Yes	<input type="checkbox"/>
Abs.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Non / No	<input type="checkbox"/>
											Abs.	<input type="checkbox"/>

Si des amendements ou des résolutions nouvelles étaient présentés en assemblée, je vote **NON** sauf si je signale un autre choix en noircissant la case correspondante :
 In case amendments or new resolutions are proposed during the meeting, I vote **NO** unless I indicate another choice by shading the corresponding box:

-Je donne pouvoir au Président de l'assemblée générale / I appoint the Chairman of the general meeting.....

-Je m'abstiens / I abstain from voting

-Je donne procuration [cf. au verso renvoi (4)] à M. ou Mme, Raison Sociale pour voter en mon nom

I appoint [see reverse (4)] Mr or Mrs, Corporate Name to vote on my behalf.....

JE DONNE POUVOIR AU PRÉSIDENT DE L'ASSEMBLÉE GÉNÉRALE
Cf. au verso (3)

I HEREBY GIVE PROXY TO THE CHAIRMAN OF THE GENERAL MEETING
See reverse (3)

JE DONNE POUVOIR À : Cf. au verso (4) pour me représenter à l'Assemblée
I HEREBY APPOINT: See reverse (4) to represent me at the above mentioned Meeting
 M. ou Mme, Raison Sociale / Mr or Mrs, Corporate Name

Adresse / Address

ATTENTION : Pour les titres au porteur, les présentes instructions doivent être transmises à votre banque.
CAUTION: As for bearer shares, the present instructions must be valid only if they are directly returned to your bank.

Nom, prénom, adresse de l'actionnaire (les modifications de ces informations doivent être adressées à l'établissement concerné et ne peuvent être effectuées à l'aide de ce formulaire). Cf au verso (1)
 Surname, first name, address of the shareholder (changes regarding this information have to be notified to relevant institution, no changes can be made using this proxy form). See reverse (1)

Pour être pris en considération, tout formulaire doit parvenir au plus tard :
 To be considered, this completed form must be returned no later than:

sur 1^{ère} convocation / on 1st notification sur 2^{ème} convocation / on 2nd notification
 à la banque / to the bank 26 juin 2026 / June 26, 2026

Date & Signature

« Si le formulaire est renvoyé daté et signé mais qu'aucun choix n'est coché (carte d'admission / vote par correspondance / pouvoir au président / pouvoir à mandataire), cela vaut automatiquement pouvoir au Président de l'assemblée générale »
 'If the form is returned dated and signed but no choice is checked (admission card / postal vote / power of attorney to the President / power of attorney to a representative), this automatically applies as a proxy to the Chairman of the General Meeting'

CONDITIONS D'UTILISATION DU FORMULAIRE

<p>(1) GENERALITES : Il s'agit d'un formulaire unique prévu par l'article R. 225-76 du Code de Commerce qui s'applique aux assemblées générales d'actionnaires de sociétés de droit français.</p> <p>QUELLE QUE SOIT L'OPTION CHOISIE :</p> <p>Le signataire est prié d'inscrire très exactement, dans la zone réservée à cet effet, ses nom (en majuscules), prénom usuel et adresse (les modifications de ces informations doivent être adressées à l'établissement concerné et ne peuvent être effectuées à l'aide de ce formulaire).</p> <p>Pour les personnes morales, le signataire doit renseigner ses nom, prénom et qualité.</p> <p>Si le signataire n'est pas l'actionnaire (exemple : Administrateur légal, Tuteur, etc.) il doit mentionner ses nom, prénom et la qualité en laquelle il signe le formulaire de vote.</p> <p>Le formulaire adressé pour une assemblée vaut pour les assemblées successives convoquées avec le même ordre du jour (article R. 225-77 alinéa 3 du Code de Commerce).</p> <p>Les documents prévus à l'article R. 225-76 du Code de Commerce sont annexés au formulaire sauf s'ils sont disponibles sur un site internet dont l'adresse est précisée au recto. Ne pas utiliser à la fois « Je vote par correspondance » et « Je donne pouvoir » (article R. 225-81 alinéa 8 du Code de Commerce).</p> <p>Un guide méthodologique de traitement des assemblées générales, incluant une grille de lecture de ce formulaire de vote par correspondance est disponible sur le site de France Post Marche : https://www.france-post-marche.fr/</p> <p>La version française de ce document fait foi.</p>	<p>(3) POUVOIR AU PRÉSIDENT DE L'ASSEMBLÉE GÉNÉRALE</p> <p>Article L. 225-106 du Code de Commerce (extrait) :</p> <p>"Pour toute procuration d'un actionnaire sans indication de mandataire, le président de l'assemblée générale émet un vote favorable à l'adoption de projets de résolutions présentés ou agréés par le conseil d'administration ou le directoire, selon le cas, et un vote défavorable à l'adoption de tous les autres projets de résolution. Pour émettre tout autre vote, l'actionnaire doit faire choix d'un mandataire qui accepte de voter dans le sens indiqué par le mandant".</p>	<p>Cette information porte notamment sur le fait que le mandataire ou, le cas échéant, la personne pour le compte de laquelle il agit :</p> <p>1° Contrôle, au sens de l'article L. 233-3, la société dont l'assemblée est appelée à se réunir ;</p> <p>2° Est membre de l'organe de gestion, d'administration ou de surveillance de cette société ou d'une personne qui la contrôle au sens de l'article L. 233-3 ;</p> <p>3° Est employé par cette société ou par une personne qui la contrôle au sens de l'article L. 233-3 ;</p> <p>4° Est contrôlé ou exerce l'une des fonctions mentionnées au 2° ou au 3° dans une personne ou une entité contrôlée par une personne qui contrôle la société, au sens de l'article L. 233-3.</p> <p>Cette information est également délivrée lorsqu'il existe un lien familial entre le mandataire ou, le cas échéant, la personne pour le compte de laquelle il agit, et une personne physique placée dans l'une des situations énumérées aux 1° à 4°.</p> <p>Lorsqu'en cours de mandat, survient l'un des faits mentionnés aux alinéas précédents, le mandataire en informe sans délai son mandant. A défaut par ce dernier de confirmation expresse du mandat, celui-ci est caduc.</p> <p>La caducité du mandat est notifiée sans délai par le mandataire à la société.</p> <p>Les conditions d'application du présent article sont précisées par décret en Conseil d'Etat."</p>
<p>(2) VOTE PAR CORRESPONDANCE</p> <p>Article L. 225-107 du Code de Commerce (extrait) :</p> <p>"Tout actionnaire peut voter par correspondance, au moyen d'un formulaire dont les mentions sont fixées par décret en Conseil d'Etat. Les dispositions contraires des statuts sont réputées non écrites.</p> <p>Pour le calcul du quorum, il n'est tenu compte que des formulaires qui ont été reçus par la société avant la réunion de l'assemblée, dans les conditions de délais fixées par décret en Conseil d'Etat. Les formulaires ne donnant aucun sens de vote ou exprimant une abstention ne sont pas considérés comme des votes exprimés".</p> <p>La majorité requise pour l'adoption des décisions est déterminée en fonction des voix exprimées par les actionnaires présents ou représentés. Les voix exprimées ne comprennent pas celles attachées aux actions pour lesquelles l'actionnaire n'a pas pris part au vote, s'est abstenu ou a voté blanc ou nul. (articles L. 225-96 et L. 225-98 du Code de Commerce et, s'agissant des sociétés ayant adopté le statut de la société européenne, et articles 57 et 58 du Règlement du Conseil (CE) N°2157/2001 relatif au statut de la société européenne).</p> <p>Si vous votez par correspondance : vous devez obligatoirement noircir la case "Je vote par correspondance" au recto.</p> <p>1 - Il vous est demandé pour chaque résolution en noircissant individuellement les cases correspondantes :</p> <ul style="list-style-type: none">- soit de voter "Oui" (vote exprimé par défaut pour les projets de résolutions présentés ou agréés, en l'absence d'un autre choix);- soit de voter "Non";- soit de voter "Abstention". <p>2 - Pour le cas où des amendements aux résolutions présentées ou des résolutions nouvelles seraient déposées lors de l'assemblée, il vous est demandé d'opter entre vote contre (vote exprimé par défaut en l'absence d'un autre choix), pouvoir au président de l'assemblée générale, abstention ou pouvoir à personne dénommée en noircissant la case correspondant à votre choix.</p>	<p>(4) POUVOIR À UNE PERSONNE DÉNOMMÉE (PERSONNE PHYSIQUE OU MORALE)</p> <p>Article L. 225-106 du Code de Commerce (extrait) :</p> <p>"I - Un actionnaire peut se faire représenter par un autre actionnaire, par son conjoint ou par le partenaire avec lequel il a conclu un pacte civil de solidarité.</p> <p>II - Le mandat ainsi que, le cas échéant, sa révocation sont écrits et communiqués à la société. Les conditions d'application du présent alinéa sont précisées par décret en Conseil d'Etat.</p> <p>III - Avant chaque réunion de l'assemblée générale des actionnaires, le président du conseil d'administration ou le directoire, selon le cas, peut organiser la consultation des actionnaires mentionnées à l'article L. 225-102 afin de leur permettre de désigner un ou plusieurs mandataires pour les représenter à l'assemblée générale conformément aux dispositions du présent article.</p> <p>Cette consultation est obligatoire lorsque, les statuts ayant été modifiés en application de l'article L. 225-23 ou de l'article L. 225-71, l'assemblée générale ordinaire doit nommer au conseil d'administration ou au conseil de surveillance, selon le cas, un ou des salariés actionnaires ou membres des conseils de surveillance des fonds communs de placement d'entreprise détenant des actions de la société. Cette consultation est également obligatoire lorsque l'assemblée générale extraordinaire doit se prononcer sur une modification des statuts en application de l'article L. 225-23 ou de l'article L. 225-71.</p> <p>Les clauses contraires aux dispositions des alinéas précédents sont réputées non écrites."</p>	<p>Article L. 22-10-41 du Code de Commerce :</p> <p>"Toute personne qui procède à une sollicitation active de mandats, en proposant directement ou indirectement à un ou plusieurs actionnaires, sous quelque forme et par quelque moyen que ce soit, de recevoir procuration pour les représenter à l'assemblée d'une société mentionnée au premier alinéa de l'article L. 22-10-39, rend publique sa politique de vote.</p> <p>Elle peut également rendre publiques ses intentions de vote sur les projets de résolution présentés à l'assemblée. Elle exerce alors, pour toute procuration reçue sans instructions de vote, un vote conforme aux intentions de vote ainsi rendues publiques. Les conditions d'application du présent article sont précisées par décret en Conseil d'Etat."</p>
<p>Les informations à caractère personnel recueillies dans le cadre du présent document sont nécessaires à l'exécution de vos instructions de vote. Vous disposez d'un certain nombre de droits concernant vos données (accès, rectification, etc.). Ces droits peuvent être exercés auprès de votre teneur de compte aux coordonnées indiquées par ce dernier.</p>		

FORM TERMS AND CONDITIONS

<p>(1) GENERAL INFORMATION: This is the sole form pursuant to article R. 225-76 du Code de Commerce which is applicable to shareholders general meetings of companies incorporated under French law.</p> <p>WHICHEVER OPTION IS USED:</p> <p>The signatory should write his/her exact name and address in capital letters in the space provided e.g. a legal guardian: (Change regarding this information have to be notified to relevant institution, no change can be made using this proxy form).</p> <p>If the signatory is a legal entity, the signatory should indicate his/her full name and the capacity in which he is entitled to sign on the legal entity's behalf.</p> <p>If the signatory is not the shareholder (e.g. a legal guardian), please specify your full name and the capacity in which you are signing the proxy.</p> <p>The form sent for one meeting will be valid for all meetings subsequently convened with the same agenda (article R. 225-77 alinéa 3 du Code de Commerce). The documents referred to in article R. 225-76 du Code de Commerce are attached to this form unless if these documents are available on a website whose address is specified on the front of this form. Please do not use both "I vote by post" and "I hereby appoint" (article R. 225-81 alinéa 8 du Code de Commerce).</p> <p>A guide relating to the general meetings processing, including an interpretation grid of this proxy form, is available on the France Post Marché website at: https://www.france-post-marche.fr/</p> <p>The French version of this document governs; The English translation is for convenience only.</p>	<p>(3) PROXY TO THE CHAIRMAN OF THE GENERAL MEETING</p> <p>Article L. 225-106 du Code de Commerce (extract):</p> <p>"In case of any power of representation given by a shareholder without naming a proxy, the chairman of the general meeting shall issue a vote in favor of adopting a draft resolutions submitted or approved by the Board of Directors or the Management Board, as the case may be, and a vote against adopting any other draft resolutions. To issue any other vote, the shareholder must appoint a proxy who agrees to vote in the manner indicated by his principal."</p>	<p>This information relates in particular to the event that the proxy or, as the case may be, the person on behalf of whom it acts:</p> <p>1° Controls, within the meaning of article L. 233-3, the company whose general meeting has to meet;</p> <p>2° Is member of the management board, administration or supervisory board of the company or a person which controls it within the meaning of the article L. 233-3;</p> <p>3° Is employed by the company or a person which controls it within the meaning of article L. 233-3;</p> <p>4° Is controlled or carries out one of the functions mentioned with the 2° or the 3° in a person or an entity controlled by a person who controls the company, within the meaning of the article L. 233-3.</p>
<p>(2) POSTAL VOTING FORM</p> <p>Article L. 225-107 du Code de Commerce (extract):</p> <p>"Any shareholder may vote by post, using a form the wording of which shall be fixed by a decree approved by the Conseil d'Etat. Any provisions to the contrary contained in the memorandum and articles of association shall be deemed non-existent.</p> <p>When calculating the quorum, only forms received by the company before the meeting shall be taken into account, on conditions to be laid down by a decree approved by the Conseil d'Etat. The forms giving no voting direction or indicating abstention shall not be considered as votes cast."</p> <p>The majority required for the adoption of the general meeting's decisions shall be determined on the basis of the votes cast by the shareholders present or represented. The votes cast shall not include votes attaching to shares in respect of which the shareholder has not taken part in the vote or has abstained or has returned a blank or spoilt ballot paper (articles L. 225-96 and L. 225-98 du Code de Commerce and, for the companies which have adopted the statute of European company, articles 57 and 58 of the Council Regulation (EC) n°2157/2001 on the statute for a European company).</p> <p>If you wish to use the postal voting form, you have to shade the box on the front of this form: "I vote by post".</p> <p>1 - In such event, please comply for each resolution the following instructions by shading boxes of your choice:</p> <ul style="list-style-type: none">- either vote "Yes" (in absence of choice, vote expressed by default for the approved draft resolutions),- or vote "No",- or vote "Abstention". <p>2 - In case of amendments or new resolutions during the general meeting, you are requested to choose between vote "No" (vote expressed by default in absence of choice), proxy to the chairman of the general meeting, "Abstention" or proxy to a mentioned person individual or legal entity by shading the appropriate box.</p>	<p>(4) PROXY TO A MENTIONED PERSON (INDIVIDUAL OR LEGAL ENTITY)</p> <p>Article L. 225-106 du Code de Commerce (extract):</p> <p>"I - A shareholder may be represented by another shareholder, by his or her spouse, or by his or her partner who he or she has entered into a civil union with.</p> <p>II - The proxy as well as its dismissal, as the case may be, must be written and made known to the company. A Conseil d'Etat decree specifies the implementation of the present paragraph.</p> <p>III - Before every general meeting, the chairman of the board of directors or the management board, as the case may be, may organise a consultation with the shareholders mentioned in article L. 225-102 to enable them to appoint one or more proxies to represent them at the meeting in accordance with the provisions of this Article.</p> <p>Such a consultation shall be obligatory where, following the amendment of the memorandum and articles of association pursuant to article L. 225-23 or article L. 225-71, the ordinary general meeting is required to appoint to the board of directors or the supervisory board, as the case may be, one or more shareholder employees or members of the supervisory board of the company investment funds that holds company's shares. Such a consultation shall also be obligatory where a special shareholders' meeting is required to take a decision on an amendment to the memorandum and articles of association pursuant to article L. 225-23 or article L. 225-71.</p> <p>Any clauses that conflict with the provisions of the preceding sub-paragraphs shall be deemed non-existent."</p>	<p>This information is also delivered when a family tie exists between the proxy or, as the case may be, the person on behalf of whom it acts, and a natural person placed in one of the situations enumerated from 1° to 4° above.</p> <p>When during the proxy, one of the events mentioned in the preceding subparagraphs occurs, the proxy informs without delay his constituent. Failing by the latter to confirm explicitly the proxy, this one is null and void.</p> <p>The termination of the proxy is notified without delay by the proxy to the company.</p> <p>The conditions of application of this article are determined by a Conseil d'Etat decree."</p>
<p>Personal data included in this form are necessary for the execution of your voting instructions. You have certain minimum rights regarding your data (access, correction...). These rights may be exercised using the contact details provided by your custodian.</p>		

PARTICIPATE AND VOTE AT THE GENERAL MEETING OF JUNE 30, 2026

A. PRELIMINARY FORMALITIES TO BE CARRIED OUT TO PARTICIPATE IN THE GENERAL MEETING

Each shareholder, no matter the number of share possessed and the manner they are held, can participate to the General Meeting, subject to the formalities set out below.

Shareholders shall provide proof of the registration of their shares in their name or that of the intermediary registered on their behalf no later than Tuesday June 23, 2026 (i.e. before the fifth business day preceding the general meeting at midnight, Paris time), either in the registered accounts held by the Company, or in the bearer shares accounts held by the authorized intermediary.

You may prove your status as a shareholder as follows:

- for registered shareholders: your status as a shareholder is evidenced only by the registration of your shares in a registered account no later than zero hour Paris time on Tuesday June 23, 2026;
- for holders of bearer shares: you must contact your financial intermediary, indicating that you wish to participate in the General Meeting, and ask this intermediary to draw up a certificate of participation noting the registration or book entry of your shares no later than zero hour, Paris time, on Tuesday June 23, 2026.

B. MODALITIES OF ATTENDANCE TO THE GENERAL MEETING

To participate in the General Meeting, shareholders, whether registered or bearer, may (1) attend in person or (2) vote by e-mail or be represented by giving a proxy to the Chairman of the Meeting, to their spouse, to the person with whom a civil solidarity pact has been concluded, to another shareholder or to any other natural person or legal entity of their choice in accordance with the conditions set forth in Articles L.225-106 and L.22-10-39 of the French Commercial Code, or (3) by Internet.

1. TO ATTEND TO THE COMPANY GENERAL MEETING

The shareholders wishing to personally attend the General Meeting must request an admission card as soon as possible to receive the card in a timely manner:

- For registered shareholders:
 - o either by returning the single form duly completed and signed using the pre-paid reply envelope enclosed with the invitation received by post mail; or
 - o by logging in on the website www.sharinbox.societegenerale.com using their usual access codes or their login email (if they have already activated their Sharinbox by SG Markets account), together with the password they already have. The password to connect to the site was sent to them by post when they first contacted Société Générale Securities Services. It can be re-sent by clicking on "Obtain your codes" on the home page of the website. Once connected, they should follow the procedure described on the screen to access the VOTACCESS platform and request their admission card; the registered shareholder who would not have received his/her admission card may spontaneously attend the General Meeting with an identification document.

- For holders of bearer shares:
 - o either by asking the authorized intermediary managing their share-accounts to send them an admission card. Should the admission card not be received by Tuesday June 23, 2026, zero hour, Paris time, the shareholder shall ask the authorized intermediary managing their share-accounts to issue a certificate of participation in order to prove their status as shareholders; or
 - o by logging in on the Internet portal of their account holder with their usual access codes. The shareholder will then have to click on the icon that will appear on the line corresponding to their Inventiva shares to access the Votaccess website and follow the procedure described on the screen. Only the bearer shareholder whose account holder has subscribed to the Votaccess website will be able to fulfil their request for admission card via Internet.

On the day of the General Meeting, each shareholder will have to prove her quality during the registration process.

2. VOTE AT THE GENERAL MEETING BY MAIL USING THE VOTING FORM

2.1 You hold registered Inventiva shares

2.1.1 You have received a voting form at your address

YOU GIVE PROXY TO THE PRESIDENT	YOU GIVE PROXY TO AN INDIVIDUAL OR LEGAL ENTITY OF YOUR CHOISING	YOU VOTE REMOTELY
<p>Check the second box of the form;</p> <ul style="list-style-type: none"> - date and sign at the bottom of the form. <p>Send your request by postal mail directly to the <i>Services des Assemblées</i> of Société Générale, 32, rue du Champs de Tir, CS 30812, 44308 Nantes Cedex 3, at the latest three days before the meeting, that is Saturday June 27, 2026.</p> <p>Your votes will be added to those of the President.</p> <p style="text-align: center;">✓ You have voted.</p>	<p>Check the third box of the form;</p> <ul style="list-style-type: none"> - specify the identity and complete contact information of the person who will represent you; - specify your last name, first name and address or check them if they are prefilled; - date and sign at the bottom of the form. <p>Send your request by postal mail directly to the <i>Services des Assemblées</i> of Société Générale, 32, rue du Champs de Tir, CS 30812, 44308 Nantes Cedex 3, at the latest three days before the meeting, that is Saturday June 27, 2026.</p> <p style="text-align: center;">✓ You gave proxy.</p>	<p>Check the first box of the form;</p> <ul style="list-style-type: none"> - specify your vote; - date and sign at the bottom of the form. <p>You want to vote "in favor" of each resolution: do not blacken any box. You want to vote "against" a resolution or to "abstain": blacken the box "no" or "abs" that corresponds to the number of the resolution concerned.</p> <p>Send your request by postal mail directly to the <i>Services des Assemblées</i> of Société Générale, 32, rue du Champs de Tir, CS 30812, 44308 Nantes Cedex 3, at the latest three days before the meeting, that is Saturday June 27, 2026.</p> <p style="text-align: center;">✓ You have voted.</p>

2.1.2 You did not receive a voting form at your address

You can get copy of the remote voting form on Inventiva's website (www.inventivapharma.com, in the Investors' Section (*Espaces Investisseurs*), subsection documentation - General Meetings). You just have to print it, complete it and return it to the *Services des Assemblées* of Société Générale, 32, rue du Champs de Tir, CS 30812, 44308 Nantes Cedex 3 as specified in section 2.1.1 above.

You can, in any case, send a written request on plain paper to Inventiva to request a remote voting form.

2.2 You hold Inventiva bearer shares

You need to reach out to your financial intermediary holding your securities account in which you Inventiva shares are registered to request a remote voting form. Each demand must be addressed by the financial intermediary to the *Services des Assemblées* of Société Générale, 32, rue du Champs de Tir, CS 30812, 44308 Nantes Cedex 3 at the latest six days before the date of the General Meeting (Article R. 225-75 of the French Commercial Code): complete the form as specified in section 2.1.1 above and return the form duly completed to your financial intermediary which will forward it to the *Services des Assemblées* of Société Générale, 32, rue du Champs de Tir, CS 30812, 44308 Nantes Cedex 3. Your financial intermediary will add to your request a certificate of ownership of shares dated at least 5 business days before the date of the General Meeting. The form need be received by the *Services des Assemblées* of Société Générale at least 3 calendar days before the General Meeting (i.e. on Saturday June 27, 2026).

2.3 How to fill your voting form

HOW TO FILL OUT THE FORM?

TO VOTE BY POST
Blacken this box

If you do not wish to vote "YES" on the resolutions presented, blacken one of the two boxes (No or Abstention) for the resolutions concerned

Warning:

- if you do not blacken a box, the meaning of your vote will be counted as "Yes";
- any abstention expressed will not be considered as a vote.

TO GIVE PROXY TO THE CHAIRMAN OF THE MEETING
Blacken this box.

CADRE RÉSERVÉ À LA SOCIÉTÉ - FOR COMPANY'S USE ONLY

Identifiant - Account: Vote simple / Single vote
 Numéro / Registered: Vote double / Double vote
 Nombre d'actions / Number of shares: Particulier / Private
 Nom / Name: Nombre de voix / Number of voting rights

JE VOTE PAR CORRESPONDANCE / I VOTE BY POST

Je vote OUI à tous les projets de résolutions présentés ou agréés par le Conseil d'Administration ou la Société, à l'EXCEPTION de ceux que je signale en cochant comme suit l'une des cases "Non" ou "Abstention". I vote YES of the draft resolutions approved by the Board of Directors, EXCEPT those indicated by a checked box, one of the boxes "No" or "Abst".

	1	2	3	4	5	6	7	8	9	10	A	B
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Abst. / Abst.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
OUI / Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Abst. / Abst.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
OUI / Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Abst. / Abst.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
OUI / Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Abst. / Abst.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
OUI / Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Non / No	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Abst. / Abst.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
OUI / Yes	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Si des amendements ou des résolutions nouvelles étaient présentés en assemblée, je vote NON sauf si je signale au cadre ci-dessus en cochant la case correspondante. In case amendments or new resolutions are presented during the meeting, vote NO unless I indicate another choice by checking the corresponding box.

Je donne pouvoir au Président de l'Assemblée Générale de voter en mon nom. I appoint the Chairman of the general meeting to vote on my behalf.

Je n'abdique pas mon droit de vote. I do not waive my voting right.

Je donne pouvoir à un autre membre (M. ou Mme) de voter en mon nom. I appoint the member (M. or Mrs) to vote on my behalf.

Pour plus de détails, voir l'ensemble des documents de présentation au site web. For more information, see the complete set of documents on the website.

à la banque / by my bank à la Société / by my company ** communication en recommandation ** communication en recommandation ** communication en recommandation

JE DONNE POUVOIR AU PRÉSIDENT DE L'ASSEMBLÉE GÉNÉRALE

Je donne pouvoir à M. M. ou Mme. Reason: Société / M. Mrs or Mrs, Corporate Name

Adresse / Address

DO NOT FORGET TO BLACKEN THE BOX of your choice in case amendments or new resolutions are presented.

DATE AND SIGNATURE

WHATEVER YOUR CHOICE IS, PLEASE DATE AND SIGN HERE

CHECK (OR, IF NECESSARY, WRITE)

ATTENTION: Pour les titres au porteur, les présentes instructions doivent être transmises à votre banque.

CAUTION: If it is about bearer securities, the present instructions will be valid only if they are directly returned to your bank.

Nom, prénom, adresse de l'abonné (les modifications de ces informations doivent être adressées à l'Établissement concerné).
 Nom, first and name, address of the shareholder (changes regarding this information have to be notified to relevant institution, no change can be made using the proxy form). (See remarks (1)).

3. VOTING OR GIVING PROXY AT THE GENERAL MEETING VIA INTERNET

Inventiva provides its shareholders with the website *Votaccess* dedicated to Internet voting prior to the General Meeting. This site allows each shareholder to cast his or her vote by telecommunication means, prior to the General Meeting, under the conditions defined below. The secured platform *Votaccess*, allowing to vote on the resolutions

3

or to give proxy by Internet, will open as of Thursday June 11, 2026 at 9 a.m., Paris time, until Monday June 29, 2026, at 3 p.m, Paris time.

Shareholder may also name or revoke a proxy by Internet, under the conditions set out below, prior to the General Meeting, on the *Votaccess* website or by e-mail at the following address: agiva30062026@inventivapharma.com

3.1 You hold registered Inventiva shares

Login the *Votaccess* website via the website for the management of your registered shares (www.sharinbox.societegenerale.com), with your access code and password:

- **Access code:** it appears at the top of your statements;
- **Password:** it has been sent to you by mail when you first reached out to Société Général Securities Services. If you have lost or forgotten your password, go to the home page of the site and click on "Get your codes". You will then have to click on the name of the General Meeting under the heading "Current Operations" of the home page. You will then need to select the transaction, follow the instructions for the purpose of voting or giving a proxy. Click on "Vote" to access the voting site.

The possibility to vote via Internet before the General Meeting will end the day before the meeting, that is Monday June 29 at 3 p.m., Paris time. However, to avoid a potential saturation of the website *Votaccess*, the shareholders are advised not to wait until the day before the General Meeting to vote.

You also may give or revoke a proxy by sending an e-mail with an electronic signature, obtained by you from a third party certifier duly authorized pursuant to legal and regulatory provisions in force, to the electronic address agiva30062026@inventivapharma.com specifying, as for pure registered shareholders, your name, first name, address and your Société Générale access code (information available at the top left of their account statement), or, as for administered registered shareholders, your access code with your authorized intermediary, as well as the name, first name and address of the appointed or revoked agent. In order for the duly signed and completed appointments or revocations of proxy to be validly taken into account, they must reach the Company no later than Saturday June 27, 2026, as regards notification made by electronic means.

For any request, SGSS is available to shareholders from 9:30 a.m. to 6:00 p.m. on the following telephone number: + 33 (0)2 51 85 67 89.

3.2 You hold Inventiva bearer shares

You want to vote or give a proxy via Internet, prior to the General Meeting: log in, with your usual access code, on your bank's portal dedicated to the management of your shares. To access the *Votaccess* website and vote, you just have to click on the icon that will appear on the line corresponding to your Inventiva shares.

It is specified that only holders of bearer shares whose account-holding institution has subscribed to *Votaccess* will be able to access the website. If your account-holding institution is not connected to *Votaccess*, the notice of appointment or revocation of a proxy can still be effectuated by email, pursuant to Articles R. 22-10-24 and R. 225-79 of the French Commercial Code according to the following procedures: by sending an email to agiva30062026@inventivapharma.com. This email must contain the following information: name of the Company, last name, first name, address, bank references of the principal, as well as the last name, first name and, if possible, address of the agent. You must ask your authorized intermediary to send a written confirmation to *Services des Assemblées* of Société Générale, 32, rue du Champs de Tir, CS 30812, 44308 Nantes Cedex 3. In order for appointments or revocations of proxies to be validly taken into account, the confirmations must be received at the latest the day before the General Meeting at 3 p.m. (Paris time). In order for the duly signed and completed appointments or revocations of proxy to be validly taken into account, they must reach the Company no later than Saturday June 27, 2026, as regards notification made by electronic means.

INVENTIVA
GENERAL MEETING OF JUNE 30, 2026
REQUEST FOR ATTACHMENTS

I, the undersigned:

Last name: _____

First name: _____

Address: _____

Email: _____

Owner of _____ registered shares*,

And/or of _____ bearer shares,

of the Company **INVENTIVA**, whose registered office is located: 50, rue de Dijon, Daix (21121), France, registered with the Commerce and Companies Register of Dijon under the No. 537 530 255 RCS Dijon,

acknowledge having received the documents relating to the above-mentioned General Meeting and referred to in Article R.225-81 of the French Commercial Code,

request the sending of the documents and information related to the General Meeting of June 30, 2026, as they are identified in Article R.225-83 of the French Commercial Code, with the exception of those attached to the single voting form.

Mode of transmission (if not specified, documents will be sent by email):

By Email

By Post

Made in _____ on ___ / ___ / 2026

Signature

* In accordance with Article R.225-88 paragraph 3 of the French Commercial Code, the shareholders owning registered shares can, upon single request, obtain the sending by the Company of the documents and information identified in Articles R.225-81 and R.225-83 of the French Commercial Code, for each subsequent General Meeting. Should the shareholder wish to benefit from this option, this must be mentioned on the present request.